Functional Consequences of Chromosomal Rearrangements in Neurodevelopmental Disorder by KAGISTIA HANA UTAMI
FUNCTIONAL CONSEQUENCES OF 











NATIONAL UNIVERSITY OF SINGAPORE 
2014 
FUNCTIONAL CONSEQUENCES OF 
CHROMOSOMAL REARRANGEMENTS IN 
NEURODEVELOPMENTAL DISORDER 
 
KAGISTIA HANA UTAMI 




A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PAEDIATRICS 
YONG LOO LIN SCHOOL OF MEDICINE 









I hereby declare that this thesis is my original work and it has been written by me 
in its entirety. I have duly acknowledged all the sources of information which 
have been used in the thesis.  






Kagistia Hana Utami 







I would like to start by acknowledging people who made it possible for me to 
pursue my PhD, my supervisors: Dr. Valere Cacheux, who has been generous in 
devoting her time in between her busy schedules to guide me and actively 
involved in supervising me from distance miles away; my heartfelt thanks to Dr. 
Sonia Davila, who has been extremely supportive during the course of my study, 
provided unlimited amount of time in guiding and supervising me, especially to 
improve my scientific writing; Dr. Stacey Tay Kiat Hong, for accepting me as a 
student under her department and providing constructive ideas from clinical point 
of view.  
This thesis would not have been possible without the collaborators: Dr. Robyn 
Jamieson, Dr. Sylvain Briault, and Dr. Pierre Sarda, who have provided patients 
samples and assistance in manuscript writing. 
I wish to express my sincere appreciation to the following people: Dr. Axel 
Hillmer, for his helpful guidance in analyzing genome sequencing data, 
continuous supports and manuscript writing; Dr. Irene Aksoy, for her patience in 
teaching me the basics of culturing embryonic stem cells for the first time, and her 
constructive suggestions to develop my project; Dr. Larry Stanton for allowing 
me to use his cell culture lab space; Dr. Vladimir Korzh, for the hours of 
discussion about neural crest cells biology and the access to the zebrafish facility; 
 iii 
 
Dr. Sinakaruppan Mathavan, who kindly assisted with the bioinformatics analysis 
on the evolutionary conservation of candidate genes. I also thank my Thesis 
Advisory Committee for their helpful suggestions, Prof. Fu Xin Yuan and Dr. 
Bruno Reversade. 
My big thanks to my Indonesian friends in Biopolis: Lanny, Teddy, Astrid, and 
Herty who have given me continuous supports throughout my entire journey. I 
would also like to thank all the people that I have got to know during my time at 
GIS: Seong Soo, Wei Yong, and Edward Chee for keeping the quiet level 5 
become more enjoyable. Sonia’s group lab members: Vikrant, Katrin, Clarabelle, 
Lisa, Melissa and Zai Yang, for their help in one way or another.  
I would like to thank the Agency for Science and Technology Research 
(A*STAR) who have awarded me a Singapore International Graduate Award 
(SINGA) scholarship, including conferences supports throughout my study. I am 
very grateful for the opportunity.   
My deepest gratitude goes to my parents for their endless encouragement and 
giving me the greatest love and support. This thesis is dedicated to you. Finally, I 
would also especially thank Ryan for his patience and generous understanding. 
Last but not least, for the patients who donated their cells to the studies that make 




TABLE OF CONTENTS 
 
Declaration ............................................................................................................... i 
Acknowledgement .................................................................................................. ii 
Table of Contents ................................................................................................... iv 
Summary ................................................................................................................. x 
List of tables ......................................................................................................... xiii 
List of figures ....................................................................................................... xiv 
List of Abbreviations .......................................................................................... xvii 
Chapter 1: Introduction ........................................................................................... 1 
1.1 Neurodevelopmental disorders overview ................................................. 1 
1.1.1 Developmental Delay (DD)/Intellectual disability (ID) ......................... 2 
1.1.2 Language Delay (LD) ............................................................................. 2 
1.1.3 Speech Delay (SD) ................................................................................. 3 
1.1.4 Autism spectrum disorders (ASD) ......................................................... 4 
1.2 Clinical evaluation of NDDs ......................................................................... 4 
1.3 Causes of NDDs ....................................................................................... 6 
1.3.1 Environmental contributions of NDDs ................................................... 6 
1.3.2 Genetics of Neurodevelopmental Disorders ........................................... 9 
1.4 Genetic evaluation for NDDs ...................................................................... 11 
 v 
 
1.4.1 G-banding karyotyping ......................................................................... 11 
1.4.2. Fluorescence in situ hybridization (FISH)........................................... 14 
1.4.3 Array comparative genomic hybridization (aCGH) ............................. 15 
1.4.4 Next generation sequencing.................................................................. 19 
1.5 Pathophysiology of NDDs .......................................................................... 25 
1.6 Overview of DNA Paired-End Tag (DNA-PET) sequencing ..................... 30 
1.7 Thesis aims .................................................................................................. 35 
Chapter 2: Materials and Methods ........................................................................ 37 
2.1 Patient samples and clinical information .................................................... 37 
2.1.1 Patient CD5........................................................................................... 39 
2.1.2 Patient CD10......................................................................................... 39 
2.1.3 Patient CD8........................................................................................... 40 
2.1.4 Patient CD9........................................................................................... 41 
2.1.5 Patient CD14......................................................................................... 41 
2.1.6 Patient CD6........................................................................................... 42 
2.1.7 Patient CD23......................................................................................... 42 
2.2 G-Banding karyotype .................................................................................. 43 
2.3 Fluorescence in situ hybridization (FISH) .................................................. 43 
2.4 Genomic DNA isolation .............................................................................. 44 
2.5 Array comparative genomic hybridization (aCGH) .................................... 45 
2.6 DNA-PET .................................................................................................... 45 
 vi 
 
2.7 Post-sequencing analysis ............................................................................. 46 
2.8 Filtering of normal structural variation (SVs) ............................................. 48 
2.9 Functional analysis of regulatory regions ................................................... 49 
2.10 Validation of breakpoints by Sanger sequencing ...................................... 50 
2.11 Quantitative Real Time PCR (qPCR)........................................................ 50 
2.12 CNV analysis from published studies ....................................................... 53 
2.13 Functional analysis by pluripotent stem cells ........................................... 53 
2.13.1 Cell lines used and maintenance ......................................................... 53 
2.13.2 Induction of iPSC from fibroblast ...................................................... 53 
2.13.3 Neural progenitor cells differentiation ............................................... 54 
2.13.4 Neuronal differentiation ..................................................................... 55 
2.13.5 pSUPER shRNA cloning and transfection ......................................... 55 
2.13.6 shRNA vector for GTDC1 .................................................................. 57 
2.13.7 EdU proliferation assay ...................................................................... 57 
2.13.8 Immunocytochemistry ........................................................................ 58 
2.13.9 Immunocytochemistry quantification analysis ................................... 59 
2.13.10 Microarray ........................................................................................ 60 
2.13.11 Gene enrichment analysis for microarray ......................................... 61 
2.14 Functional analysis by zebrafish ............................................................... 61 
2.14.1 Fish lines and maintenance ................................................................. 61 
2.14.2 Embryo preparation ............................................................................ 61 
2.14.3 RNA probe synthesis .......................................................................... 62 
 vii 
 
2.14.4 Whole mount in situ hybridization ..................................................... 62 
2.14.5 Morpholino microinjection ................................................................. 63 
2.14.6 Human MED13L mRNA synthesis .................................................... 63 
2.14.7 Alkaline phosphatase staining ............................................................ 64 
2.14.8 Alcian Blue staining ........................................................................... 64 
2.14.9 Image quantification analysis ............................................................. 65 
2.14.10 qPCR analysis ................................................................................... 65 
Chapter 3: Results: Discovery of Candidate Genes for NDDs ............................. 67 
3.1 Study background ........................................................................................ 67 
3.2. Characterization of SVs by DNA-PET ...................................................... 68 
3.3 Breakpoint characterization through detailed SVs analysis ........................ 70 
Patient CD5.................................................................................................... 70 
Patient CD10.................................................................................................. 74 
Patient CD8.................................................................................................... 76 
Patient CD9.................................................................................................... 81 
Patient CD14.................................................................................................. 82 
Patient CD23.................................................................................................. 85 
Patient CD6.................................................................................................... 88 
3.4 Secondary CNV screening in published studies and databases .................. 91 
Chapter 4: Results: Dissecting Functional Role of MED13L during 
Neurodevelopment and Neural crest cells (NCCs) Specification ......................... 93 
4.1 Study background ........................................................................................ 93 
 viii 
 
4.2 Expression profile of MED13L orthologuein zebrafish .............................. 97 
4.3 Loss of function of med13b in zebrafish embryo ...................................... 100 
4.4 Loss of med13b impaired craniofacial cartilage development .................. 102 
4.5 med13b suppression affects neurodevelopment in zebrafish embryo ....... 104 
4.6 MED13L knockdown in neural stem cells did not affect proliferation ..... 105 
4.7 MED13L knockdown did not affect neuronal maturation ......................... 109 
4.8 Transcriptome profiling of MED13L-deficient neurons ........................... 110 
Chapter 5: Results: Studying the role of GTDC1 during neurogenesis .............. 114 
5.1 Study background ...................................................................................... 114 
5.2 Somatic cells reprogramming from patient’s fibroblasts .......................... 115 
5.3 Phenotypic characterization of patient’s NPCs and GTDC1-deficient NPCs
 ......................................................................................................................... 117 
5.4 Transcriptome profiling of patients and shGTDC1 cells .......................... 123 
Chapter 6: Discussion ......................................................................................... 128 
6.1 Clinically relevant gene disruptions in the chromosomal rearrangement 
breakpoints ...................................................................................................... 129 
6.2 Limitations of DNA-PET sequencing ....................................................... 134 
6.3 Large phenotypic spectrum in patients with MED13L disruptions ........... 135 
6.4 MED13L haploinsufficiency contributes to craniofacial anomalies and ID
 ......................................................................................................................... 137 
 ix 
 
6.5 Morphological alterations in neurons derived from patient’s iPSCs and 
GTDC1-deficient cells..................................................................................... 139 
Chapter 7: Conclusion......................................................................................... 144 
Chapter 8: Future Directions ............................................................................... 146 
Appendix A: List of SVs per patients. ................................................................ 162 






Neurodevelopmental Disorders (NDDs) are heterogeneous groups of conditions 
characterized by impairments in cognition, communication and/or motor skills 
resulting from abnormal development of the central nervous system (CNS). They 
are usually diagnosed during childhood or infancy. NDDs occur as frequent as 1-
3% in the general population, and the diagnostic yield has been estimated to be 
between 15-25% using the currently available techniques. Although mutations in 
more than 450 genes have been implicated in NDDs, the majority of affected 
patients are still undiagnosed due to genetic and phenotypic heterogeneity. 
Chromosomal rearrangements are known contributors to NDDs, which have been 
routinely detected by G-banding karyotyping and fluorescence in situ 
hybridization at extremely low resolution.  
The first aim of my study was to identify novel candidate genes in NDDs by 
performing genome paired-end tag sequencing in patients with unexplained 
NDDs carrying known chromosomal rearrangements. These analyses led to the 
identification of several disrupted genes within the chromosomal breakpoint 
regions, and one candidate gene from private structural variants (SVs) of one 
patient. In total, eight disrupted genes were identified in the breakpoint regions of 
six patients, Guanine nucleotide binding protein (G-protein), q (GNAQ), RNA-
binding protein, fox1 homolog (C.elegans) (RBFOX3), unc-5 homolog D 
(C.elegans) (UNC5D), X-linked inhibitor of apoptosis (XIAP), transmembrane 
protein 47 (TMEM47), non-SMC condensing II complex, subunit G2 (NCAPG2), 
 xi 
 
glycosyltransferase-like domain containing 1 (GTDC1), and mediator complex 
subunit 13-like (MED13L). Gene disruption in four out of seven patients were 
likely to explain the phenotypic features in these patients, and two candidate 
genes (MED13L and GTDC1) were selected for further functional study.  
The second part of the study focused on characterizing one candidate gene, 
MED13L, and its potential involvement in the clinical manifestation seen in the 
patient CD23. Overlapping mutations and variants encompassing MED13L have 
been reported previously and associated with large phenotypic spectrum 
consistent with the clinical presentation of the patient described in this study.  
Zebrafish studies showed that MED13L is required for cranial neural crest 
migration and its disruption in this animal model recapitulated craniofacial defects 
seen in patients.  Transcriptomic analysis in neuronal cells lacking MED13L 
showed significant gene expression changes in components of Wnt and FGF 
signaling pathways. 
The third aim of the study was to functionally characterize the role of GTDC1 by 
using patient’s induced pluripotent stem cells (iPSCs)-derived neurons. GTDC1 
was identified as the sole candidate gene based on trio-sequencing that was 
disrupted in a balanced translocation (Patient CD6). Slower proliferation rate of 
progenitor cells and altered neuronal morphology were observed in both patient’s 
cells and GTDC1 knockdown cells, suggesting that GTDC1 may contribute to 
neurodevelopmental phenotype in the patient.  
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Taken together, this study highlights the clinical relevance of gene disruptions due 
to chromosomal rearrangements, and provides novel insights into the functional 
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CHAPTER 1: INTRODUCTION 
 
1.1 NEURODEVELOPMENTAL DISORDERS OVERVIEW 
Neurodevelopmental disorders (NDDs) are one of the most common health 
burdens in pediatric health care. Up to 3% of the general population is estimated 
to have some form of NDDs(1), and the prevalence tends to be higher in 
developing countries with lower socioeconomic status and poor health care.(2) 
NDDs are defined as an umbrella term for a heterogeneous group of conditions 
characterized by impairments in cognition, communication, behavior and/or 
motor skills resulting from abnormal brain development.(3, 4) There are no 
curative pharmacological treatments for cognitive delay.(5) Thus, children with 
NDDs usually undergo treatment with a variety of rehabilitative therapies and 
early intervention strategies to optimize their developmental potential. NDDs can 
be classified based on abnormalities in certain areas, such as intellectual 
functioning, speech, language, fine motor skills and may coexist with a known 
syndrome. In some cases, the presence of minor dysmorphism (facial and other 
superficial physical anomalies) or multiple congenital anomalies (MCA) may 
coexist with NDDs symptoms. The most common clinical features observed in 
NDDs patients include intellectual disability (ID) or developmental delay (DD), 
speech delay (SD), language delay (LD), and Autism Spectrum Disorder (ASD), 




1.1.1 DEVELOPMENTAL DELAY (DD)/INTELLECTUAL DISABILITY (ID) 
According to the new criteria of Diagnostic and Statistical Manual of 
Mental Disorder (DSM)-V(6), developmental delay (DD) or intellectual 
disability (ID) is characterized by an impairment of general mental 
abilities that impact adaptive functioning in conceptual domain (language, 
reading, writing), social domain and practical domain (organizing task). 
The term DD is used for younger children (less than 5 years of age), 
whereas ID is applied to older children when Intelligence Quotient (IQ) 
assessment is valid and reliable. Children with DD usually present with 
significant delays in the developmental milestones at the expected age.(7, 
8) DD/ID is estimated to occur in 1-3 of every 100 live births. ID is a 
newly recommended term to replace ‘Mental Retardation’ according to 
Rosa’s Law and documented by the new International Classification of 
Diseases (11
th
 revision).(9)  
ID is defined by an IQ with four degrees of severity: mild ID (IQ 50-70), 
moderate ID (IQ 35-49), severe ID (IQ 20-34) and profound ID for IQ 
below 20. DD/ID can appear as a distinct, isolated condition or coexist as 
part of well-defined syndromes such as autistic disorder, or X-linked ID 
syndromes.  
1.1.2 LANGUAGE DELAY (LD) 
Language encompasses the understanding, processing and production of 
communication. Language delay (LD) occurs more frequently than ID in 
the general population. It is estimated to be in the range of 5-8% in pre-
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school children, and might co-occur with other conditions such as autism 
or cleft palate.(10) LD is typically recognized by difficulty with grammar, 
words or vocabulary, units of words meaning, and the use of language 
particularly in social contexts.(11) LD is diagnosed by using the early 
Language Milestone scale that focuses on expressive, receptive and visual 
language.(12) Children diagnosed with LD possess higher risk for learning 
disabilities as they have difficulties in reading, and written language, 
which subsequently lead to academic underachievement and lower IQ 
score. The difference between LD and speech delay (SD) is that LD 
pertains to both expressive and receptive delays, whereas speech delay is 
specific to speech mechanism alone. 
1.1.3 SPEECH DELAY (SD) 
Speech refers to the mechanics of oral communication or the motor act 
communicating by articulating verbal expressions.(11) Early signs of SD 
include stuttering or dysfluency, articulation problems, inability to speak, 
which occur at the age of onset below 5 years old.(11) However, not all 
children develop linguistic skills at the same speed or to equivalent 
proficiency.(13) Similar to LD, SD is a common childhood problem that 
affects 3-10% of children, which could manifest with other disorders such 





1.1.4 AUTISM SPECTRUM DISORDERS (ASD) 
According to a new classification in DSM-V, ASD is defined as a 
behavioral disorder recognized in early childhood that shows selective 
impairment mainly in social interaction, communication, language 
development, and restricted or repetitive patterns of behavior 
(stereotyped), which largely limit everyday functioning.  ASD has recently 
been reclassified as a collective presentation of Rett syndrome, Asperger 
syndrome and Autistic disorder or Pervasive Developmental Disorder Not 
Otherwise Specified (PDD-NOS) that were previously presented as 
distinct subtypes of ASD in the DSM-IV manual. ASD affects about 1 in 
110 individuals, with age of onset of three years old. ASD is highly 
heritable compared to other types of NDDs, and the presentation of ASD 
patients are largely variable, with symptoms ranging from mild to severe 
in terms of behavioral and IQ performance.  
1.2 CLINICAL EVALUATION OF NDDS 
Patients and their families may benefit from an established etiologic diagnosis for 
the possibilities of recurrence risk, treatment options and prevention strategies. 
Generally, two clinical evaluations are required in the first year of life, yearly 
evaluations until the early school years and a re-evaluation during puberty. In 
clinical genetics, establishing a diagnosis usually require a process of gathering 
data from visit history, repeated physical examinations and staged diagnostic 
 5 
 
testing.(14, 15)  In 1997, Curry and colleagues (14) described the recommended 
‘gold standard’ for clinical evaluation of NDDs, which is summarized in Figure 1. 
 
Figure 1. Recommended clinical evaluation scheme for early diagnosis of NDDs. The 
patients are initially investigated from the prenatal, perinatal and postnatal history. The 
family pedigree of three generations is important to determine possibility of inherited 
disorders. Next, physical examination is important to monitor developmental milestones. 
Based on the phenotypic data and patient history, different types of genetic diagnostic 
tests are recommended for follow-up, such as Fragile X test for a suspected phenotype or 
chromosomal karyotyping. 
 
First, clinicians will assess the prenatal and birth history records, as these are 
important determinants of a likelihood of perinatal complications such as birth 
trauma or asphyxia. Second, the family history including three-generation 
pedigree is required to examine possible transmission of neurological traits 
running in the family such as learning disabilities or psychiatric disorders. Then, 
the child will undergo complete physical examination, focusing on the minor 
anomalies such as dysmorphisms, measurements of growth parameter and head 
circumference that is compared with normal developmental stages. Facial features 
assessment, with special attention on the inter-eye distance, width of the nasal 
root, forehead size, and appearance of the nose, upper lip, palate and jaw usually 
provide clues for specific syndromic diagnoses, such as Down syndrome. When a 
patient present features that resemble a specific diagnosis for which genetic 
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testing is available, this analysis should be performed first. For example, Fragile 
X syndrome test (FRAXA), or Down syndrome test. However, when a detailed 
clinical history, physical examination and family history are not suggestive of a 
specific disorder, unbiased genome-wide screening such as G-banding 
karyotyping or chromosomal microarray should be considered as a first line 
genetic testing of individuals with NDDs.(16)  
1.3 CAUSES OF NDDS 
 
NDDs can be caused by environmental insults, such as exposure to viral 
infections, birth traumas, toxins or radiation, which mostly occur during prenatal 
periods. Mounting evidence has shown that genetic factors play a major role in 
NDDs, and the majority of the cases (approximately ~60%) have unknown 
etiology.(17)  
1.3.1 ENVIRONMENTAL CONTRIBUTIONS OF NDDS 
Environmental insults occurring at different time points during fetal development 
could interfere with normal brain development and may contribute to cognitive 
impairments in NDDs. Understanding the environmental risk factors is 
particularly important to identify potentially amenable factors for clinical 
intervention. Formation of the CNS is a highly dynamic process that requires 
orchestrated steps from early embryonic development to reach adult maturation, 
and the developing brain is more vulnerable to environmental insults.  
Previous studies have shown that environmental stressors could influence normal 
neurodevelopment, which include complications during the prenatal period and 
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complications during delivery. Perinatal asphyxia, or lack of oxygen intake in the 
newborn is one of the most frequent causes of NDDs that may result in increase in 
mortality and morbidity such as an increased risk cognitive impairment(18). 
Smoking, alcohol use, drugs and exposure to toxins during pregnancy may be 
associated with birth defects. Prenatal exposure to toxins from drugs abuse or 
alcohol use have been shown to exert adverse effects on neurodevelopmental 
outcome.(19) (20) In utero exposure to nicotine in animal models resulted in 
behavioral and cognitive impairments, suggesting that prenatal exposure to 
nicotine may perturb neurodevelopment.(21) Furthermore, epidemiological 
studies have shown that maternal smoking was associated with slightly poor 
academic achievement, and increased symptoms of attention-deficit disorder and 
hyperactivity in the offspring.(22)  
Folate deficiency has also been associated with specific birth defects affecting 
neurodevelopment such as neural tube defects (NTDs).(23) Impaired folate 
metabolism was originally observed in mothers of infants with NTDs in 1960s, 
and folate supplementation during pregnancies has substantially reduced the 
occurrence and recurrence of NTDs. (24, 25) Nutritional status, physiological 
condition and psychological states of pregnant mothers appeared to be associated 
with increased risk of developing NDDs in their newborn. Large-scale population 
study showed that maternal metabolic conditions such as diabetes, hypertension 
and obesity have been associated with autism, DD or impairments in specific 
domains of development in the offspring.(26, 27) Depression or anxiety during 
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pregnancy also have been shown to be correlated with decreased IQ, learning and 
memory deficits and delayed social development in their offspring.(28)  
In addition, prenatal infections such as rubella or even fever have been linked to 
an increased risk of developing neuropsychiatric disorders, including 
schizophrenia and autism.(29) A large study involving 10,000 autism cases 
provided significant association with maternal viral infection in the first 
trimester(30). Maternal effect risk of NDDs also came from studies observing 
short inter-pregnancy intervals between first and second-born child pregnancies. 
Data gathered from registry-based studies have shown significant correlation 
between NDDs incidence and short interpregnancy intervals. A group in 
California reported that closely spaced pregnancies were associated with 
increased risk of autistic disorder in the later-born child, with the largest increase 
observed in < 1 year apart(31). Subsequent studies in Sweden, Denmark and 
Norway population showed similar trend of increased risk of developing NDDs 
such as autism or schizophrenia (31-34). The proposed theory from these studies 
was due to deficiency of essential micronutrients during pregnancy, and short 
inter-pregnancy intervals were not sufficient to restore nutritional status after 
delivery.  
Apart from maternal effect, father’s age appears to be a risk factor for NDDs-
associated diseases such as autism. A recent study has found that sperm from 
older fathers contain more DNA mutations compared to sperm from young men, 
and these mutations are commonly segregated into their autistic offspring.(35) 
Advanced maternal age did not seem to correlate with the risk of autism, 
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suggesting paternal age as an important determinant in autism incidence.(36) 
Another group investigating the rate of mutations in older fathers provides further 
evidence of paternal age bias towards risk of carrying additional de novo mutation 
per year (35, 36).  
1.3.2 GENETICS OF NEURODEVELOPMENTAL DISORDERS 
Accumulating evidence has demonstrated that NDDs have a strong genetic 
component, based on twin studies, family segregation studies, or spontaneous 
genetic mutations.  
In 1938, a British geneticist, Lionel Penrose conducted a detailed examination in 
1280 patients with ID and their family members over a period of 7 years (37), and 
he observed that family members of ID-affected individuals were at risk of 
developing NDDs, and the risk was reduced with decreasing relatedness(38). He 
proposed de novo mutations in sporadic cases, multifactorial inheritance, and 
incomplete penetrance for the non-Mendelian segregation of the phenotype being 
the major genetic cause of cognitive impairments. Recent studies have shown that 
in accordance to his theory, the majority of sporadic NDDs cases arise from 
spontaneous de novo mutations.(39-46) Despite its high frequency in the 
population, a large proportion of NDDs cases (~60%) have unknown etiology, 
and thus the majority of them remain undiagnosed. Some forms of syndromic 
NDDs account for a total of ~10%, which include FXS (~1-2%), tuberous 
sclerosis (~1%), Rett syndrome (~0.5%), and Neurofibromatosis 1 (less than 1%). 
Furthermore, other rare monogenic disorders with more subtle pattern of 
malformations were accounted in an even smaller proportion of NDD cases.  
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Numerous efforts have been made in large-scale population studies to determine 
common genetic variants in several forms of NDDs, without any success.(47, 48) 
Interestingly, many studies observed that mutations found in different genes have 
been identified for seemingly identical form of NDDs, and mutations in the same 
gene may result in different disease outcomes.(47)  These observations led to an 
emerging view that rare de novo mutations, instead of common variants, are more 
likely to contribute to NDDs, which emphasized a considerable genetic and 
phenotypic heterogeneity in this disease.(49) These rare variants typically 
constitute different forms of genetic mutations with large effects such as 
chromosomal anomalies, copy number variants (CNVs), and single nucleotide 
variants (SNVs) that could inactivate or alter gene dosage(50).  
Recent advances in technologies over the past two decades such as microarray 
comparative genomic hybridization (aCGH) and next-generation sequencing 
(NGS) have identified up to more than 400 candidate genes associated with 
NDDs.  Some of these genes are involved in general physiological processes 
required for normal development, including cell adhesion, gene transcription, 
metabolism, synaptogenesis and chromatin remodeling that converge on similar 
neurodevelopmental pathways.(49) Altered gene dosage involved in these 
processes could disrupt the neuronal networks and interfere with a normal brain 




1.4 GENETIC EVALUATION FOR NDDS  
 
Since early 1970s, patients with ID or DD, with or without dysmorphic features 
were routinely assessed with conventional cytogenetic methods by obtaining 
samples from peripheral blood as the first line of genetic evaluation. Cytogenetic 
is a branch of genetics that studies chromosomes and examines the function and 
structure of chromosomes, and its encoded DNA that build the genome.(51) 
Conventional cytogenetic techniques such as G-banding karyotyping or FISH are 
very informative and have allowed better understanding of human diseases, 
normal phenotypic variation and karyotypic evolution. Importantly, due to its 
genome-wide coverage and rapid turnaround time, cytogenetic analysis has been 
instrumental for rapid genetic evaluation of unexplained NDDs. 
 
1.4.1 G-BANDING KARYOTYPING 
G-banding karyotyping is a conventional cytogenetic method that relies on 
harvesting chromosomes in mitosis by treating cells with tubulin inhibitors such 
as colcemid that depolymerize the mitotic spindle and arrest the metaphase 
chromosomes in the cells. The chromosomes are assayed by staining with Giemsa 
dye, and this process is therefore referred to as G-banding. This technique was 
developed in the late 1960s, and the principle relies on the identification of the 
alternating light and dark staining bands comprising each chromosomal locus, and 
allowed for identification of large chromosomal rearrangements at a resolution of 
5-10 Mb(16).  
 12 
 
These structural chromosomal changes involve an exchange between two 
chromosomes, or translocation, inverted piece of chromosome in the opposite 
direction, or inversion, deleted portion of a chromosome, or deletion, and 
additional copy of chromosome regions, or duplication (Figure 2). Based on a 
large cytogenetic survey in 1991, the risk of serious congenital anomalies is 
estimated to be 6.7% for individuals carrying de novo balanced chromosome 
rearrangements (translocation and inversion).(46)  
 
Figure 2. Illustration of cytogenetically visible chromosome rearrangements. 
Translocation occurs when there is an exchange of genetic material between two 
chromosomes, illustrated by chromosome A and B. The rearranged chromosome is 
referred as derivative chromosome (Der(A) or Der(B)). Duplication is depicted as an 
additional copy of certain chromosomal region, resulting in a duplicated segment. 
Deletion occurs when there is a loss of genetic material in the chromosome. Inversion 
occurs when there is a chromosomal break within a chromosome that results in a reversed 
orientation of the genetic material within the chromosomal break. Dotted white lines 




The presence of balanced rearrangements could potentially explain the phenotype 
when the rearrangement occurs de novo or segregated with a disease within the 
family. Typically, balanced rearrangements retain a single chromosomal allele 
expressing normal expression and one derivative allele containing the 
rearrangement breakpoint. This rearrangement breakpoint may disrupt a gene that 
lead to an absent or altered gene dosage through gene truncation, inactivation, 
gain of function or creation of chimeric fusion genes. 
According to the recent guideline in American College of Medical Genetics 
(ACMG), G-banding techniques are recommended as a first-tier genetic testing 
for specific group of patients with clinically suspected chromosome aneuploidy, 
such as Down, Turner and Klinefelter syndromes, or a family history suggestive 
of chromosomal rearrangements.(16) This is based on the earlier observations that 
a sizeable proportion of NDDs cases (at a range of 4-28.4%) are attributable to 
chromosome abnormalities, including trisomy, subtelomeric rearrangements and 
balanced chromosomal rearrangements (Table 1).(14, 15) Furthermore, 
subtelomeric chromosome rearrangements have been found in 6% of idiopathic 












Bourgeois and Benezech(54) 600 ID France 9 
Kodama(55) 197 Severe ID Japan 4 
Rasmussen(56) 1,905 ID Denmark 18.8 
Wuu(57) 470 ID Taiwan 8.1 
Gustavson(58) 171 Mild ID Sweden 11.9 
Srsen(59) 324 ID Czech 28.4 
Wuu(60) 1,323 ID Taiwan 7.87 
Schwartz(61) 350 ID/DD U.S. 11.9 
Table 1. Frequency of chromosome abnormalities in patients with ID/DD based on 
G-banding karyotype analysis. These studies assess the presence of chromosome 
anomalies (including trisomies) among individuals with neurological deficits.  
 
The diagnostic yield of routine G-banding karyotyping is approximately 3.7%. 
Meta-analysis of 33 studies by the International Standard Cytogenetic Array 
Consortium estimated that balanced translocations are identified in ~0.3% of 
individuals with ID who were tested with G-banding karyotyping.(62) However, 
G-banding techniques are limited to the detection of microscopically visible 
chromosomal aberrations (Megabases in size), and the precise breakpoint cannot 
be precisely delineated without further validation by ‘chromosome walking’, 
using probes surrounding the breakpoints by fluorescence in situ hybridization 
(FISH) analysis. 
1.4.2. FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 
 
G-banding karyotyping provides an unbiased view of the whole chromosomes, 
which is useful for genetic testing in individuals with unknown cause and no 
family history. However, for patients with phenotypes suggestive of specific 
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disorder such as trisomy disorder, subtelomeric or microdeletion/duplication 
syndromes, a focused FISH analysis is a useful step to investigate specific 
syndromes. When the FISH analyses reveal abnormalities, FISH should be 
performed on both parents to identify a carrier parent. FISH analysis involves 
hybridization of fluorescently labeled polymorphic marker probes such as 
Bacterial Artificial Chromosomes (BACs) or fosmids into the denatured DNA of 
metaphase chromosomes or interphase nuclei. FISH can detect submicroscopic 
aberrations of less than 5 Mb, and the resolution relies on the size of the probes 
used. For example, BACs provide resolution of 150-200 kb, whereas cosmid 
probes provide a resolution of 30-40 kb. FISH analysis has enabled identification 
of many disease genes associated with congenital anomalies at the chromosomal 
breakpoints, such as dystrophin in Duchenne Muscular Dystrophy (DMD),(63) 
DISC1 in schizophrenia,(64, 65) and ATP7A in Menkes disease, as well as 
subtelomeric deletion syndromes (66, 67) The diagnostic yield for FISH analyses 
in patients with ID/DD is approximately 6.8%. However, FISH can only detect 
known regions, therefore it can only be used when the phenotype is suggestive of 
a particular disorder or having a prior knowledge of certain genomic region to be 
investigated.  
1.4.3 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) 
 
aCGH was first developed by Daniel Pinkel in 1998(68), and the method has 
continued to improve over the last ten years. aCGH has higher resolution and 
sensitivity to detect CNVs such as deletions and duplications that were previously 
difficult to detect by G-banding and FISH analyses. The principle of aCGH relies 
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on utilizing cloned BACs or synthesized oligonucleotides DNA fragments 
covering across chromosomal loci in the genome that are spotted on the array 
chip. Copy numbers are determined based on the differences in the hybridization 
pattern intensities between two differentially labeled DNA (patient and reference 
DNA).  
CNVs are defined as alteration of copy number in certain genomic locus that is 
greater than 1 kb in size. The resolution varies depending on the tiling array used; 
1 Mb resolution BAC arrays, tiling resolution BAC arrays, or 100k SNP arrays.  
The presence of CNVs could have functional consequences through diverse 
mechanisms, including dosage changes, gene interruption, generation of fusion 
genes, position effect by altering regulatory sequences of genes near the 
breakpoint, and unmasking a recessive allele.(69) These mechanisms could 
potentially affect genes that have a role in disease, and thus may pinpoint a 
disease-associated locus.  However, it has been shown that large-scale CNVs are 
in fact scattered randomly throughout the genome covering 360 Mb (12% of the 
genome) in the healthy individuals.(70, 71) These studies suggested that these 
CNVs are unlikely to be disease-related, and could be the source of genetic 
variations between individuals.(70, 71)  Based on high resolution genomic 
microarray studies, it has been estimated that on average every individual 
possesses ~1000 CNVs that range in size from 500 bp to 1.2 Mb.(71) Following 
this genome wide prevalence of large-scale CNVs in healthy individuals, the 
Database of Genomic Variants (DGV; http://dgv.tcag.ca/dgv/app/home) was 
launched in 2008 as a resource that extensively cataloged and mapped precise 
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localization of CNVs and inversions from hundreds of disease-free individuals. 
DGV is an invaluable resource for clinical aCGH applications that could filter out 
CNVs that are present in normal individuals and help to define the candidate 
disease susceptibility loci. Following the recent ACMG guidelines, aCGH has 
replaced G-banding karyotyping as the first line genetic testing for individuals 
with DD/ID without a specific diagnosis, and has greatly improved the diagnostic 
yield. 
aCGH is a powerful approach to identify CNVs associated with NDDs, and many 
studies have reported the identification of recurrent microdeletions or 
nicroduplications associated with specific clinical features.(72-75) Clinically 
relevant CNVs are defined as pathogenic when they are large in size (>500 Kb), 
overlap with known microdeletion/duplication syndromes, or encompass genes 
with known phenotypes.(76) In addition, recent studies suggested that rare and de 
novo CNVs were considered to be clinically relevant and might be responsible for 
15-20% of NDDs cases.(72, 77, 78) The diagnostic yield of NDDs using aCGH 
was approximately 15%, which was nearly four-fold higher than karyotyping.(74)  
Recurrent microdeletions or microduplications identified in patients with nearly 
identical phenotypes have allowed clinical geneticists to classify these patients 
into locus-specific syndromes.(79) This novel classification has greatly improved 
diagnostic outcome in certain group of patients. However, it is extremely 
challenging to identify the causative gene within the affected region for follow-up 
functional studies, because these regions may comprise multiple genes.  
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As an example, the 17q21.31 microdeletion syndrome (also referred as Koolen-
De Vries syndrome) was the first microdeletion syndrome identified through 
aCGH in patients with DD/ID.(79) Subsequent studies(72, 80) reported additional 
patients with 17q21.31 deletion that show nearly identical phenotype to the first 
study, including ID, hypotonia, characteristic facial features, epilepsy, heart and 
kidney defects. Another clinically-defined microdeletion syndrome is at 15q24 
locus. The first report described four individuals with idiopathic ID, 
microcephaly, digit abnormalities, genital abnormalities, hypospadias, and facial 
dysmorphism. All had a common deletion in 15q24 region. Further 
microdeletions in the same region ranging from 1.7-3.9 Mb in size were reported 
with nearly identical phenotypes, which lead to a consistent and well-recognized 
clinical diagnosis.(81, 82) However, a number of genomic loci has been recently 
identified with variable inheritance and penetrance, which complicates a clinical 
interpretation, such as CNVs at loci 1q21.1(83, 84), 15q13.3,(85, 86) and 
16p13.1.(87, 88)   
In terms of molecular characteristics of CNVs, recent aCGH studies performed in 
large cohort of NDDs patients have provided an insight into the molecular 
signatures of CNVs in these individuals. Baptista et al compared phenotypically 
normal and abnormal carriers of translocation and found that translocation in 
diseased cohort were more likely to be associated with cryptic genomic 
imbalances at the breakpoint regions.(89) Girirajan et al postulated that the 
additive effect of second large CNV in NDDs patients in addition to the existing 
microdeletion or microduplication syndrome caused a more severe clinical 
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phenotype, due to a combined effect of rare variants.(90) These studies suggested 
that the co-occurrence of rare CNVs with existing variants contributed to the 
levels of cognitive impairments severity in NDDs. Despite its improved 
resolution, aCGH is unable to detect copy-neutral rearrangements or complex 
intra-chromosomal aberrations.  
1.4.4 NEXT GENERATION SEQUENCING 
When the first draft of human genome sequence was announced in 2001, it took 
more than 13 years for the Human Genome Project (HGP) to sequence 3 billion 
base pairs by Sanger sequencing. The method used involve creating massive 
libraries of sheared DNA fragments inserted into large vector such as BACs, 
sequencing each fragments and assembling these fragments based on sequence 
overlaps. Although Sanger sequencing is highly accurate due to its long reads 
capacity, it is not a preferred method to sequence human genome on a large-scale 
due to its high cost and labor intensiveness. Recent advances in next-generation 
sequencing (NGS) technology have revolutionized the potential for gene 
discovery and human genetic variations in the past few years. In contrast to 
Sanger sequencing that typically produces a single long read (800 bp - 1 Kb), 
NGS generates millions of short reads (starting from 35 bp) using reversible 
sequencing chemistries. NGS technologies have substantially reduced the time 
and costs required for genome-wide screening, and also have increased resolution 
compared to conventional methods.  
The era of NGS technology began in 2004 when the 454 Pyrosequencing was 
developed by Roche Applied Science, allowing thousands of sequencing reactions 
 20 
 
in high density picoliter reactors to be carried out in parallel, massively increasing 
the sequencing throughput.(91) In 2006, Illumina launched the Solexa Genome 
Analyzer (GA) for reversible termination sequencing method by attaching single-
stranded DNA fragments to a single molecule array or flow cell, allowing solid-
phase bridge amplification of single molecule DNA templates. Subsequently 
thereafter, in 2007 Applied Biosystem introduced a ‘supported oligonucleotide 
ligation and detection’ (SOLiD) system for a massively parallel sequencing by 
hybridization-ligation. Earlier studies employing NGS technologies to catalog 
genome variation maps mainly utilized SOLiD platform (92).  
In early 2010, Illumina released HiSeq 2000, which adopts similar sequencing 
strategy to Illumina/Solexa GA system that is able to produce up to 600 Gb in 7 
days, and more cost-effective than SOLiD or 454 system per million bases. HiSeq 
2000 also allows multiplexing of samples by barcoding with primers and adapters, 
to process hundreds of samples in parallel. These NGS platforms differ greatly in 
the read length, output data capacity per run and the time needed for each run. 
















Synthesis in the presence of dye 
terminators 
400-900  0.7 Gb 2400 
454 Roche Pyrosequencing on solid support 700  600 Gb 10 
Illumina 
HiSeq 2000 
Sequencing by synthesis with 
reversible terminators 
50-100  120 Gb 0.07 
ABI/SOLiD 
Massively parallel sequencing 
by ligation 
35-50  90 Kb 0.13 
Table 2. Comparison of widely-used sequencing platform technology, adapted from 
Morozova et al., 2008(93) Different sequencing machines have their own advantages  
and disadvantages in terms of read length, error rate, output data for each run and the cost 
required for each million bases. 
 
Depending on the platform, sequencing methods and applications for specific 
experiments, NGS techniques are able to identify either structural variations 
(SVs) or single nucleotide variations (SNVs). SVs are typically defined as 
variation in a DNA region greater than 1 kb and include structural changes such 
as translocations, inversions, insertions/deletions (indels) and CNVs. Similar to 
CNVs, SVs can lead to diverse mechanistic outcomes, including altered gene 
dosage, positional regulatory change, chimeric fusion gene formation and 
reorganization of functional elements.(94) SNVs are single nucleotide change in a 
DNA region that may alter protein-coding, regulatory region or splicing 
mechanism. For SVs identification, mate-paired library genome sequencing could 
provide information for the presence of SVs through discordantly mapped 
sequencing reads.  
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Mate-paired libraries are generated by ligating two adjacent DNA fragments 
(paired-end reads) separated by a certain size (1.5- 5 kb) in the genome, thus 
referred to as long-insert paired end sequencing. Mate-paired library relies on the 
presence and exact distance of both reads (paired-end reads) to map the sequence 
assembly to the reference genome. The paired reads that are not in correct 
orientation, correct position in the chromosome or correct size between reads are 
informative for SVs annotation, including CNVs and balanced rearrangements 
(translocation, inversion and complex copy-neutral rearrangement).(92, 95) Due 
to detailed position of breakpoint from sequencing output, this approach could 
substantially reduce the time consumed for positional cloning of candidate genes 
or mapping balanced rearrangements breakpoints by BAC-probe-oriented 
chromosome walking in FISH.  
Following this application, many studies have employed this technique to map the 
breakpoints of disease-associated balanced rearrangements in NDDs patients by 
various methods such as chromosome-sorting(96), targeted capture of 
breakpoints,(97) or large-insert jumping libraries.(98, 99)  Talkowski et al 
reported 33 gene-disruptive loci in 38 NDDs patients carrying balanced 
rearrangements, and determine the possible correlation of these genes to the 
phenotypes (98) Cuppen et al. described a detailed analysis on the genetic 
architecture of complex chromosomal rearrangements (CCR) involving more than 
3 breakpoints through paired-end sequencing, providing a mechanistic insight into 
the reorganization of shattered chromosomes.(100) Recently, the Genome 
Institute of Singapore has developed a large-insert genome paired-end tag 
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sequencing, referred to as DNA-PET, which is the primary method used in this 
thesis, and it will be described in section 1.4. However, paired-end tag sequencing 
techniques are limited to detection of SVs and unable to detect small 
rearrangements such as SNVs. 
Alternatively, whole genome sequencing (WGS) can detect both SVs and SNVs 
in a high throughput manner. In principal, WGS employs paired-end reads 
approach by sequencing short-reads from both forward and reverse ends, and 
reads can be aligned by overlapping sequence data. Recent study utilized WGS in 
a large cohort of patients with unexplained severe ID and their parents, which 
resulted in an improved diagnostic yield of up to 42-62% by using this method. 
(101)  This is particularly beneficial for diagnosis of a genetically heterogeneous 
condition such as ID, in which WGS can provide unbiased genome-wide 
screening with a very high resolution. However, WGS is limited by the large 
amount of data output generation, requires labor-intensive and time consuming 
bioinformatics analysis, and the cost of sequencing per genome is still relatively 
expensive compared to paired-end tag sequencing method. Furthermore, data 
analysis and interpretations of non-coding variants are very challenging, although 
the technology is still improving and annotation of gene desert regions are likely 
to improve in the coming years by ENCODE project.   
To overcome this limitation, targeted enrichment technologies provide 
opportunities to sequence only protein-coding genes or specific sets of genes. 
Theoretically, majority of disease causing mutations reported so far occurs in the 
coding regions, which account for <1% of the genome. Thus, by sequencing only 
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a minor fraction of the genome, whole exome sequencing (WES) requires shorter 
time to generate libraries, to produce sequence output, less amount of sequence 
data for high-throughput data analysis, and is less expensive compared to WGS. 
WES technologies are able to detect SNVs and CNVs based on the sequencing 
read-depths. Over the past few years, experimental and analytical approaches 
related to WES have established a standardized scheme for disease gene 
discovery in Mendelian disorders. Typically, every individual possess ~20,000-
24,000 variants identified by WES, and more than 95% of these variants are 
known as polymorphic in human population as documented by Database of Single 
Nucleotide Polymorphisms (dbSNPs) or 1000 Genome Project. Filtering of these 
polymorphic variants is likely to reveal rare variants that might have impact on 
disease phenotypes. In favor to the low-cost of WES, parental samples are usually 
included in WES analysis to identify rare de novo variants, in which germline 
variants inherited from the parents can be excluded. Recent studies have reported 
a significant excess of de novo SNVs found in NDDs patients with severe ID, or 
autism. A recent study reported a large-scale WES trio analysis in 100 severe ID 
patients resulting in identification of de novo SNVs that could explain the 
phenotype in ~50% of the cases.(102) This analysis produced a diagnostic yield 
of about ~16% based on de novo mutations in known and novel genes. 
Subsequent trio-exome sequencing study in autism families showed an excess of 
de novo mutations in brain-expressed genes that might be associated with autism 
and carry large effects.(103)  
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WES is a powerful tool for clinical application and novel disease gene discovery. 
However, large structural variants such as translocation or inversion could not be 
detected through WES. Despite the successful identification of potentially 
pathogenic mutations through WES, WGS or PET sequencing, there are 
challenges in interpreting NGS data and their causal role in disease. Each 
individual generally carries private variants that have unknown clinical 
significance, as well as potentially damaging mutations, which may lead to false 
assignments of disease-causing mutations or may raise ethical issues such as 
incidental findings of other disease-causing mutations based on unbiased genome-
wide screening.(104, 105)  
1.5 PATHOPHYSIOLOGY OF NDDS 
The underlying pathology of NDDs has been mainly studied through phenotypic 
characteristics of brain morphology, post-mortem brain tissues, and animal model 
knockouts of genes identified through genetic analysis. Phenotypic characteristics 
of brain morphology typically analyzed through structural magnetic resonance 
imaging (MRI), or functional MRI (fMRI), both are safe and non-invasive tools 
for evaluating gross neuroanatomical changes of the brain. MRI uses strong 
magnetic signals to define morphological differences in the brain, whereas fMRI 
measures neural activity in the brain based on changes in the blood flow. The 
majority of neuroimaging studies in NDDs have focused largely on autism, Down 
syndrome or other syndromic disorders (FXS, Williams or, Velocardiofacial 
syndrome), rather than DD, SD or ID as single entities. Clinically, individuals 
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with these syndromes usually have lower IQ, and possess difficulties in language 
and communication.  
One of the most replicated neuroanatomical changes in children with autism is the 
age-specific brain anatomic abnormalities. Abnormal brain overgrowth is 
observed at early ages (1-2 years), that subsequently decline or shown as arrested 
growth in early adulthood suggesting possible degeneration due to cell cycle 
defect, neuronal loss or apoptosis defects.(106) Based on MRI studies that 
measure brain size and head circumference, the abnormal early overgrowth is 
specifically found in several regions of the brain including the frontal lobe, 
temporal cortex and amygdala that are known to be important for development of 
higher order social, emotion, language and communication abilities.(106-109) 
Subsequent studies showed enlarged cerebellum in children with autism, but 
smaller cerebellar volumes in DD patients.(110, 111) At the tissue level, brain 
enlargement reflects both increased cerebral gray and white matter, especially 
white matter immediately underlying the cortex.(112-115) However, fMRI studies 
investigating perceptual skills and overall intelligence in ASD patients did not 
produce consistent results, indicating that not all brain systems are equally 
affected. Overall, these studies suggested dynamic changes of brain pathology 
across developmental stages, with age-specific defects, showing that defects 
present at younger ages may not be present at older ages and conversely. 
(Example: overgrowth of amygdala at young age, but not at older age.) This 
theory implies that the age-related changes will mark gene expression, molecular 
features, synaptic composition, cellular characteristics, and circuit patterns. The 
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overgrowth phenomenon was hypothesized to be due to excess neurons from cell 
cycle defects or failure of apoptosis.(116, 117) To this end, follow-up studies 
were performed by measuring neuron numbers in post-mortem brain tissues of 
children with autism.(118)  
Recent study discovered that brain overgrowth in autism involved excess number 
of neurons (~67% more) in the prefrontal cortex, a brain region that is important 
for social, communication and complex cognitive behaviour.(119) Another post-
mortem study showed excess number of von Economo neurons (~53% more) in 
the frontoinsular cortex in autism brains than in controls.(120) Von Economo 
neurons are a subtype of neurons that is primate-specific and mainly located in the 
dorsolateral prefrontal cortex and fronto insular cortex, which is important for 
expressing emotion and higher cognitive functioning. Another post mortem study 
found decreased density of Purkinje cells in the cerebellar hemisphere in children 
with autism and ID, which contradicts the MRI finding of enlarged cerebellum in 
autism.(121, 122) Further stereological study in amygdala did not show consistent 
findings; one study reported smaller size of densely-packed neurons in 
amygdala(123), while other group found fewer number of neurons in 
amygdala.(124)  
Both neuroimaging and post-mortem studies poses different challenges and 
limitations. Neuroimaging techniques provide complete documentation of 
different phases during development. Although MRI studies may show some 
minor abnormalities or variations in structure, autism is a condition for which 
there is a diagnostic or easily recognizable pattern on neuroimaging. Post-mortem 
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brain studies typically examined older adults with autism, and most of the studies 
are performed in small sample sizes, due to number of tissue and quality of tissues 
available. Therefore, the earlier developmental time window is not explored, 
which is the critical time period where MRI studies showed enlargement of brain 
structures. Further studies to identify novel quantitative imaging biomarkers that 
could detect early disturbance of neurodevelopment would need to be pursued to 
facilitate early detection of NDD.  
The majority of animal models for NDDs are based on monogenic disease 
models, such as Rett syndrome, FXS, and tuberous sclerosis. Apart from 
behavioral study of specific tasks or abilities in knockout mice, morphological 
changes in neurons have provided insight into specific defects that alter normal 
neurodevelopment, such as neurite numbers, dendritic arborization, synaptic 
plasticity, and axonal outgrowth. One example of well-characterized 
pathophysiology in NDDs is FXS, a leading cause of inherited autism and ID that 
is caused by trinucleotide expansion repeat permutation of 55-200 CGG repeats in 
FMR1 gene located at chromosome X.(125, 126) FMRP regulates synaptic 
protein synthesis by binding to ribosomes and repressing translation of target 
mRNAs. In Fmr1
- /-
 mouse model, Huber and colleagues(127) showed that the 
absence of FMRP leads to increased protein synthesis and enhanced long-term 
depression in the hippocampus, due to excessive glutamatergic signaling via 
metabotropic Glutamate Receptor 5 (mGluR5).(128) Fmr1 KO mice have 
abnormal dendritic spine morphology, and increased spine density, which 
recapitulated the neuronal profiles of post-mortem brains in patients with FXS.  It 
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has been postulated that excessive protein translation is the underlying cause of 
NDDs phenotype in FXS patients, as demonstrated by compensating FMRP 
function led to correction of some FXS phenotypic features.(129) Therefore, 
therapeutic strategies for FXS have been directed towards modulating mGlur5 
activity. These efforts resulted in the identification of several mGlur5 antagonists 
that are currently in preclinical trials and clinical development.(129, 130) Some of 
these preclinical studies have resulted in preliminary improvement in motor 
learning and better accuracy on performance tasks.(131-133)  
This example showed the advantage of characterizing highly penetrant mutations 
in understanding molecular pathogenesis and development of therapeutic targets 
based on genetic findings. However, the majority of idiopathic NDDs cases have 
no single major genetic cause, but are instead induced by rare mutations in 
different individuals with similar diagnoses. Thus, it remains challenging to 
establish a single defining pathology through animal models. One alternative 
solution is to utilize the patient’s derived iPSCs that can be differentiated into 
respective cell types, such as neurons or neural progenitor cells. This approach 
has the potential to improve the validation of biological hypothesis by examining 
phenotypic assays of derived cell types in similar genetic background of the 




1.6 OVERVIEW OF DNA PAIRED-END TAG (DNA-PET) 
SEQUENCING 
Large structural rearrangements such as translocation, inversion, deletion and 
duplication have functional roles in human traits and diseases, which have been 
previously characterized mainly by karyotyping, FISH and aCGH. WES recently 
has demonstrated its ability to detect CNVs in higher resolution based on 
sequencing read depth.  However, neither aCGH nor exome sequencing can 
identify copy number neutral rearrangements, such as insertions, inversions, and 
translocations. For studies focusing on identification of such rearrangements, 
paired-end tags sequencing (PET) is the most ideal approach.  
The principle of PET technique is to sequence only the short 5’ and 3’ tags of 
specific insert size of DNA fragments derived from genomic DNA in a massive 
and highly parallel manner.(92, 95, 134, 135) This strategy was initially applied 
by Snyder and colleagues to systematically analyze SVs of two cell lines derived 
from healthy individuals, which revealed extensive variation in the human 
genome.(92) Another study has extended the analysis in eight individuals using 
cloning-based PET sequencing, and provided SVs map that is used as a reference 
for normal SVs in the population.(95) These studies used short DNA fragments or 
a few kilobases (3 Kb) pair fragments insert sizes, which limit the detection 
ability of larger rearrangements, often missed repetitive sequences, and resulted in 
very low-coverage (less than 10-fold).  
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To this end, our institute has recently established a modified PET-sequencing 
technique, by using larger insert sizes compared to the regular protocol.(134, 136-
138) Different insert sizes have been tested and 10 Kb fragment has proven to be 
the optimal fragment size for SV analysis.(134, 136) In theory, larger insert sizes 
are superior than shorter fragments due to the higher ability to detect complicated 
DNA sequence features such as repetitive sequences. Moreover, it provides higher 
physical coverage (50 to 100-fold per genome) compared to short-insert PET 
sequencing. The experimental scheme of large-insert DNA-PET sequencing is 
illustrated in Figure 3, as adapted from Yao et al.(134)  
 
Figure 3. DNA-PET sequencing workflow.  
Genomic DNA is sheared into ~10 kb fragments, and LMP cap linkers were attached to 
each fragment end. After correct fragment sizes were selected, each fragment was 
circularized by adding biotinylated internal adaptors. Upon restriction digest, fragment 
containing each ends (5’ and 3’ end) of genomic fragment were released to be further 
ligated with SOLiD sequencing adaptors, and PCR amplified for high-throughput 




After massively parallel sequencing, the PETs are mapped back to the reference 
genome by examining the tags orientation and size of insert DNA fragments. Both 
5’ and 3’ PETs with incorrect tags orientation, larger or shorter mapping distance, 
or located in different chromosomes are referred to as discordant PETs (dPETs) 
that are indicative of SVs, with classification as illustrated in Figure 4.  
 
Figure 4. Classification of SVs based on dPET mapping criteria.  
Balanced translocation is characterized by two paired-end reads that are mapped at 
different chromosomes. Inversion is classified by two paired-reads in adjacent 
coordinates showing reverse strand orientation in the same chromosome. Deletion is 
detected when two paired reads with the same orientation are mapped in a longer 
distance. Unpaired inversion is recognized by a single paired reads in a reverse 
orientation. Isolated translocation is classified by a single paired end reads that is located 




These discordant mapping criteria allowed the identification of large SVs in a 
single sequencing run; this was previously not feasible using conventional 
methods. DNA-PET sequencing requires validation by longer-read sequencing 
such as Sanger method, or FISH analysis for accurate SVs annotation. However, 
DNA-PET is limited to the identification of large SVs, and it is unable to detect 
point mutations or SNVs. This strategy has been applied by several groups from 
our institute to study complex genomic architecture of cancer genome and 
revealed distinct hard-wired patterns of somatic rearrangements.(136-138) To 
apply such a technique in the identification of germline and de novo SVs in 
human disorders, several adjustments in the filtering criteria were necessary to 
provide less stringent threshold and normalized parameter compared to cancer 
genomes. Cross-comparison of investigated genomes to other normal genomic 
libraries enabled exclusion of germline SVs found in normal population, which 
usually accounts for >95% of identified SVs. Sequencing artifacts produced by 
chimeric ligation products during library construction or technical noise were 
removed by using filtering criteria described in the Method (Chapter 2).  
In principle, the DNA-PET sequencing with its capabilities to detect balanced and 
unbalanced rearrangements is attractive to apply in mapping the breakpoints of 
chromosome rearrangements for novel disease gene identification.  As it has been 
described in the earlier part of this chapter, many studies have documented 
disease-associated chromosomal rearrangements that were identified through 
breakpoint-cloning method. DNA-PET sequencing is an ideal method to apply in 
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such a setting to rapidly pinpoint the breakpoint regions of chromosomal 
rearrangements that segregate with disease phenotypes in familial cases, or rare de 
novo events. Potentially, DNA-PET can be applicable to examine non-syndromic 





1.7 THESIS AIMS 
In this thesis, I focused primarily on the functional impact of chromosomal 
rearrangements in NDDs. The major aims of this thesis are: (i) to explore the 
application of DNA-PET in mapping disrupted genes within chromosomal 
rearrangements for identification of novel NDDs genes, and (ii) to functionally 
validate selected candidate genes by various disease modeling strategies. The 
schematic workflow of the thesis is outlined in Figure 5.  
 
Figure 5. Study design of the thesis. Seven patients were included for this study, of 
which three of them were suspected of certain phenotype and undergone specific 
genetic/metabolic testing, in addition to the routine G-banding karyotyping and aCGH. 
Four other patients were undiagnosed and only tested for chromosome analysis. Each of 
these patients carried chromosomal rearrangements that have been identified prior to 
DNA-PET sequencing. These patients were then analyzed by DNA-PET sequencing, 
followed by SVs filtering analysis and validation to identify candidate genes. After 
extensive analysis, several candidate genes were selected for further functional 




Chapter 1 describes an overview of NDDs, the strategy of clinical/genetic 
evaluations to assess patients, and followed with the causes and pathophysiology 
of NDDs. To begin with the discovery of candidate genes, the patients were 
selected by the clinical geneticists. These subjects belonged to the non-syndromic 
NDDs category and had undergone exhaustive genetic testing and each of them 
carried distinct but previously undescribed chromosomal rearrangements. The 
clinical data of these patients and execution of the experimental methodologies 
will be explored in Chapter 2. 
 DNA-PET sequencing is utilized as the main approach to pinpoint the 
chromosomal breakpoints in these patients, and to detect additional clinically 
relevant variants from sequencing data. The results obtained from sequencing data 
and variants analysis for each patient is described in detail in Chapter 3. 
Focusing on one candidate gene, MED13L, Chapter 4 will delineate the 
functional impact of its disruption on neural-crest derived organs and its 
correlation to ID phenotypes based on assays performed in zebrafish and human 
embryonic stem cells-derived neurons. Follow-up validation on another candidate 
gene, GTDC1, will be explored by using induced pluripotent stem cells derived-
neurons in Chapter 5. Ultimately, these data offer broad perspectives on altered 
gene dosage as a result of chromosomal rearrangements and provides an insight 




CHAPTER 2: MATERIALS AND METHODS 
2.1 PATIENT SAMPLES AND CLINICAL INFORMATION 
All DNA samples were obtained from peripheral blood lymphocytes or cultured 
skin fibroblasts of patients seen in the Children’s Hospital of Westmead in 
Sydney, Australia, Centre Hospitalier Regionale d’Orleans in Orleans, France and 
Centre Hospitalier Regional University de Montpellier, Hospital Arnaud-de-
Villeneuve, Montpellier, France as described in Table 3.  Patient samples and 
clinical data were collected after written informed consent from patient’s parents 
was obtained, in accordance with local Institutional Review Board (IRB) 
approved protocols from National University of Singapore in Singapore, 
Children’s Hospital Westmead in Sydney, Australia, Centre Hospitalier Regional 
University de Montpellier, Hospital Arnaud-de-Villeneuve, Montpellier,  in 






from the hospital 
CD5 Centre Hospitalier Regionale d’Orleans France EBV-LCL 
CD6 Centre Hospitalier Regionale d’Orleans  France EBV-LCL and 
Fibroblast 
CD14 Centre Hospitalier Regionale d’Orleans  France EBV-LCL 
CD8 Children’s Hospital of Westmead Sydney Fibroblast 
CD9 Children’s Hospital of Westmead Sydney gDNA 
CD10 Children’s Hospital of Westmead Sydney gDNA 
CD23 Centre Hospitalier Regional University de 
Montpellier 
France EBV-LCL 
Table 3. List of patients and participating hospitals included in this study. Patients 
were recruited by the clinicians in the hospital. Source of samples obtained from each 
hospital were indicated: EBV-LCL; Eppstein-Barr virus lymphoblastoid cell lines, 





Figure 6. Patients’ pedigree and their partial karyotypes indicating the 
rearrangements.  
Seven patients were included in the study. Patients IDs are assigned as (CD(number)) 
corresponding to the clinical description for each patient below. Prior karyotypic analysis 
identified unique chromosomal rearrangements in each patient, and the karyotype is 
indicated below the pedigree. Filled boxes/circles indicated male/female probands having 
chromosomal rearrangements, along with a phenotype, and dotted boxes/circles indicated 
unaffected carriers. Patients that were analyzed by DNA-PET sequencing are indicated 
by the red arrow. Abbreviations are as follows: LD, Language Delay; DD, 




2.1.1 PATIENT CD5 
This case is a familial balanced translocation detected in a father and his two sons 
presenting with variable degrees of NDD features. The first son displayed autistic 
behavior and global DD at three years of age with absence of speech, feeding and 
sleeping difficulties, and stereotypic movements. At 4 years of age he showed 
improvement in communication and speech. Chromosome analysis revealed a 
translocation 46,XY,t(9;17)(q12q24) (Figure 6), which is in common with his 
father and sibling. During genetic counseling the father reported that he suffered 
from LD and DD during childhood that was not explored at that time, and that had 
resolved by adolescence. His second son was found to have DD and autistic 
features at the age of two years. The father’s (Patient CD5) DNA was obtained for 
DNA-PET sequencing and downstream analysis. Breakpoint analysis by Sanger 
sequencing was performed on both sons. Chromosome analysis in the 
phenotypically normal biological mother of the two affected sons revealed a 
normal karyotype.  
2.1.2 PATIENT CD10 
The patient was born at term by lower segment Caesarean section, due to breech 
presentation. Delay in developmental milestones was noted at 18 months of age 
involving both walking and speech. At 9 years old, comprehension and 
behavioural difficulties were noted at school. Karyotype analysis revealed a 
balanced translocation 46,XX,t(6;8)(q16.2;p11.2) (Figure 6). Metabolic screening 
and FRAXA testing were normal. Karyotypic analysis in his parents revealed that 
the translocation was derived from his mother, and she had no intellectual 
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difficulties, but was reported to have had a ‘hole in the heart’ in childhood that 
closed spontaneously. His mother had another subsequent pregnancy and 
amniocentesis revealed a female fetus with the same balanced translocation. This 
second child was noted to have plagiocephaly soon after birth and had feeding 
difficulties in early infancy, which gradually resolved. At 2 years old, his sister 
had LD with low-average fine motor and gross motor skills. Right intermittent 
exotropia was noted. An MRI brain scan showed closed lip schizencephaly 
involving the right frontal lobe with polymicrogyria in the right Sylvian fissure. 
MRI brain scans in her brother and mother were normal.  
2.1.3 PATIENT CD8 
Patient CD8 was one of monozygotic twins (Figure 6). At the age of three years, 
he had an acute EBV infection with prolonged hepatosplenomegaly and 
abnormality of liver function tests. Immunological investigations showed reduced 
IgM, decreased CD4 T-helper cells and decreased natural killer (NK) cell 
function. At the age of five years, mild ID was diagnosed, as well as a specific 
language disorder affecting his receptive and expressive skills. Both twins had 
articulation problems with velo-pharyngeal incompetence. In view of the 
velopharyngeal incompetence, 22q11.2 FISH (TUPLE1) was requested and the 
result was normal. Karyotype analysis revealed a complex inversion 
46,Y,inv(X)(?p22?q26) (Figure 6), derived from his phenotypically normal 
mother. His identical twin showed similar clinical features and carried the same 
karyotype. His maternal uncle was reported to have recurrent infections and a 
maternal great uncle died at eight months of age, due to liver abnormalities, 
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emphasizing that the male carriers of this inversion in this family had features of 
X-linked lymphoproliferative disease. In view of possible features of Duncan 
disease or XLP-1 due to SH2D1A mutations, western blot analysis performed on 
the patient’s whole cell lysates of mononuclear cells showed normal expression of 
SAP, protein encoded by SH2D1A. 
2.1.4 PATIENT CD9 
The patient was born by normal delivery after an uneventful pregnancy. Mild 
delay in early motor and speech developmental milestones was reported. At age 
twelve, he was found to have average intellectual ability, an expressive language 
disorder, and specific learning difficulties in maths, spelling and reading; as well 
as attention deficit disorder. Chromosome analysis revealed a paracentric 
inversion of chromosome 5: 46,XY,inv(5)(q22q35.1) (Figure 6). Both parents 
have normal karyotypes and did not show any phenotypic abnormality.  
2.1.5 PATIENT CD14 
The patient was the only child of a young, healthy and unrelated couple. The 
patient was born at 38 weeks by caesarean section. At 8 months, psychomotor 
delay was noted and confirmed at 20 months. Clinical examination at the age of 7 
years 9 months showed a relatively small-sized boy with microcephaly (-4.7 SD 
for age). Physical examination revealed slightly down-slanting palpebral fissures, 
deep-set eyes, flat nasal bridge, bulbous nasal tip, large dysplastic posteriorly 
rotated ears, widely spaced nipples, dorsal kyphoscoliosis, bilaterally tapering 
fingers, unilateral simian crease, shawl scrotum and hypoplastic genitalia. 
Neurological examination showed axial hypotonia with hypertonia of the lower 
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limbs. The patient had psychomotor retardation with absence of speech. Brain 
magnetic resonance imaging showed microcephaly at age 14 months and at 7 
years 8 months. His electroencephalogram was normal for his age and he did not 
have a history of seizures. Chromosome analysis revealed a normal karyotype, 
and telomeric FISH showed a subtelomeric deletion of the long arm of 
chromosome 7q (Figure 6), which was inherited from his asymptomatic father.  
2.1.6 PATIENT CD6 
The patient is the fifth child from a second marriage of a healthy mother and 
father. During pregnancy, amniocentesis was done for advanced maternal age and 
revealed a de novo translocation 46,XY,t(2;8)(q23;q21) (Figure 6). Ultrasound 
examination was normal and the pregnancy continued to term. The baby was born 
at term with Apgar score of 10 at both 1 and 5 minutes. At the age of two years, 
he presented with global DD without dysmorphic features or growth delay. He 
had excessive salivation and deep tendon reflexes. He initially walked on tiptoe, 
but subsequently reverted back to normal by six years of age. At the age of four 
years, he had cognitive difficulties, SD and LD. DNA of the patient, and both 
biological parents were used for DNA-PET analysis. Mother and father are 
referred to as CD15 and CD16, respectively.  
2.1.7 PATIENT CD23 
The patient is the only child of healthy and unrelated parents. She was diagnosed 
with Pierre-Robin sequence at birth, characterized by cleft palate, glossoptosis 
and retrognathia, which was corrected by surgery. She had multiple limb 
contractures and camptodactyly, including metatarsus adductus of the thumb and 
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bilateral equinovarus foot deformity. At 4 years of age she had language 
difficulties with absence of speech. Other developmental milestones were 
significantly delayed and she required special education. Physical examination 
revealed dysmorphic features including flat occiput, hypertelorism, flat philtrum, 
and broad nasal bridge. Strabismus and hirsutism were noted. Additionally, she 
had scoliosis during puberty (about 14 years). Her EEG showed epileptiform 
discharges and she was seizure-free on anti-epileptic drug treatment. 
Chromosome analysis revealed a balanced translocation between chromosome 12 
and 19. Both parents had normal karyotypes and did not show any phenotypic 
abnormality. Array-CGH performed on the patient’s genomic DNA showed no 
additional chromosomal imbalances.  
2.2 G-BANDING KARYOTYPE  
 Karyotypes were determined from G-banding analysis using standard protocol 
according to the ISCN nomenclature, which was performed in the participating 
hospitals. Subsequent G-banding karyotype confirmation was performed for each 
patient samples by the Cytogenetics Unit, Genome Institute of Singapore (GIS).  
Metaphase chromosomes were prepared from Epstein-Barr virus-transformed 
lymphoblastoid cell lines (EBV-LCL) or cultured skin fibroblast cells obtained 
from patients, parents or siblings.  
2.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)  
FISH was performed on metaphase chromosomes using standard protocols.(139, 
140) BAC and fosmid probes were obtained from BACPAC Resources, CHORI. 
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Probes were labeled by nick-translation kit (Enzo) with Biotin-16-dUTP or 
Digoxigenin-11-dUTP (Roche). The probes were blocked with 1 µg/µl Human 
Cot1 DNA (Life Technologies), and were resuspended at a concentration of 5 
ng/µl in hybridization buffer (2xSSC, 10% Dextran Sulfate, 1x PBS, 50% 
Formamide). Prior to hybridization, metaphase slides were pre-treated with 0.01% 
pepsin for 5 min at 37 C followed by 1x PBS rinse, 1% formaldehyde 10 min 
treatment, 1xPBS rinse (5 min) and dehydration through ethanol series (70%, 
80%, and 100%). Probes and slides were co-denatured for 5 min at 75 C and 
hybridized overnight at 37 C. After post-hybridization washes, the slides were 
revealed with avidin-conjugated fluorescein isothiocyanate (Vector Laboratories) 
or anti-Digoxigenin-Rhodamine (Roche). Slides were mounted with VectaShield 
(Vector Laboratories) and observed under an upright fluorescence Nikon 
microscope. Image analysis was performed using ISIS Metasystems software.   
2.4 GENOMIC DNA ISOLATION 
Genomic DNA from EBV-LCL, fibroblast, or blood from the patient was 
extracted by Qiagen Blood and Cell Culture DNA Kits (Qiagen), according to 
manufacturer’s instruction. EBV-LCL and fibroblast cell lines were maintained to 
a minimum number of passages prior to DNA extraction. Quality and quantity of 
the extracted DNA were measured using NanoDrop 1000 Spectrophotometer and 





2.5 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION 
(ACGH) 
aCGH was performed in all patient samples using the SurePrint G3 Human 2 x 
400k aCGH Microarray (Agilent Technologies Inc. Santa Clara) according to the 
manufacturer’s instruction. The microarray slides were scanned on the Agilent 
Microarray Scanner. Data were processed by Genomic Workbench software, 
standard edition 5.0.14 (Agilent). The Aberration Detection Method (ADM-2) 
algorithm was used to identify DNA copy number variations (CNV). The ADM-2 
algorithm identified all aberrant intervals in a given sample with consistently high 
or low log ratio based on the statistical score. Filtering option of minimum of 
three probes in region was applied and using a centralization threshold of 6. NCBI 
Build 36 was used as a reference genome. To compare the detection rate between 
aCGH and DNA-PET, aCGH raw data was used as a standard to validate small 
CNVs identified by DNA-PET and interpreted the copy number change by 
looking at the individual probe ratio, using a cutoff of 0.1 (<0.1 indicated 
deletion, >0.1 indicated duplication).  
2.6 DNA-PET 
DNA-PET libraries were constructed for seven patients and two parents of one 
patient according to Hillmer et al.(136). Briefly, genomic DNA was hydrosheared 
to 7-11 kb DNA fragments. Long Mate Paired (LMP) cap adaptors were ligated to 
the hydrosheared and end repaired DNA fragments. The cap adaptor-ligated DNA 
 46 
 
fragments were separated by agarose gel electrophoresis, recovered using the 
QIAEXII Gel Extraction Kit (QIAGEN) and circularized with a biotinylated 
adaptor that connects the cap adaptors at both ends of the DNA fragments. 
Missing 5’ phosphate groups of cap adaptors created a nick on each strand after 
circularization of the DNA. Both nicks were translated outwards by >50 bp into 
the circularized genomic DNA fragment by DNA polymerase I (NEB). The nick-
translated constructs were then digested with T7 exonuclease and S1 nuclease 
(NEB), to release paired-end tag (PETs) library constructs. These constructs were 
ligated with SOLiD sequencing adaptors P1 and P2 (Life Technologies), and 
amplified using 2x HF Phusion Master Mix (Finnzymes OY) for sequencing.  
High throughput sequencing of the 50 bp libraries was performed on SOLiD 
sequencers (v3plus and v4, respectively) according to the manufacturer’s 
recommendation (Life Technologies), for all samples except for the mother of 
Patient CD6. Sequence tags were mapped to the human reference sequence 
(NCBI Build 36) and paired using SOLiD System Analysis Pipeline Tool 
Bioscope, allowing up to 12 color code mismatches per 50 bp tag and up to 4 
color code mismatches per 35 bp tag. For sample CD5 and CD8, two DNA size 
fractions were merged during library construction due to technical optimization in 
the early stage of this project, which resulted in a reduced sensitivity to identify 
small deletions and low physical coverage.   
2.7 POST-SEQUENCING ANALYSIS 
The majority of the PET sequences mapped accordingly to the reference genome 
NCBI Build 36 (concordant PETs or cPETs) with expected mapping orientation 
 47 
 
(5’ tag to 3’ tag) and expected mapping distance (according to the selected 
fragment size). The distribution of cPET in the genome was used to compute copy 
number information based on random simulation of different blocks of genomic 
fragments over the coverage, according to the Supplementary Methods in Hillmer 
et al. (136) Briefly, the genome was divided into non-overlapping windows of 
equal size that was set as a parameter, and relies on the overall coverage of the 
sequence data. PETs of 1x genome coverage were simulated by generating 
randomly distributed fragments across the reference genome adjusted to the size 
distribution of the actual experimental library and the tags at both ends of the 
fragments were subsequently extracted. The simulated tags were then mapped 
back to the reference genome, and paired using the same ABI SOLiD mapping 
and pairing pipeline. The tag density in each window was then corrected for its 
mappability by computing the ratio of number of mapped tags of the experimental 
library to the simulated library within the window, thus referred to as cPETs. 
The remaining portion of the PETs mapped discordantly to the reference genome 
(discordant PET or dPETs), classified as those with incorrect paired-tag 
orientation and incorrect genomic distances. These dPETs provided information 
to search for genomic rearrangements; with specific criteria for different types of 
SVs according to PET mapping orientation and genomic region, as described in 
the Figure 4 (Chapter 1.6). The overlapping dPETs representing similar SVs were 
clustered together as dPET clusters and counted as the cluster size, according to 
the criteria described in the Supplementary Method of Hillmer et al. (136) with 
refined data curation as described in Ng et al.(138) as described below:  
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(i) to obtain a 5’ and 3’ anchor region, the mapping location of the 5’ and 3’ tags 
of dPET was extended by the maximum insert size of the respective genomic 
library in both directions; (ii) if the 5’ and 3’ tags of a second dPET mapped 
within 5’ and 3’ window of the first dPET, the two PETs are defined as a cluster 
of the size 2, and the 5’ and 3’ windows were extended to match the size of the 
second dPET; (iii) the number of dPETs clustering together overlapping similar 
genomic position was represented by cluster size.  
The following criteria were applied to remove sequencing artefacts for annotation 
of germline SVs: (i) dPET clusters with anchor regions of less than 1,000 bp were 
excluded; (ii) dPET clusters of size 6 or higher were considered a stringent cutoff 
to reduce the number of false positives; (iii) dPET clusters with potential 
sequence homology between aligned breakpoints (BLAST scores) of more than 
2000, as these SVs were difficult to validate by PCR due to high sequence 
homology. 
2.8 FILTERING OF NORMAL STRUCTURAL VARIATION (SVS) 
Comparison of clusters across different genomes was performed as described by 
Ng et al.(138). The normal SVs were filtered using the following data sources: (i) 
in-house DNA-PET data of 23 normal individuals (25 DNA-PET data sets); (ii) 
the pilot release set of 1000 Genome Project  from Mills et al. (141); (iii) 
published SVs identified from paired-end sequencing studies of 18 normal 
individuals(92, 95); and (iv) the DGV. The fraction of predicted SV which 
overlapped with a published SV was calculated by the percentage of overlap 
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relative to the larger event, with a cutoff of 80% or more for filtration of shared 
SVs with normal individuals. Thus, SVs seen in normal individuals were 
excluded, with the assumption that they are less likely to underlie the disease, 
although this stringent analysis could potentially miss common variants with 
reduced penetrance of the disease in the population.  
For the identification of matching SVs within the parent-offspring trio in patient 
CD6, cross-genome comparison was generated for the trio, including normal 
individual datasets. Filtering of sequencing artifacts were performed according to 
DNA-PET data curations. SVs were classified into; (i) maternal-identical SVs, 
shared between mother and offspring, (ii) paternal-identical SVs, shared between 
father and offspring, (iii) identical germline SVs, shared within the trio and 
presumably found in normal population, (iv) non-identical SVs, de novo SVs 
exclusively found in the offspring, (v) total SVs in each individual, paternal, 
maternal or offspring. The rates for maternal and paternal inheritance were 
calculated using the percentage of maternal/paternal-identical SVs to the total 
number of maternal/paternal SVs. Filtration of normal SVs, and parental SVs 
(maternal-identical SVs and paternal-identical SVs) resulted in specific de novo 
SVs found in the offspring.  
2.9 FUNCTIONAL ANALYSIS OF REGULATORY REGIONS  
The hg18 coordinates of genomic regions from each patient’s SVs list were 
converted to hg19 in LiftOver from UCSC genome browser. SVs occurring within 
intronic region of genes or non-coding regions were assessed for the probability 
 50 
 
score of functional regulatory regions in RegulomeDB and ENCODE data in 
UCSC genome browser.(142, 143) RegulomeDB score of 1-2 indicates functional 
binding site of certain transcription factor.(144) 
2.10 VALIDATION OF BREAKPOINTS BY SANGER 
SEQUENCING 
Primers were designed by Primer3 program (http://primer3.ut.ee), and the 
amplicons spanning the breakpoint were predicted by dPET clusters according to 
human genome assembly NCBI Build 36. PCR was carried out with JumpStart 
REDAccuTaq LA polymerase (Sigma Aldrich) in a 50 µl reaction volume and 
with 100-500 ng of genomic DNA as a template. The following program was 
used: i) Initial denaturation at 96 C for 30 sec, ii) 40 cycles of 15 sec at 94, 30 
sec at 58C, 10 min at 68, iii) 68C for 10 min. PCR products showing single 
bands were purified by Gel Extraction Kit (Qiagen) and used as templates for 
sequencing in both directions by Sanger sequencing. The sequences of junction 
fragments were aligned to the human genome reference sequence using Blat in 
UCSC Genome Browser (145) . 
2.11 QUANTITATIVE REAL TIME PCR (QPCR) 
Total RNA was extracted from patient’s EBV-LCL or fibroblasts using RNAeasy 
kit (Qiagen). Reverse transcription of 2 µg RNA derived from patients, 2 
lymphoblast controls, 2 fibroblast controls and commercially available human 
tissue panel RNA (Clontech) was performed in 20 µl of SuperScript III Reverse 
Transcriptase reaction buffer (Life Technologies) using random hexamer primers. 
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qPCR reactions were performed in the ViiA7 Real Time PCR system (Life 
Technologies) with ten-fold dilution of cDNA, 200 nM of each primer using the 
SybrGreen PCR Master Mix (Life Technologies). Data were analyzed using 2
∆∆Ct
 
method, and normalized against control sample with human ACTB. Each 
measurement was performed in triplicate. The controls used in this study are 
derived from EBV-LCL or skin fibroblast cells of 4 normal individuals. Primers 
used to quantify transcript expression of affected genes in patients are listed in 
Table 4.  
Primer Name Primer Sequence Primer Location 
GNAQ F1 GGACAGGAGAGAGTGGCAAG exon 2 
GNAQ R1 GAGTGTGTCCATGGCTCTGA exon 2 
RBFOX3 F1 GCCACGGCCCGAGTGATGAC exon 8 
RBFOX3 R1 ACACGACCGCTCCGTAAGTCG exon 10 
UNC5D F1 GCACTTCTCTTTGTCCTGTGG exon 1 
UNC5D R1 TTCTCAATGCTTTGGGGTTT exon 2 
XIAP F1 CAACACTGGCACGAGCAGGG exon 1 
XIAP R1 CATGGCAGGGTTCCTCGGGT  exon 2 
XIAP F2 GCTGGATTTTATGCTTTAGGTGA exon 2 
XIAP R2 ACCAGACACTCCTCAAGTGAA exon 3 
TMEM47 F1 AGCCTGGTCCTTTACCCAAT exon 3 
TMEM47 R1 AGGGTTCAGGCAATAAAGGA exon 3 
TMEM47 F2  TTCTCATTGCATTCCTGGTG exon 2 
TMEM47 R2  TTAGGGTTCAGGCAATAAAGGA exon 3 
SH2D1A F1 AGGCGTGTACTGCCTATGTG exon 1 
SH2D1A R1 TGCAGAGGTATTACAATGCCTTG exon 2 
ODZ1 F1 GCAACCAGTTGAAGGAGAGC 
 
exon 6 
ODZ1 R1 ACGCCAGAATAAACCAGGTG 
 
exon 7 
NCAPG2 F1 AAGAAAGTTCGGCAGGGAGT exon 10 
NCAPG2 R1 TGCAGCATTTGATCGAACTT exon 11 
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NCAPG2 F2 AAGAGGACGGAAGGGAGAAG exon 15 
NCAPG2 R2 GGAAGCACAGAGGCAAACTT exon 16 
MCPH1 F1 AGGAAAACTTACCCGGAGGA exon 8 
MCPH1 R1 AGGTCCTTAAAGCCGTCACA exon 9 
MCPH1 F2 TCCTGAAAGATGTAGTGGCCT exon 1 
MCPH1 R2 TGTCCCAAGTGCTCTGGTAG exon 2 
MCPH1 F3 CTACCAGAGCACTTGGGACA exon 3 
MCPH1 R3 AGCTGCAGGGAACAATGATTC exon 4 
GTDC1 F1 CACAGGTGGGAGCATGATAA exon 6-7 
GTDC1 R1 CAACATTGCCACTCCAAAGA exon 8 
GTDC1 F2 CAGGACCCTCTTTGCAAGTT exon 3-4 
GTDC1 R2 GGCATGAATCTGCTCACATC exon 5 
GTDC1 F3 CAGACCCAAGGATCTGGAAA exon 5 
GTDC1 R3 CTCTGCTCTGGCTGAAAAGG exon 6 
MED13L F1 GAGCCTGGAGGATTGTCACT exon 1 
MED13L R1 GACATCACGACGCCATACAC exon 2 
MED13L F2 AGTGAGCATTTGTCCTGTGCT exon 5 
MED13L R2 CTGCATACCTCCACTCTCACC exon 8 
MED13L F3 CTGCAGCCACTTTCATTAGAGAT exon 16 
MED13L R3 TCGGAGAGAATCAGGGTAACATA exon 17 
MED13L F4 TCTGCCTCTGCTCCTGGTAT exon 21 
MED13L R4 CATCAAGCTCAACAGCCAAA exon 22 
Table 4. qPCR primers used to measure transcript level in the EBV-LCL for each 
patient and human tissue panel. One or more candidate genes were tested for each 
patient as follows: (i) Patient CD5: GNAQ and RBFOX3; (ii) Patient CD10: UNC5D; 
(iii) Patient CD8: XIAP, TMEM47, SH2D1A, and ODZ1; (iv) Patient CD14: MCPH1 





2.12 CNV ANALYSIS FROM PUBLISHED STUDIES 
CNV information within genes from 10,151 cases of DD and 8,329 adult controls 
were extracted from published data by Cooper et al.(72) and from DECIPHER 
data base (with a collection of >17,000 cases). These data were used to obtain 
CNV counts within our listed candidate genes. For control dataset, the first SVs 
release set of 1000 Genome project consisting of 185 individuals was used. CNVs 
were counted in both cases and controls of the candidate genes in these datasets. 
Chi-square test was performed from comparison of CNV counts present in cases 
versus controls.  
2.13 FUNCTIONAL ANALYSIS BY PLURIPOTENT STEM CELLS 
2.13.1 CELL LINES USED AND MAINTENANCE 
Human embryonic stem cells (hESCs) H1 cells and induced pluripotent stem cells 
(iPSCs) were grown in feeder-free conditions on Matrigel-coated plates (BD 
Biosciences) in mTESR1 media (Stem Cells technologies). 
2.13.2 INDUCTION OF IPSC FROM FIBROBLAST 
Human fibroblasts were reprogrammed to iPS cells by retroviral transduction of 
transcription factors following established protocols(146). For virus production, 
293-GP2 viral packaging cells (Clontech) were plated at 80% confluence per 100-
mm dish and transfected with 8μg of each retroviral vectors (plasmids expressing 
OCT4, KLF4, c-MYC and the mouse Sox factor) and 8 μg of VSVG plasmid 
using Fugene6 (Roche) following the manufacturer’s instructions. The virus-
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containing media was collected 48 hours after transfection, filtered through a 0.45 
μm pore-size cellulose acetate filter (Whatman), and concentrated using Amicon 
ultra centrifugal filter units (Millipore) during 15 minutes at 3,000 rpm. Fibroblast 
culture was then infected with virus-containing media with four reprogramming 
factors mixed in equal volumes. The media was changed the next day. After 2 
days, the cells were refreshed with human ES media containing DMEM/F12 (Life 
Technologies) supplemented with 20% Knock-out serum and 10ng/ml of bFGF 
(Life Technologies). ES-like colonies were picked and transferred into 24-well 
plates, followed by mild trypsinization overnight, and the media was changed the 
next day. Picked iPSCs were further expanded for further characterization in 
feeder free condition.   
2.13.3 NEURAL PROGENITOR CELLS DIFFERENTIATION 
NPC differentiation of ESCs and iPSCs was done based on established 
protocols(147). Cells were first plated in clumps on matrigel-coated 6 well-plates 
using mTESR1 media in a concentration of 5  104/cm2. The following day, the 
media was changed with NPC media composed of (1:1) DMEM-F12/Neurobasal 
media (Life Technologies) supplemented with N2 and B27 without vitamin A 
supplements (Life Technologies) and CHIR99021 (4µM), SB431542 (3µM), 
CompoundE (0.1µM) and human LIF (10 ng/ml). After 7 days, cells were 
passaged using Accutase at 1:6 dilution (Sigma-Aldrich) and grown in the same 
media using CHIR99021 (3µM) and SB431542 (2µM) together with LIF 




2.13.4 NEURONAL DIFFERENTIATION 
For neuronal differentiation, NPCs were plated on poly-L-ornithine/Laminin-
coated plates at a density of 200,000 cells per 6 well (approximately 20,000 
cells/cm
2
) and grown in (1:1) DMEM-F12/Neurobasal (Gibco) media 
supplemented with N2 and B27 supplements (Gibco) together with GDNF 
(20ng/ml) (R&D systems), BDNF (20ng/ml) (R&D systems), dibutyryl-cyclic 
AMP (1mM) (Sigma-Aldrich) and Ascorbic Acid (200nM) (Sigma-Aldrich) for 
four weeks. For characterization, neurons were passaged using Accutase and re-
plated at very low density (5,000 cells per 24 well) on poly-L-ornithine/Laminin 
coverslips. 
2.13.5 PSUPER SHRNA CLONING AND TRANSFECTION 
ShRNA sequences targeting candidate genes were designed through Dharmacon 
shRNA design software: (http://www.dharmacon.com/designcenter 
/designcenterpage.aspx.) and oligos were purchased commercially (IDT 
Technologies). The sequences of the oligos are as follows: 









 Table 5. shRNA sequences for cloning into pSUPER vectors. shRNAs were designed 
to target MED13L gene and cloned into pSUPER-Neo vector for stable transfection into 




Oligos were annealed using the annealing buffer (100 mM Tris Buffer pH 8.0, 10 
mM EDTA pH 8.0, 5 M NaCl in H2O) in 50 µl reactions. The reaction is 
incubated as follows: 90 for 4 minutes, 70 for 10 minutes, 60 for 10 minutes, 
50 for 10 minutes, 37 for 20 minutes, and 20 for 5 minutes. pSUPER-Neo  
plasmid (OligoEngine) was used for shRNA cloning. Approximately 5 µg of 
plasmid was linearized using BglII (40 U) and HindIII (10 U) for 4 hours at 37 
C. Linearized plasmid was checked for a single band using agarose gel 
electrophoresis, and purified using QiaQuick PCR Purification Kit (Qiagen). 
Annealed product was used for ligation reaction with the linearized plasmid with 
the following composition: 2 µl of annealed Oligos, 1 µl of T4 Ligase buffer, 500 
ng of linearized pSUPER plasmid, 1 µl of T4 Ligase enzyme in 10 µl ligation 
reaction.  
The ligation reaction was incubated overnight at 16 C. On the next day, 
approximately 5 µl of ligation reaction was added to 25 µl of One Shot TOP10 
Competent cells (Invitrogen), and incubated on ice for 30 minutes. Heat shock 
reaction was performed at 42 C for 45 seconds, and directly incubated on ice for 
2 minutes. SOC medium was added to the mixture, and incubated in the 37 C 
horizontal shakers for 1 hour. The transformation reaction was inoculated to the 
LB plate with 100 µg/ml Ampicilin, and grown overnight at 37 C. Single 
colonies were picked and grown in 3 ml LB/Amp for plasmid isolation using 
Qiagen Miniprep (Qiagen). Positive clones were selected upon digestion with 
EcoRI (10 U) and HindIII (10 U), showing 280 bp fragments on agarose gel 
electrophoresis. Negative clones showed 220 bp fragment size. Positive clones 
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were stored in glycerol stock, and amplified for plasmid transfection using Endo-
Free Plasmid Maxi kit (Omega-Biotek). Approximately 2.5 µg of plasmid DNA 
was transfected to hNPCs by Fugene6 Transfection reagent (Promega). 
2.13.6 SHRNA VECTOR FOR GTDC1 
Pre-designed pLKO.1 vectors harboring a shRNA sequence targeting GTDC1 
were obtained commercially (Sigma-Aldrich). The sequences of the duplexes are 
shown in Table 6.  







Table 6. shRNA sequence for GTDC1. shRNAs were selected based 
AGGTCACCACCTGCGC on commercially available lenti-shRNAs for GTDC1. 
 
Viral particles were produced using the pLKO.1 protocol available online and 
concentrated using Amicon ultra centrifugal filter units (Millipore) during 15 
minutes at 3000x rpm and 4
o
C. For infection, NPCs derived from H1 human ES 
cells were seeded in 6-well plates at about 200.000 cells per well in NPC medium. 
Following infection, the medium was replaced with fresh media.  
2.13.7 EDU PROLIFERATION ASSAY  
Proliferation assay was quantified by using 5-ethynyl-2´-deoxyuridine (EdU) 
incorporation kit, Click-iT EdUAlexa Fluor 647-Flow assay (Molecular Probes, 
Life Technologies, USA). EdU (20 µM) was added into NPCs for 2 hours and 
incubated in 37
o
 C, 5% CO2 incubators. Cells were harvested after 2 hours. Click-
IT reaction was performed according to manufacturer’s protocol (Molecular 
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Probes). The percentages of EdU-incorporated cells were quantified by using BD 
LSR II Flow Cytometry analyser in Biopolis Shared Facility.  
 
2.13.8 IMMUNOCYTOCHEMISTRY 
Cells were plated on ethanol-treated coverslips and fixed with 4% 
paraformaldehyde in phosphate buffered saline (PBS) at 4 C for 1 hour and 
incubated with Tris Buffer Saline (TBS) containing 5% of FBS, 1% BSA (Bovine 
Serum Albumin, Sigma-Aldrich) and 0.1% of Triton X-100 (Sigma-Aldrich) for 
45 minutes at room temperature. Primary antibodies were incubated with fixed 
cells overnight at 4°C, and cells were subsequently stained with secondary 
antibody conjugated to Alexa Fluor 594 or 488 (Molecular probes) (4 ug/ml) for 1 
hour at room temperature in the dark. Images were captured using a ZEISS 
AxioObservor DI inverted fluorescence microscope (Carl Zeiss International). 




Antibody  Cat. No. Company Species Working 
dilution 
Oct4 Sc8628 Santa Cruz Goat 1:250 
SSEA1 Sc21702 Santa Cruz Mouse 1:100 
Nanog Sc30328 Santa Cruz Goat 1:100 
Nestin MAB353 Millipore Mouse 1:500 
Nestin Ab22030 Abcam Mouse 1:500 
Musashi AB5977 Millipore Rabbit 1:500 
Pax6 PRB-278P Covance Rabbit 1:100 
Ki67 7B11 Life technologies Mouse 1:100 
NeuN MAB377 Millipore Mouse 1:100 
TuJ1 MMS-435P Covance Mouse 1:500 
Map2 A2320 Millipore Mouse 1:1000 
TuJ1 PRB-435P Covance Rabbit 1:2000 
Med13l Ab87831 Abcam Rabbit 1:100 
Icam1 BBA3 R&D system Mouse 1:100 
Table 7. List of primary antibodies used in this study. These antibodies are used to 
characterize pluripotency (Oct4, Nanog, and SSEA1), differentiated neural progenitors 
(Nestin, Musashi, and Pax6), proliferation capacity (Ki67), neuronal state (NeuN, TuJ1, 
and Map2), candidate gene (Med13l), and glycosylation status (Icam-1). 
 
2.13.9 IMMUNOCYTOCHEMISTRY QUANTIFICATION ANALYSIS 
To determine the proportion of positive cells in each sample, images were 
captured at 40 magnification from at least five randomly selected areas. ImageJ 
software was then used to compute the total number of cells (DAPI stained 
nuclei) and the number of cells expressing TuJ1, MAP2 or NESTIN. Nuclei size 
was measured by ImageJ from at least 60 nuclei per image. Neurite outgrowth 
was characterized by counting the number of neurite extensions per cell body, and 
counted at least 10 Tuj1-positive neurons per image. All data were expressed as 
the mean ± standard error of the mean from three individual experiments. 
Neuronal maturation was measured by colocalization with PlugIn in ImageJ, 
based on the threshold quantification of overlapping signal between TUJ1 and 
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MAP2-positive neurons. Statistical analysis was carried out using student’s paired 
t-test between control and samples, and significance was defined with p values  
0.05.  
2.13.10 MICROARRAY 
Whole Genome Gene Expression Direct Hybridization Human Ref-12 Expression 
BeadChip microarrays (Illumina) were used for genome-wide expression analysis. 
For hybridization, cRNAs from duplicate or triplicate samples were synthesized 
and labelled using TotalPrep RNA Amplification Kit (Ambion), following the 
manufacturer's instructions. After measuring the quality of RNA, the cRNAs are 
hybridized into the BeadChip arrays according to the manufacturer’s protocol 
(Illumina). Scanned data from the BeadChip raw files for all samples were 
retrieved and background corrected using GenomeStudio software (Illumina), and 
subsequent filtering analyses were completed in GeneSpring GX (Agilent). 
Replicates were grouped together for the interpretation, and validated using 
Principle Component Analysis (PCA), to test the reproducibility between 
duplicates. Data were normalized using percentile-shift with a baseline to median 
of all samples, and averaged within array. False intensities were filtered based on 
the averaged probe set and present flags. Data were normalized within arrays, 
corrected for multiple testing according to Benjamini–Hochberg and applied 
statistical test based on analysis of variance (ANOVA) with definition of genes 




2.13.11 GENE ENRICHMENT ANALYSIS FOR MICROARRAY 
Differentially expressed genes were assessed for Gene Ontology analysis in 
DAVID Functional Annotation tools (http://david.abcc.ncifcrf.gov) and Panther 
(http://www.pantherdb.org). Functional classification based on biological 
function, known pathways are used for further analysis. Heatmap for raw fold 
change and hierarchical clustering using Euclidean distance was generated by 
MeV microarray software suite (http://www.tm4.org/mev.html).  
2.14 FUNCTIONAL ANALYSIS BY ZEBRAFISH  
2.14.1 FISH LINES AND MAINTENANCE 
Zebrafish were maintained at 28.5
o
 on a 14-hour light/10-hour dark cycle. 
Embryos were staged by examination of the head angle and time of birth. All 
embryos and fish were raised and cared using established protocols on Research 
Animal Care, Zebrafish Facility in the Institute of Molecular and Cell Biology. 
Transgenic HuC:GFP line is maintained by Dr.Vladimir Korzh group in IMCB.  
2.14.2 EMBRYO PREPARATION 
Embryos were staged until desired developmental time point and fixed by 4% 
paraformaldehyde at 4 C overnight. The next day, the embryos are washed in 
PBS for several times at room temperature, and dehydrated into increasing 
concentration of Methanol (25%-50%-75%) in PBS. The embryos were stored in 




2.14.3 RNA PROBE SYNTHESIS 
The antisense RNA probes were synthesized by DIG RNA Labelling mix solution 
(Roche), 1 transcription buffer and RNA Polymerases (Roche) for 2-4 hours at 
37 C. For med13b, the cDNA clone was obtained commercially from Open 
Biosystem (Clone ID: 7050861).  Antisense probes are designed by PCR primers 
as follows: 
Gene Sequences 
sox10 F: GGGATTCAGA GCGCGAGCGA 
 R: CGCGCATTTAGGTGACACTATAGAAGTGACAGGTACT AGCATCATGTG 
twist1b F: CCCTCCGTGA CGCAGGAGGA 
 R: CGCGC ATTTAGGTGACACTATAGAAGTG TTCGTTGAGTGTGTGTGTTT 
islet1 F: TCCAGGCTCAAACTCCAC 
 R: GGATCCATTAACCCTCACTAAAGGGAATGTCCGACCGTTTACTTACAG 
Table 8. PCR primer sequences to synthesize RNA in situ probes. PCR primers were 
designed to include T7 or SP6 promoter to hybridize into the Expressed Sequence Tags 
library clones. Resulted PCR products will contain the respective promoter (T7 or SP6) 
required for the mRNA synthesis. 
 
2.14.4 WHOLE MOUNT IN SITU HYBRIDIZATION 
Whole mount in situ hybridizations of zebrafish embryo (WISH) were carried out 
as previously described by Thisse et al.(148) Briefly, embryos were rehydrated 
with PBS from concentrated MeOH, and digested with Proteinase K according to 
embryo stage. The embryos were then fixed in 4% PFA and washed several time 
with PBS, before pre-hybridization at 70 C in shaking water bath. Hybridization 
of 300 ng of antisense probe was performed overnight at 70 C. The next day, 
embryos were washed in salt-solutions (decreasing 2 SSC concentration) at 70 
C, and blocked for 1 hour at room temperature in a blocking solution (5% Lamb 
serum, 2 mg/ml BSA, 1% Dymethyl Sulfoxide in 0.1% PBS-Tween). Anti-DIG 
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Alkaline Phosphatase antibody at dilution 1:2000 (Roche) was added to the 
blocking solution and incubated overnight at 4C. The next day, alkaline-
phosphatase staining solution, NBT-BCIP, was added to the Alkaline-Tris buffer 
containing 100 mM Tris-HCl pH 9.5, 50 mM MgCl2, 100 mM NaCl and 0.1% 
Tween 20, and used for staining the washed embryo for 2-3 hours at room 
temperature. Embryos were fixed in 4% PFA upon desirable staining intensities, 
and mounted on 50% glycerol:PBS for capturing images on Leica microscopes.  
2.14.5 MORPHOLINO MICROINJECTION 
Antisense oligonucleotide morpholinos (MOs) were purchased from GeneTools. 
Two antisense morpholino oligonucleotides for med13b sequences were designed 
by the manufacturer to target the start codon (med13b-1-Start: 
ATGGCAGAGCCCCTCGTTTGTTAGA) and the splice site between exon 14-
15 (med13b-2-Splice: AGAACTCATCATCAAAGCGCAGTCC). Subsequently, 
4 ng of each MO was injected into the yolk of one to two-cell stage embryo from 
wild type AB-fish strains. Injected embryos then incubated at 28.5
o
 C until 
reaching the appropriate developmental stage. The embryos were then fixed in 4% 
paraformaldehyde (PFA) overnight in 4
o




2.14.6 HUMAN MED13L MRNA SYNTHESIS 
Full length human MED13L cDNA was amplified by using primers Hmed13l-F 
5’-AGGATCATGACTGCGGCAGC-3’ and Hmed13l-R 5’- 
TCGCGGAGGATCATGACT-3’ from a HapMap lymphoblastoid cell lines 
GM12878 cDNA. Full length MED13L cDNA was subcloned into TOPOII Dual 
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Promoter vector by using Topo TA Cloning Kit (Invitrogen, Life Technologies) 
for capped mRNA synthesis using mMESSAGE Machine T3 Kit (Ambion, Life 
Technologies) according to manufacturer’s instruction. Capped mRNA was 
purified by using RNAeasy mini kit (Qiagen) and co-injected together with MOs 
for rescue experiments.  
2.14.7 ALKALINE PHOSPHATASE STAINING 
Embryos were fixed at 72 hpf in formalin (3.7% formaldehyde:PBS) at room 
temperature for 30 minutes. Fixed embryos were then washed in methanol 
dehydration series (50%-70%-100%) for 5 minutes and acetone for 30 minutes. 
After washing step with 0.1% PBS-Tween twice for 5 minutes, embryos were 
transferred to NTMT buffer (0.1 M Tris pH 9.5, 0.05 M MgCl2, 0.02 M NaCl, 1% 
Tween-20 in ddH2O) three times for 5 minutes. Embryos were then incubated in 
staining solution containing NTMT and 1:50 NBT/BCIP solution (Roche) for 
maximum 30 minutes. After the staining is completed, embryos were fixed in 
formalin and kept in 50% glycerol:PBS for capturing images using Leica 
microscope.  
 2.14.8 ALCIAN BLUE STAINING 
Embryos were fixed at 5 dpf with 4% PFA for 2 hours at room temperature. After 
fixation, embryos were dehydrated to Ethanol (50%) for 10 minutes at room 
temperature. Embryos were then transferred to Alcian Blue staining solution 
(0.4% Alcian Blue (w/v) in 70% Ethanol) to rock at room temperature overnight. 
To remove the pigmentation in older embryos, embryos were bleached the next 
day in 3% H2O2 and 2% KOH for 20 minutes. To clear the tissue, embryos were 
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soaked in 20% Glycerol/0.25% KOH for 30 minutes, and prepared for imaging in 
the same solution.  
2.14.9 IMAGE QUANTIFICATION ANALYSIS 
Images of up to 5 individual embryos for morphants analysis were captured for 
uninjected siblings, control morpholino-injected embryos, morphants, and rescued 
embryos, and further quantified by using ImageJ for the size of the eyes, and body 
length. The areas and lengths were tested for statistical significance by student’s 
paired t-test and p value  0.05 was considered as significant. 
2.14.10 QPCR  
 
Total RNA was extracted from 1-72 hpf zebrafish embryo using RNAeasy kit 
(Qiagen). Reverse transcription of 2 µg RNA was performed in 20 µl of 
SuperScript III Reverse Transcriptase reaction buffer (Life Technologies) using 
random hexamer primers. qPCR reactions were performed in the ViiA7 Real 
Time PCR system (Life Technologies) with ten-fold dilution of cDNA, 200 nM of 
each primer using the SybrGreen PCR Master Mix (Life Technologies). Data 
were analyzed using 2
∆∆Ct
 method, and normalized against zf-18s ribosomal RNA 
or zf-actin. Each measurement was performed in duplicates. The controls used in 
this study are the uninjected clutchmates or control MO-injected embryos. List of 





Primer name Primer sequence 
zf_med13b F1 ACCTGTTCAAAGACTGCAACTTC 
zf_med13b R1 ACATGTTGTCCATGAACTGTCTG 
zf_sp8a F1 ACTCCATTGGCCATGTTAGC 
zf_sp8a R1 CCGTTAAGGAGAACGAGCTG 
zf_sp8b F1 CATCCCTACGAGTCGTGGTT 
zf_sp8b R1 GGCAGAGTGGCTTAAACTCG 
zf_fgfr3 F1 CGGTGGAGATGGAGAGAGAG 
zf_fgfr3 R1 GGGGGAATTTGGACAGTTTT 
zf_18s rRNA F1 CGCCACTTGTCCCTCTAAGAA 
zf_18s rRNA R1 GTAGTTCCGACCGTAAACGAT 
zf_actin F1 TACAGCTTCACCACCACAGC 
zf_actin R1 AAGGAAGGCTGGAAGAGAGC 
Table 9. List of zebrafish qPCR primers for validation of microarray fold change. 
med13b primer was used to assess MO knockdown efficiency and developmental stages 
expression level. Sp8a and fgfr3 were top-ranked genes with significant upregulation in 
MED13L-deficient neurons based on the microarray. 18s and actin specific to zebrafish 




CHAPTER 3: RESULTS 
DISCOVERY OF CANDIDATE GENES FOR NDDS 
3.1 STUDY BACKGROUND  
Chromosomal rearrangements such as translocation, inversion, duplication or 
deletion occur in the germline at a rate of 1 in every 2,000 live births and about 
15% of NDDs-associated phenotypes are attributed to cytogenetically visible 
abnormalities. Balanced and unbalanced rearrangements may disrupt genes, 
affecting regulatory elements, altering copy number and giving rise to position 
effect of the neighboring chromosomal regions.(149) Chromosome abnormalities 
have provided useful means for disease gene identification in clinically well-
defined genetic disorders (as described in the Chapter 1). However, the majorities 
of NDDs cases (60-80%) are idiopathic, and are unclassifiable into specific 
syndromes. These are predominantly isolated cognitive impairments such as 
learning delay or intellectual disability and often associated with multiple 
congenital anomalies. These general clinical features present challenges in 
diagnosis, counselling and management.  
Karyotyping and chromosomal microarrays are currently first-tier diagnostic tools 
applied for investigation of chromosomal abnormalities in individuals with 
NDDs.(62) Furthermore, advances in NGS technologies have enabled more rapid 
detection of SVs in a very high resolution, which has led to a flood of new 
variants associated with NDDs in the past few years. DNA-PET sequencing, an 
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NGS-based technology established in our institute, adapted long-insert sizes of 7-
11 kb (rather than regular 1.5-2 kb size) genomic DNA fragments, resulting in 
high physical coverage for the identification of genomic SVs. By combining a 
classical approach of disease gene identification based on chromosomal 
rearrangements with NGS technology, the first part of this study is aimed to 
delineate novel candidate genes associated with NDDs by mapping the 
chromosomal breakpoint regions in seven patients carrying cytogenetically visible 
chromosomal rearrangements and presenting cognitive impairments (DD, SD, ID) 
with or without multiple congenital anomalies. 
3.2. CHARACTERIZATION OF SVS BY DNA-PET  
Genomic DNA libraries from seven patients and parents of one patient (n = 9) 
were generated and sequenced using SOLiD sequencing platform. About 60 
million non-redundant PET reads were obtained on average per patient, resulted 
in a relatively high physical coverage (mean = 127 from 9 datasets) (Table 10).  
Sample PETa) 




Coveragec) dPET (NR)d) 
CD5 42,680,822 6,070-15,900 15,377,825 58.1 3,291,424 
CD10 44,421,203 7,100-9,230 32,994,073 93.5 5,781,459 
CD8 57,591,305 7,470-14,880 27,552,231 103.0 3,177,920 
CD9 61,252,841 5,130-10,350 40,545,617 122.2 13,659,051 
CD14 87,508,075 8,650-11,110 41,231,642 143.0 3,871,310 
CD23 70,741,827 7,580-10,090 48,798,329 151 3,530,694 
CD6 55,695,575 8,110-10,900 47,991,119 161.5 2,466,666 
CD15 *) 82,692,289 8,560-12,100 59,076,344 215.3 3,650,581 
CD16 *) 45,724,748 5,860-7,870 38,584,959 93 3,285,306 
Table 10. Summary of DNA-PET post-sequencing analysis  
a





) Physical coverage of cPETs determined by average number of cPET 
connections crossing a chromosomal position; 
d
) Non-redundant discordant PETs; *) Unaffected 




After filtering, approximately 96% of the SV calls generated for each library were 
compared with healthy individuals according to the DGV, 1000 Genome Project 
SVs Pilot Release set, and previously published studies of paired-end sequencing 
in control individuals (Chapter 2.7). After extraction of ‘normal’ SVs, the number 
of patient-specific SVs was reduced into 7 – 27 events per patient (Table 11).  
Sample Karyotype dPET SVs SVs(-) fSV
s 
D BT IB I UI TD In 
CD5 t(9;17)(q12;q24) 505 284 270 14 12 2 0 0 0 0 0 
CD10 t(6;8)(q16.2;p11.2) 927 616 601 15 9 2 1 0 0 1 2 
CD8 inv(X)(p22;q26) 724 387 368 19 9 0 0 1 1 7 0 
CD9 inv(5)(q22;q35.1) 390 581 574 7 2 0 0 0 0 3 0 
CD14 Del7qter 1,053 618 596 22 20 0 0 0 0 0 2 
CD23 t(12;19)(q12;q24) 999 641 614 27 19 2 0 0 4 2 0 
CD6 t(2;8)(q23;p21) 1,030 635 618 17 9 2 0 3 3 3 0 
CD15 46,XX 913 558 543 15 9 0 1 0 1 4 0 
CD16 46,XY 1,003 682 654 28 24 0 1 0 0 3 0 
 
Table 11. Summary of DNA-PET findings to identify SVs in nine individuals 
Abbreviations: SVs(-), SVs present in normal individuals; fSVs, final list of SVs per individual 
after filtering; D, deletion; BT, balanced translocation; IB, isolated breakpoints; I, Inversion; UI, 
Unpaired Inversion; TD, Tandem Duplication; In, Insertion. 
 
Sanger sequencing was used to determine precise breakpoints from SOLiD-
predicted breakpoints. PCR validation was confirmed in 31 out of 40 SVs that 
were randomly selected from 94 SVs, suggesting an approximately 77% 
validation rate. This number is consistent with previous studies employing the 
DNA-PET to investigate cancer genomes, showing validation rates within the 
range of 69-80%.(134, 136, 137) In parallel to DNA-PET sequencing, array CGH 
was performed to compare the overlaps of deletions/duplications from both 
techniques as a systematic validation. On average, the concordance rate between 
aCGH and DNA-PET of copy number detection were about 93%, suggesting high 
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overlap between both approaches. Based on this, SVs detected by both techniques 
were considered as validated. Similar to other NGS-based studies (150), aCGH 
was used to systematically validate SVs finding from NGS data, where any 
discordance between two techniques was considered as a false positive. 
3.3 BREAKPOINT CHARACTERIZATION THROUGH 
DETAILED SVS ANALYSIS 
Each patient was analyzed individually to identify the potential candidate genes 
disrupted by cytogenetically visible rearrangements, with the assumption that 
these were the most likely causative events. DNA-PET predicted breakpoints 
matching the known chromosomal rearrangements were validated by PCR 
followed by Sanger sequencing and FISH. Transcript expressions of candidate 
genes within the chromosomal breakpoints or other potential SVs were evaluated 
by qPCR.   
PATIENT CD5 
In the first patient (Patient CD5), the monoallelic t(9;17) translocation was 
transmitted to his two sons (CD21 and CD22) who displayed different levels of 
cognitive impairment including DD, absence of speech, and autistic features 
(Figure 7). aCGH analyses were performed for all three affected subjects, and did 





Through DNA-PET SVs analysis, two abnormally oriented clusters corresponding 
to the balanced translocation were identified between chromosome 9 and 17 
(Table S1). The predicted breakpoint coordinate from DNA-PET was used to 
validate the region by PCR amplification and Sanger sequencing. The breakpoint 
was validated at position chr9:79,572,001-79,572,005 and chr17:74,764,927-
74,767,964. Sanger sequencing analysis in the two affected sons revealed similar 
breakpoint in the three translocation carriers (Figure 8).  
Figure 7. Pedigree of Patient CD5 family. 
Familial translocation in this family is transmitted 





Figure 8. Validation of DNA-PET breakpoints by Sanger sequencing in Patient 
CD5. PCR validation followed by Sanger sequencing showed identical breakpoints in 
three translocation carriers; father (CD5), and two sons (CD21 and CD22). The resulting 
fusion genes predicted at the genomic level are indicated. 
 
There is a loss of 4 bp and 3,036 bp on chromosome 9 and chromosome 17, 
respectively, with a microhomology of 3 bp between paired breakpoints. The 
translocation disrupted GNAQ at intron 5 on chromosome 9 and RBFOX3 at 
intron 2 on chromosome 17.  
 
GNAQ encodes a member of the Gαq heterotrimeric protein family, and null 
Gnaq mice exhibit cerebellar ataxia, and motor coordination deficit (151). 
Heterozygous Gnaq mice were viable and did not show any obvious phenotypic 
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defect for more than 20 months (151). RBFOX3 is a neuronal specific splicing 
factor, which is exclusively expressed in the neuronal nuclei. Both disrupted 
genes shared the same orientation, breakpoints lie within introns, and the resulting 
fusion is predicted to be in frame (Figure 8). However, RT-PCR analysis on the 
patient’s EBV-LCL did not reveal any fusion transcript expression as neither gene 
was expressed in these cells. The mRNA expression of both genes in human 
tissue panel showed high expression in the fetal brain and the cerebellum (Figure 
9).  
 
Figure 9. qPCR analysis of GNAQ and RBFOX3 in human tissue panels. High 
expression of both genes are shown in brain tissues such as fetal brain, adult brain and 
cerebellum for both genes.  
 
Nine out of twelve SVs were validated by PCR, in which 5 SVs were shared with 
his two affected sons (SV1, 2, 4, 6 and 13). These five SVs overlapped with 
known CNV regions (SV1, 2, 4) or were in non-coding regions (SV6, 13) and 
were therefore excluded from further analysis (Table S1).  Overall, the 
translocation with the affected genes may have a potential functional impact, 
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since the translocation completely segregated with the language and 
developmental delay in this family. To correlate the pathogenicity of fusion genes 
to the phenotype observed, deriving neurons from induced pluripotent stem cells 
of these patients might provide clues to check whether the fusion transcripts were 
expressed and functional in the relevant cell type.  
PATIENT CD10 
In patient CD10, the impact of the t(6;8) balanced translocation was unclear, due 
to variable penetrance in the translocation carriers; his mother was asymptomatic 
and his younger sister had schizencephaly and DD (Figure 10).  
 
Figure 10. Pedigree of Patient CD10 family.  
This case showed incomplete segregation of the 
phenotype in the translocation carriers; among a 
healthy mother and two affected children. 
 
DNA-PET identified abnormal paired reads corresponding to the balanced 
translocation between chromosomes 6 and 8 (Table S2). Sanger sequencing 
refined the breakpoint coordinates on chromosome 6 at position 98,318,526-
98,318,538 and chromosome 8 at position 35,527,969-35,527,976, with 






Figure 11. Validation of DNA-PET breakpoints by Sanger sequencing. 
Sequencing of breakpoint junctions by using primers designed at DNA-PET breakpoint 
coordinates revealed a loss of 11 bp on chromosome 6 and a loss of 8 bp on chromosome 
8. There is a 3 bp (CCA) microhomology between paired breakpoints. 
 
The translocation disrupted UNC5D at intron 5 on chromosome 8, while no 
coding genes were found on chromosome 6 breakpoint. UNC5D encodes a 
member of the human dependence receptor UNC5 family, specifically expressed 
in the layer 4 of the developing neocortex in rats, which makes it an interesting 
candidate (152, 153). Since his healthy mother carried the same translocation, all 
coding exons of UNC5D were sequenced in the translocation carriers to identify a 
potential secondary mutation affecting the other allele of UNC5D, and no 
additional point mutations were found in this gene, suggesting that UNC5D 
disruption was heterozygous. UNC5D is highly expressed in the CNS (adult brain, 
fetal brain and cerebellum), low expression in the kidney, and its expression is 




UNC5D mRNA transcript is not endogenously expressed in the patient’s EBV-
LCL; therefore the transcript level differences could not be investigated.  Further 
analysis of other SVs showed 5 deletions in non-coding regions (SV1, 2, 11, 12, 
and 14) and 8 within genes (SV3, 4, 5, 6, 9, 10, 13 and 15), all of them overlapped 
with CNVs seen in normal individuals based on the DGV (Table S2).  
PATIENT CD8 
Patient CD8 carried a pericentric inversion at chromosome X inherited from his 
mother, between Xp22 and Xq26. His monozygotic twin brother harbors the same 
inversion, and they both show signs of immunodeficiency combined with mild ID 
and language delay. DNA-PET sequencing analysis revealed a 1.2 Mb inversion 
located at chromosome Xq24-25 between paired breakpoints (Table S3), which 
did not correspond to the large inversion seen in the karyotype.  
Sanger sequencing refined this breakpoint position at coordinate 
chrX:119,984,613-119,984,615 and chrX:122,839,398-122,844,862 with a loss of 
1 bp and 5,463 bp on each breakpoint junction, respectively. Due to the 
Figure 12. qPCR analysis of UNC5D 
in human tissue panel.  
Transcript expression of UNC5D in 
human tissue panel showed high 
expression in adult brain, fetal brain 




discrepancies between karyogram and NGS data, other SVs in chromosome X 
were extracted from the raw dataset with a cluster size cutoff ≥4 (Table 12).  
SV # SV Coordinate on chrX (hg18) Cluster Size Span Gene 
1  120,059,370-120,309,394 30 250,024  
2  34,649,915-125,672,128 49 91,022,213  
3  119,984,597-122,839,027 26 2,854,430 XIAP 
4  119,984,844-122,845,538 29 2,860,694 XIAP 
5  123,107,520-34,569,874 23 88,554,66 TMEM47 
6  125,658,649-123,127,427 30 2,555,127 ODZ1,SH2D1A 
7  125,828,479-125,110,988 26 737,420 CXorf64 
8  34,558,550-34,567,696 5 9,146 TMEM47 
9  34,560,395-123,109,280 5 88,548,885 TMEM47 
10 61,754,201-61,771,832 4 28,847  
Table 12. List of SVs found on chromosome X to analyze complex rearrangements. 
DNA-PET data were re-analyzed to modify the filtering parameter to include SVs with 
cluster size less than 4 (lower confidence clusters). Three additional SVs were identified 
from low confidence clusters, resulted in 10 SVs found in chromosome X.   
 
These SVs clustered into breakpoint hotspots on the p arm (SV2, 5, 8, 9), the 
centromeric region (SV10) and the q arm (SV1, 3, 4, 6, 7), suggesting a complex 
chromosomal rearrangement mechanism. The breakpoints were then validated by 
PCR and FISH in all inversion carriers (mother and twin boys) (Table S4).  
Probes used for FISH were focused on the main hotspots on Xp21 for the p-arm, 
Xq11.1 for the centromeric region, and Xq24-25 for the q-arm. The probe on 
Xq24 (RP1-315G1) and Xq25 (RP1-296G17) showed a fusion localized at the 
centromere of der(X), while the probes on Xp21 (RP11-330K13) showed a split 
signal and fused to the Xq25 (W12-499N23) (Figure 13A). And the centromeric 
probe on Xq11 (RP11-762M23) was localized on the longer chromosomal arm, 
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suggesting a highly rearranged chromosome. These data suggested two large 
sequential breaks in each arm of chromosome X (Xp21 and Xq24-25) that 
resulted in tandem duplications, deletion and isolated breakpoints (Figure 13B). 
This double inversion mechanism rearranged the landscape of chromosome X 
architecture, and appeared as a large inversion on G-banding karyotype (Figure 
13B).  
 
Figure 13. FISH validation of DNA-PET predicted breakpoints. A) Mislocalization 
signals of probes located in breakpoint hotspots were indicative of complex 
rearrangements. B) Proposed mechanism of double inversion occurred sequentially, first 
between Xp21 and Xq25, and second between Xq11 and Xq25, based on the FISH 
analysis.  
 
This complex rearrangement disrupted two genes at the inversion breakpoints: 
XIAP with a breakpoint in intron 1 and TMEM47 with a breakpoint in the second 
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intron. XIAP encodes X-linked inhibitor of apoptosis, and mutations in this gene 
have been associated with X-linked lymphoproliferative syndrome 2, XLP-2 
(MIM 300635). TMEM47 encodes a member of PMP22/EMP/Claudin protein 
family with unknown function that is ubiquitously expressed in human tissues 
including adult and fetal brain (Figure 14).  
 
 
Figure 14. qPCR analysis of 
TMEM47 in human tissue panel. 
TMEM47 is ubiquitously expressed 





Two other genes were affected by tandem duplications as part of the complex 
rearrangement (SV6,7): SH2D1A, encodes an SH2 domain containing 1A protein 
(SAP), which has been associated with X-linked lymphoproliferative syndrome 
type 1, XLP-1 (MIM: 308240). This gene was initially suspected as the primary 
cause of immunodeficiency phenotype seen in the patient, but SAP testing in 
patient’s blood lysates showed normal protein expression, thus XLP-1 was ruled 
out from the diagnosis.  ODZ1, also known as TENM1 is the second gene affected 
by this rearrangement. It encodes and Odd Oz/Ten-M homolog 1 of Drosophila 
pair-rule gene involved in post-segmentation processes, including embryonic 
development of the central nervous system (CNS), eyes, and limbs in 
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Drosophila.(154, 155) qPCR analysis of the four genes revealed a total absence of 
expression for XIAP and TMEM47 (Figure 15) and moderately variable 
expression for SH2D1A and ODZ1/TENM1 in patient’s fibroblast cell line (Figure 
16) compared to two controls, supporting the absence of functional XIAP and 
TMEM47 genes in the male patient. Considering the variable pattern of expression 
of SH2D1A and the absence of functional XIAP, these data suggest that XLP-2 
underlies the immunodeficiency symptoms of the affected twin boys. However, 
further functional studies should be pursued to fully clarify the role of each of the 
disrupted genes in this phenotype. Other autosomal SVs identified in patient CD8 
were located in the intergenic regions (SV2,3,4,5,6,7,8,9,11,12) or in the intronic 
regions (SV1 and 10) (Table S3).  
 
Figure 15. qPCR analysis of XIAP and TMEM47 in patient cells. XIAP and TMEM47 
transcripts expression were almost completely absent in the patient’s cells (dashed bar) 
compared to controls. XIAP inversion breakpoint is located at intron 1, and TMEM47 




Figure 16. qPCR analysis of SH2D1A and ODZ1 in patient’s cells. SH2D1A and 
ODZ1 showed moderate to normal transcript expression in patient’s cells compared to 
two control individuals. 
 
PATIENT CD9 
In patient CD9, sequencing analysis identified two paired-inversion clusters 
correspond to the large inversion on chromosome 5.  This large inversion spans 
53 Mb on chromosome 5q22.2 (chr5:111,966,591-111,963,149) and 5q34 
(chr5:165,575,819-165,576,628), with 1 bp deletion, and microhomologies of 3 
bp between paired breakpoints (Table S5). No gene was disrupted at the inversion 
breakpoint, and no evidence of regulatory elements sitting at both breakpoint 
coordinates was found based on RegulomeDB and ENCODE database (Table S5). 
Additionally, 5 other patient-specific SVs were identified in this patient; two were 
located in intergenic regions (SV5 and 6); two others were tandem duplications 
overlapping with known CNVs (SV4 and 7); and one intronic deletion of 4kb 
(SV1) in RNF19B gene, which has not been listed in DGV and could be a 
potentially interesting candidate to follow up. Based on this analysis, it seems 
unlikely that the large inversion on chromosome 5 is causative for the phenotype. 
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Other patient-specific SVs (Table S5) or mutations that cannot be identified by 
DNA-PET such as point mutations or exposures of environmental factors might 
explain the phenotype.  
PATIENT CD14 
Patient CD14 has a heterozygous telomeric deletion on del7q which was initially 
identified by subtelomeric FISH. This telomeric deletion was not captured within 
the list of patient’s specific SV (Table S6), which highlighted the limitation of 
DNA-PET. DNA-PET requires mappable sequences on both paired-reads for SVs 
annotation. Alternatively, by using the copy number information derived from 
DNA-PET sequencing read depths, the deletion was detected at the telomeric 




Figure 17. Telomeric deletion detected by cPET reads and aCGH. Deletion is 
depicted by a steep decline indicated by black arrow in the upper panel, corresponding to 
lower copy number, as shown by cPET copy number browser. Lower panel showed 
aCGH browser snapshot indicating a deletion in green only region. 
 
The deletion disrupted NCAPG2 at exon 14. NCAPG2 encodes a subunit of 
Condensin II complex that plays a role in compacting chromosomes preparing for 
mitosis (156). Four other genes ESYT2, WDR60, LINC00689 and VIPR2 were 
deleted in the distal telomeric region. Duplications in VIPR2 have been shown to 
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confer risk to schizophrenia (157), and a subtelomeric deletion spanning 
NCAPG2, WDR60, ESYT2, and VIPR2 has been reported in an idiopathic DD 
patient(158). However, in this case, the telomeric deletion is derived from an 
asymptomatic father. Hence, there could be other factors that might explain the 
complex clinical phenotype in this patient. 
From the list of patient-specific SVs (Table S6), there is a 37 kb deletion inside 
the Microcephalin 1 (MCPH1) gene, which was too small to be detected by G-
banding karyotyping. This deletion was observed by the aCGH, and further 
validated by Sanger sequencing, confirming a deletion from exon 6 to 9 in this 
gene. MCPH1 is an interesting candidate gene, as it has been reported to be 
causative for Autosomal Recessive Primary Microcephaly (MCPH MIM: 
251200). However, upon parental testing, this deletion was found to be inherited 
from his asymptomatic mother. To test the possibility of homozygous deletion in 
this gene, the coding regions of MCPH1 from paternal allele were sequenced by 
Sanger method and revealed 3 non-synonymous SNVs; two in exon 8 and 1 in 
exon 14. All of them were present in dbSNPs and classified as being non-
pathogenic, thus confirming heterozygous deletion in this patient.  
The mRNA expression of both MCPH1 and NCAPG2 in the patient’s 
lymphoblastoid cells were assessed by qPCR (Figure 18). NCAPG2 expression 
was reduced in patient’s cell line by using primers at exon 15-16, downstream of 
the telomeric deletion, and its expression was comparable to normal level at exon 
10-11. MCPH1 expression showed variable expression (between 30-60% 
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reduction) in patient’s cell lines by using primers at exon 1-2 and exon 8-9, 
compared to two controls.  
 
Figure 18. qPCR analysis of NCAPG2 and MCPH1 in patient’s cells. mRNA 
expression of NCAPG2 is normal in the patient’s cells at exon 10-11 (upstream of 
telomeric deletion) and reduced at exon 15-16 (downstream of telomeric deletion) in the 
patient’s cells compared to controls. NCAPG2 telomeric deletion is predicted at exon 14 
based on aCGH and cPETs window. mRNA expression of MCPH1 is reduced variably 
(up to 30-60%) in the patient’s cells by using primers at either exon positions. MCPH1 
deletion is located between exon 6 to 9.  
 
Further studies are warranted to decipher the molecular mechanism regulating 
transcription of the affected genes.   
PATIENT CD23 
Patient CD23 carried a de novo monoallelic translocation t(12;19) identified from 
G-banding karyotyping. She had Pierre-Robin sequence (severe micrognathia), 
dysmorphic features and intellectual disability. Two abnormally oriented paired 
clusters correspond to the balanced translocation between chromosome 12 and 19, 
disrupting MED13L at intron 5 on chromosome 12 and no coding genes in the 




Figure 19. Validation of DNA-PET breakpoints in Patient CD23 by Sanger 
sequencing. The illustration of translocated chromosomes between chr12 and 19 and 
Sanger sequencing validation chromatogram showing 1 bp microhomology on 
chromosome 12 breakpoint and 2 bp insertion on chromosome 19 breakpoint.  
Sanger sequencing validation confirmed the breakpoint junction at intron 4 of 
MED13L with a 1-bp microhomology in derivative chromosome 12 and 2 bp 
insertion in derivative chromosome 19 (Figure 19).  
To check whether the MED13L disruption is heterozygous, coding exons of 
MED13L were sequenced and did not reveal any other mutations on the non-
translocated chromosome.  MED13L encodes for Mediator complex subunit 13-
like, one of the subunit in CDK8 module of Mediator complex, a module that 
functions as a transcriptional repressor. MED13L mRNA expression was assessed 
by qPCR in patient’s cell lines compared to two controls by using primers at 
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different exon positions (Figure 20), and showed inconclusive results. Although a 
consistent decrease of mRNA expression is observed in the patient’s cells, further 
studies would need to be pursued in order to confirm the molecular consequences 
of the translocated allele . 
 
Figure 20. qPCR analysis of MED13L in patient’s lymphoblastoid cell lines, 
MED13L is approximately 50-60% reduced in patient‘s cells compared to two controls. 
Primers were designed at different exons within MED13L to predict the molecular 
consequences. Breakpoint is located at intron 5. 
 
The mRNA expression of MED13L across human tissue panel showed ubiquitous 
expression, with the highest expression observed in the cerebellum, fetal brain 




Figure 21. qPCR analysis of MED13L in human tissue panel. MED13L is 
ubiquitously expressed in human tissues and its highest expression is in the cerebellum.  
 
There are 25 other SVs found in this patient, of which 7 deletions spanning 
coding genes have known variants reported in DGV, and 16 other SVs were 
located in intergenic regions, with unknown functions (Table S7). Previous case 
studies reporting SVs within MED13L showed nearly identical clinical 
phenotypes as our patient. This piece of evidence together with our analysis 
suggested that MED13L translocation might have potential functional relevance. 
Further functional studies on MED13L will be described in the Chapter 4.  
PATIENT CD6 
Trio sequencing was performed for patient CD6, since the parental DNA were 
available for sequencing. This allowed for filtering of non-pathogenic germline 
SVs and to determine paternal/maternal SVs inheritance rate. This case served as 
an example for complete delineation of patient’s de novo specific SVs. Before 
filtration, 650 SVs were detected in the patient, of which 616 SVs were detected 
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in at least one of the parents or both, indicating that these were germline variants 
(Figure 22).  
 
Figure 22. Venn diagram showing total SVs found in each individual after trio 
sequencing; 345 SVs were shared between three of them, and 34 were found to be de 
novo. The number in parenthesis indicated the final number of SVs after removing 
sequencing artifacts.  
 
The paternal/maternal SV inheritance rates were found to be relatively balanced 
(46.1% and 52.5%, respectively), as expected for 50:50 inheritance ratio during 
meiosis. After filtering criteria , as described previously in the Methods (Chapter 
2.7-2.8), were applied, only four de novo SVs were found in the offspring, of 
which two SVs correspond to the previously identified balanced translocation 
t(2;8), and the other two SVs were located in intergenic regions (Table S8). The 
translocation breakpoints were validated by PCR and Sanger sequencing at 
position chr2:144,606,846 and chr8:23,007,141-23,007,144, with a loss of 5 bp in 
chromosome 8 and a microhomology of 4 bp between the flanking regions. The 
chromosome 2 breakpoint was located in the intron 5 of GTDC1 gene, and no 
coding gene was found on chromosome 8 breakpoint, suggesting that GTDC1 is 
the main candidate gene in this patient. GTDC1 encodes for a glycosyltransferase 
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domain-like containing protein 1, of unknown function. GTDC1 transcript 
expression was reduced in patient’s lymphoblastoid cell line compared to two 
controls (Figure 23).  
 
Figure 23. qPCR analysis of GTDC1 in patient’s lymphoblastoid cell line. GTDC1 
expression is reduced in the patient’s cell line compared to two controls. Breakpoint is 
located at intron 5. 
 
Based on secondary CNV screening in DD cases by Cooper et al(72) and the 
DECIPHER, there are 21 deletions/duplications overlapping with GTDC1, 
whereas no CNVs spanning GTDC1 were found in DGV, suggesting that the 
CNVs affecting GTDC1 are predominantly present in the disease population. 
GTDC1 is ubiquitously expressed in human tissues, with the highest expression 




3.4 SECONDARY CNV SCREENING IN PUBLISHED STUDIES 
AND DATABASES 
From these analyses, eight genes were disrupted at the chromosomal breakpoint 











































Table 13. Summary of the breakpoint analysis for each patient.   
Patients were initially assessed from G-banding karyotyping showing breakpoint 
position.  aCGH finding  usually showed normal finding, and DNA-PET sequencing 
precisely pinpoint  the chromosomal breakpoint, and subsequently narrowed down to the 
putative candidate gene that is disrupted.  
Figure 24. qPCR analysis of the 
expression of GTDC1 in human tissue 
panel. This analysis showed high 
expression in neurological tissues, 





In addition, MCPH1 deletion was identified by screening the patient-specific SVs 
in one patient, as the telomeric deletion was inherited by a healthy father. Among 
these genes, XIAP has been associated with X-linked lymphoproliferative disorder 
2 (XLP-2: MIM 300635) and MCPH1 has been linked to autosomal recessive 
primary microcephaly (MCPH MIM 251200).   
To further evaluate the disrupted genes and their potential implication to NDDs, 
CNV screening in DD cases from published studies and Developmental Disorder 
database DECIPHER was performed to assess the occurrence of pre-existing 
CNVs within these genes in disease population, compared to the control set in the 
same study and DGV database(72, 159, 160) (Table 14). Enrichment of CNV 
counts in cases versus controls (p ≤ 0.05) was observed in RBFOX3, GTDC1, and 
NCAPG2, suggesting that altered gene dosage in these genes might contribute to 
the neurodevelopmental phenotypes seen in the patients. 
Patient Gene 
Cases Control Chi 
square 
p-value Cooper DECIPHER Total Cooper DGV Total 
CD5 GNAQ 3 7 10 14 0 14 1 × 10-1 
CD5 RBFOX3 68 11 79 1 4 5 1 × 10-4 
CD10 UNC5D 2 8 10 0 0 0 7 × 10-2 
CD14 NCAPG2 16 14 30 1 1 2 1 × 10-2 
CD8 TMEM47 0 10 10 0 4 4 4 × 10-1 
CD6 GTDC1 11 14 35 0 0 0 4 × 10-3 
CD23 MED13L 13 10 23 2 4 6 4 × 10-1 
Table 14. CNV counts in cases and controls from published and public dataset. In 
Cooper et al. the total number of cases is 10,151 cases and 8,329 controls. The total 
number of cases in DECIPHER database is 17,000 cases. The total number of controls 
included in 1000 Genome SV Release set is 185 controls. P-values are calculated by Chi-




CHAPTER 4: RESULTS 
 
DISSECTING FUNCTIONAL ROLE OF MED13L 
DURING NEURODEVELOPMENT AND NEURAL 
CREST CELLS (NCCS) SPECIFICATION 
4.1 STUDY BACKGROUND 
MED13L is a subunit of Mediator complex that is located in the CDK8 module, a 
dissociable component of Mediator complex that has been described to have an 
activating and repressing functions in transcription regulation.(161) Mediator 
complex regulates gene expression by physically linking transcription factors to 
RNA Polymerase II.(162-164) Recent studies have shown that MED13L has a 
role in cancer pathways by specifically repressing Retinoblastoma/E2F-induced 
growth, and also targeted for degradation by FBW7, a tumor suppressor and a 
component of SCF (Skp-Cullin-F box) ubiquitin ligase to disrupt CDK8-Mediator 
association. (165) Mutations in other subunits within Mediator complex have 
been linked to DDs syndromes such as, (i) MED12 in Lujan-Fryns syndrome 
(MIM 309520),(166) X-linked Ohdo syndrome (MIM 249620)(167) and Opitz-
Kaveggia syndrome (MIM 305450);(168) (ii) MED17 mutation was found in 
infantile cerebral and cerebellar atrophy (MIM 613688)(169); (iii) MED25 in 
autosomal recessive Charcot-Marie Tooth disease Type 2B (MIM 505589).(170) 
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Mutations or SVs in MED13L has been previously reported in several case 
studies. First study reported a MED13L disruption in a translocation breakpoint of 
a patient with ID and dextro-looped transposition of great arteries (dTGA) upon 
positional cloning, and three additional patients with MED13L missense mutation 
were identified after mutation screening in dTGA patients. Thus, MED13L 
mutations were suggested to be causative for dTGA (MIM 608771). 
Subsequently, a homozygous mutation p.Arg1416His in MED13L was reported in 
two siblings presenting an isolated non-syndromic ID without cardiac defect.(171) 
In the third study, Asadollahi et al. reported three patients with ID, craniofacial 
abnormalities, and cardiac defects; of which two patients were found to have 
exonic deletions in MED13L and one patient has a triplication involving the 
whole gene. The last study suggested that patients with MED13L mutations could 
be potentially classified as a recognizable haploinsufficiency syndrome, due to 
shared clinical features among the patients with mutations in this gene.  
In this thesis, MED13L disruption was identified in a translocation breakpoint of 
patient CD23 that resulted in MED13L haploinsufficiency (Chapter 3.3). 
Interestingly, this patient showed nearly identical phenotype to the previously 
described patients with MED13L mutations.(172-175). Table 15 summarized the 
comparison of clinical phenotypes among patients carrying MED13L mutations 




Table 15. Clinical presentation of reported patients with structural variants or mutations affecting MED13L.  
bbreviations : CoA , coarctation of the aorta ; dTGA, dextro-looped transposition of great arteries ; pVSD, perimembranous ventricular septal 
defect ; TAPVC, total anomalous pulmonary venous connection ; TOF, tetralogy of Fallot; ID, intellectual disability ; DD, developmental delay ; 
SD, speech delay ; LD, language delay; NR: Not reported. 
 Category Muncke et al. 2003 Najmabadi et 
al. 2011 
Asadollahi et al. 2013 Our patient 










c.4246C>T Deletion in exon 2  (17 
Kb) 
Deletion in exon 3-4  
(115 Kb) 
Triplication of 





dTGA, pVSD, mild 
coA 
dTGA dTGA dTGA NR Pulmonary atresia, 
supracardial TAPVC, 
VSD 













DD, LD, ID 
Craniofacial 
anomalies 
NR NR NR NR NR Prominent occipital 
protuberance,  broad 
forehead with nevus 
simplex, upslanting 
palpebral fissures, flat 
nasal root, bulbous 
nose, large ears, 
macroglossia 
Upslanting palpebral 
fissures, large ears, 
flat nasal root, 

















NR NR NR NR NR Muscular hypotonia Muscular hypotonia, 
bowed legs, 
overlapping of fifth 















Figure 25. Gene and Protein structure of MED13L. The mutations or SVs in reported 
patients (P1-P9) are indicated at their coding position on mRNA and protein level. In the 
upper diagram, gene structure of MED13L is indicated. Patient 1 (t(12;17)) with a de 
novo translocation at intron 1, Patient 2, 3, 4 and 5 with a missense mutation on exon 2, 
25, 27, and 19, respectively. Patient 6 with a deletion on exon 2 and Patient 7 with a 
deletion encompassing exon 3-4. Patient 8 had a triplication involving the whole gene, 
thus not indicated in this diagram. Patient CD23 is indicated in red as Patient 9 in this 
diagram with a translocation breakpoint at intron 4.   
 
Patients with MED13L haploinsufficiency show similar syndromic features affecting 
craniofacial mesenchyme (macroglossia, bulbous nose, upslanting palpebral fissures), 
nervous system (ID) or cardiac system, which to some extent overlap with DiGeorge 
syndrome. Many parts of these affected organs are known to originate from neural crest 
cells (NCCs). NCCs are migratory and multipotent cells that give rise to a wide 
variety of different cell lineages in embryo, including melanocytes of the skin and 
inner ear, craniofacial cartilage and bone, peripheral and enteric neurons and glia 
and smooth muscle. Other components of CDK8 module in Mediator complex has 
been previously shown through animal studies to be important in NCCs-derived 
organ development: (i) med12, is required as a coactivator for Sox9-dependent 
neural crest, brain, kidney, and ear development; (ii) Med13 regulates energy 
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homeostasis in the heart. These studies suggested that components of Mediator 
complex may have specific roles in different aspects of NCCs development.  
To uncover the role of MED13L in NCCs development and neurodevelopment, 
knockdown experiments were performed in zebrafish embryos and human ES 
derived NPCs. 
4.2 EXPRESSION PROFILE OF MED13L ORTHOLOGUEIN 
ZEBRAFISH 
In human, MED13L is expressed in fetal brain, cerebellum, and skeletal muscle 
(See Chapter 3). To study the role of MED13L during embryogenesis, zebrafish 
system was used as a model for neural crest development and neurodevelopment. 
MED13L is highly conserved across vertebrate species (Figure 26), and the 
protein sequence of med13b, the closest zebrafish orthologue of MED13L showed 
65% sequence similarity to the human protein.  
 
Figure 26. Sequence conservation of MED13L across vertebrate species. 
Sequences were extracted from UCSC Genome browser and aligned by using 
CLC Main Workbench.  
In zebrafish, med13b is shown to be expressed maternally at 1-cell stage and 
gradually decreased at 6 hours post fertilization (hpf)  through the activation of 
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maternal-to-zygotic transition (Figure 27A). To determine the spatiotemporal 
expression of med13b across different time points during embryogenesis, whole 
mount in situ hybridization of zebrafish embryo was performed across different 
time points during embryogenesis. Maternal expression of med13b was detected 
at 1-2 cell stage in the blastomeres, and at 24-48 hpf the zygotic med13b 
expression was restricted to the forebrain, mid-hindbrain boundary, eye, pectoral 
fin and the lateral line (Figure 27B-F). Some of these tissues require derivatives of 
neural crest lineage to develop: pectoral fin arises from trunk neural crest, lateral 
line arises from cranial placodal ectoderm and eye development involves 




Figure 27. Expression profile of med13b in zebrafish embryo. (A) qPCR analysis of 
med13b between 1 hpf to 72 hpf showed maternal expression that is subsequently 
replaced by zygotic transcription at 6 hpf. (B-F) Maternal expression is confirmed by in 
situ hybridization, showing expression on the blastomeres at 1 and 2-cell stage (B and C), 
restricted expression in brain regions at 24 and 48 hpf (D and E), and no expression by 








4.3 LOSS OF FUNCTION OF MED13B IN ZEBRAFISH EMBRYO 
To investigate the role of med13b in development, med13b was suppressed by 
injecting antisense morpholino oligonucleotides (MO) to 1-2 cell stage zebrafish 
embryo. Embryos injected with med13b-MO and control-mismatch-MO, as well 
as uninjected clutchmate were analyzed up to 5 days-post-fertilization (dpf) for 
survival and morphology. Developmental defects in med13b morphants were 
apparent from 2 dpf. More than 95% of the embryos were affected with a curved 
body axis, underdeveloped head, pericardial edema, and microphtalmia (Figure 
28), which were categorized as severe (40%) and mild-to-moderate for 55% of the 
analyzed embryo.  
 
Figure 28. Knockdown of med13b in zebrafish embryo. med13b MO injection in ~150 
embryos per injection resulted in 3 categories of morphant phenotypes: severe, moderate 
and mild with severe developmental defect. Coinjection of MO and human MED13L 




Co-injection of approximately 150 pg of full-length human MED13L mRNA with 
med13b MO resulted in significant rescue of the eye size and head development, 
while the body length was partially rescued (Figure 29).  
 
Figure 29. Eye size of morphants was smaller than controls and could be partially 
rescued by human MED13L mRNA. The body length of morphants was not severely 
affected, and thus rescue construct did not fully restore the body length. Six 
representative embryos were selected for measurements in each group (n=6, ± SEM), *) 
p<0.05 and **) p<0.001.  
 
Knockdown of med13b did not seem to impair survival as the morphants 
displayed comparably similar survival rate compared to the control MO, 
uninjected controls and rescued embryo at 5 dpf (Figure 30), indicating a possible 
functional redundancy with other family members of Mediator complex, such as 




4.4 LOSS OF MED13B IMPAIRED CRANIOFACIAL CARTILAGE 
DEVELOPMENT 
 
To further study the implication of med13b deficiency in craniofacial and 
cartilage structure development, the migration of cranial NCCs in the morphant 
embryos were assessed by using sox10 that is expressed along the cranial ganglia 
and otic vesicle at 24 hpf (Figure 31A). In the morphants, the NCCs migration 
was impaired, as shown by clustered expression of sox10-positive cells along the 
migratory cranial ganglia at a more posterior location (Figure 31A’). Upon co-
injection of human MED13L mRNA, the location of sox10 positive cells were 
comparable to that of control embryos (Figure 31A’’), suggesting that med13b is 
required for proper migration of NCCs.  
Further assessment on cartilage development were performed on 5 days old 
morphant embryos stained by Alcian blue, a time point when all craniofacial 
cartilage has been fully formed, resulted in a severely distorted ceratohyal 
Figure 30. Survival rate of med13b MO embryos compared to wild type 
(uninjected and control MO) and rescue embryo observed on 5 dpf. Loss of 
med13b did not affect the survival rate, as shown by 2-3% differences between 
controls, rescued and morphant embryos.  
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cartilage, which was shifted posteriorly in the morphants (Figure 31B’). This 
phenotype was fully restored upon human MED13L mRNA introduction (Figure 
31B’’), which further confirmed the phenotypic defect due to MED13L 
deficiency.  These data suggest that defective cranial NCCs in early 
developmental stage contributed to craniofacial anomalies upon med13b 
suppression in these embryos.  
 
Figure 31. Expression of NCCs markers by in situ hybridization.  
(A-A’’) Expression of sox10 at 24 hpf showed expression along cranial ganglia and otic 
vesicle (ov) at 24 hpf in the control embryos (A). Delayed migration of NCCs depicted as 
clustered sox10-positive cells towards more posterior location in morphant embryo (A’) 
and rescued embryo showed comparable to normal sox10 expression (A’’). (B-B’’) 
Alcian-Blue staining at 5 dpf showed staining of ceratobranchial 1-5 (cb), Palatoquadral 
(Pq), Meckel (m) and cerathyal (ch) cartilage in the control (B). ch was severely distorted 
and shifted posteriorly in the morphants (B’), which was restored upon introduction of 





4.5 MED13B SUPPRESSION AFFECTS NEURODEVELOPMENT 
IN ZEBRAFISH EMBRYO 
Another prominent feature of patients with MED13L mutations is mild-to-
moderate intellectual disability. Considering the conserved expression of 
MED13L in the early brain development from fish to human, the role of med13b 
in early neurodevelopmental stage was investigated in the zebrafish embryo. 
Islet1 was used as a marker that is primarily expressed in the retinal ganglion cells 
(RGC), hypothalamus, and ventral telencephalon in the CNS. Med13b morphants 
showed absence of islet1 expression in RGCs and forebrain (Figure 32C’), and 
reduced expression in the hypothalamus and telencephalon, which is restored 
upon human MED13L mRNA co-injection (Figure 32C’’), suggesting impaired 
neuronal development in early embryogenesis. To better examine the events of 
neural differentiation, med13b MO was injected to transgenic HuC:GFP fish, 
where cells that start to develop as neurons initiate expression of green fluorescent 
protein (GFP) under the regulation of HuC promoter. At 48 hpf, a decrease in the 
GFP expression in the optic tectum of the midbrain in morphants was observed 
(Figure 32D’), whereas rescued embryos showed expression relatively similar to 
that of control embryos (Figure 32D’’). These results suggest that med13b have a 




Figure 32. Morpholino knockdown of med13b perturbed neuronal distribution 
across zebrafish brain.  
(C-C’’) Expression of islet1 in the hypothalamus (ht), forebrain (fb), and retinal ganglion 
cells (rgc) is shown in the control (C). Loss of islet1 expression is depicted in the fb, ht 
and rgc of morphants, suggesting developmental delay in the the morphant embryo (C’), 
which was rescued by coinjection of human MED13L mRNA (C’’). (D-D’’) HuC:GFP 
transgenic line showed distribution fo developing neurons as GFP expression across brain 
regions in the control embryos (D). Abnormal distribution of GFP expression in the 
forebrain and midhindbrain boundaries was seen in the morphant (D’), which was 
restored upon mRNA introduction. 
 
4.6 MED13L KNOCKDOWN IN NEURAL STEM CELLS DID 
NOT AFFECT PROLIFERATION 
To further assess the effect of MED13L disruption in human system, hESC-
derived neural progenitor cells (H1-NPC) were used as a model system. These 
NPCs were differentiated from H1 human ES cells (H1-hESCs) using small 
molecule inhibitor cocktails targeting GSK3β and TGF-β signaling pathways, 
based on established protocol.(147) Two shRNAs targeting MED13L were 
transfected into H1-NPC, and resulted in 50-60% suppression of MED13L 




The protein expression of neural stem cells markers NESTIN, SOX2 and 
VIMENTIN were not remarkably different between shScrambled and 
shMED13L1/2 cells, shown by immunocytochemistry (Figure 34), indicating that 
MED13L knockdown did not alter the cell fate, as they still retain NPCs 
characteristics. 
 
Figure 34. Immunocytochemistry of NPCs markers (SOX2, NESTIN, and 
VIMENTIN) in shScrambled, shMED13L1 and shMED13L2 cells. Sox2, 
Nestin and Vimentin were expressed at comparable expression levels between 
Figure 33. Knockdown efficiency of 
shMED13L cells. 
MED13L expression was significantly 
suppressed (up to ~50-60%) by two shRNAs; 
shMED13L1 and shMED13L2 in H1-NPCs. 
Data were collected based on triplicate 




shScrambled and shMED13L NPCs. Images are representative of two 
independent experiments and six field-images were taken for each experiment. 
 
NPCs were able to self-renew and proliferate until a limited number of times 
before they became post-mitotic. The proliferative capacity of these cells was not 
severely affected upon MED13L knockdown as assessed by EdU-incorporation 
assay and Ki67 labeling (Figure 35). The ratio of proliferating cells at different 
cell cycle phases did not show significant differences between shScrambled and 
shMED13L cells. Ki67-expressing cells represented proliferating cells in the 
overall G1 to G2/M cell cycle phase, also did not show any significant differences 






Figure 35. Proliferating cells in different cell cycle phases measured by EdU-
incorporated cells and Ki67 staining. EdU-incorporated cells were measured using 
flow cytometry, and showed no significant differences among shScrambled and 
shMED13L cells. Experiments were performed twice in duplicates. Similarly, percentage 
of Ki67-positive staining were calculated per total number of DAPI-stained nuclei and 
also revealed no significant differences. Ki67-positive cells was counted based on five 






4.7 MED13L KNOCKDOWN DID NOT AFFECT NEURONAL 
MATURATION  
To investigate the impact of MED13L disruption in neurons, H1-derived NPCs of 
both shScrambled and shMED13L cells were maintained at low passage and 
further differentiated into neurons. Neurons generated using this technique 
consists of a mixed population of different neuronal subtypes, and not directed 
towards specific neuronal lineage. At four weeks, these cells express mature 
neuron marker, MAP2 and early differentiating neuron marker TuJ1. The 
expressions of both markers in shMED13L1/2 neuronal cells were comparably 
similar to shScrambled cells (Figure 36), indicating that MED13L suppression did 
not affect neuronal maturation. This result contradicted the observation in 
zebrafish morphants, which showed abnormal distribution of developing neurons 
in zebrafish brain. This could be explained by a lack of positional identity in 
neuronal cell culture to determine specific brain regions, and the neurons 
generated in vitro may not be identical to the affected neuronal cell type in 
zebrafish morphants.  
 
Figure 36. Expression of early neuronal marker (TuJ1) and mature neuronal 
marker (MAP2) in shScrambled, shMED13L1 and shMED13L2 cells assessed by 
immunocytochemistry. TuJ1 and MAP2 were co-expressed at similar level in 
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shScrambled and shMED13L cells at 4-weeks differentiation. Images are representative 
of two independent experiments and six field-images were taken for each experiment. 
 
 
4.8 TRANSCRIPTOME PROFILING OF MED13L-DEFICIENT 
NEURONS   
To further characterize whether MED13L knockdown have impact on other genes 
that might provide clues on its regulation in the genome, microarray experiments 
on shMED13L1/2 neurons were performed at week 4, as this time point is a 
critical transition period between neural progenitors to become post-mitotic 
neurons. In total, 1,117 genes were differentially expressed in shMED13L 
neurons. The top two upregulated genes were SP8, a zinc finger transcription 
factor gene and FGFR3, a fibroblast growth factor receptor 3 gene. Both were 
found nearly 10-times upregulated in shMED13L1 and shMED13L2 neurons. 
Both were confirmed to be upregulated as well in shMED13L NPCs and med13b 
morphant embryos by quantitative RT-PCR (Figure 37). Four other genes with 
known expression in zebrafish NCCs development according to ZFIN database, 
such as pharyngeal arches (calcr), lateral line (rspo3), and pectoral fin (hoxa5 and 
atp1a2) were significantly downregulated (Log2FC = -3.83 to -2.39, p<0.05). 
These data suggest that MED13L suppression also affects the regulation of genes 






Pathway enrichment analysis using PANTHER software was applied on 1,147 
genes and revealed 16 components within canonical Wnt pathway being 
significantly differentially expressed in shMED13L1/2 neurons (Figure 38). 
Figure 37. qPCR analysis of SP8 and FGFR3 in MED13L-knockdown cells. 
This analysis showed upregulated expression of SP8 and FGFR3 in shMED13L1 
and shMED13L2 NPCs and neurons, as well as med13b MO, thus confirming the 




Figure 38. Heatmap clustering of shMED13L1/2 neuronal cells. NCCs genes (shown 
in red) and components of Wnt pathway are differentially expressed in shMED13L1/2 
neurons, compared to shScrambled cells. The dendogram show the hierarchical clustering 






Eight genes from Wnt pathway were selected and validated by qPCR, confirming 
the microarray-predicted changes in these genes for neurons and NPCs, as well as 
med13b morphant embryos, supporting the notion that Wnt signaling is 
deregulated in cells lacking MED13L (Table 16).  
 
Gene Name shRNA/Morphant Microarray 
Fold Change 
qRT-PCR Fold Change 
Neuron  NPC  med13b MO 
WNT7A 
  
shMED13L-1  3.278 2.329 7.639 1.139 
shMED13L-2  3.112 2.371 34.004 
LRP5 
  
shMED13L-1  1.343 1.778 1.375 1.384 
shMED13L-2  1.489 3.349 1.662 
FRZB 
  
shMED13L-1  -5.497 0.096 0.533 0.609 
shMED13L-2  -6.017 0.112 0.365 
PCDHB15 
  
shMED13L-1  -1.576 0.294 0.51 n.o. 
shMED13L-2  -1.939 0.211 0.793 
PCDH17 
  
shMED13L-1  1.488 1.488 1.603 n.o. 
shMED13L-2  1.788 1.473 3.822 
HOXA5 
  
shMED13L-1  -5.277 0.066 0.366 0.701 
shMED13L-2  -6.701 0.02 0.416 
SFRP4 
  
shMED13L-1  -2.180 0.122 0.304 n.o. 
shMED13L-2  -2.614 0.169 0.227 
FZD9 
  
shMED13L-1  1.696 1.465 1.781 0.718 
shMED13L-2  2.745 1.605 2.212 
Table 16. qPCR validation of microarray-predicted changes in shMED13L NPCs, 
Neurons and med13b MO. Eight genes that represent the components of canonical 
Wnt signaling pathways were selected for PCR validations in MED13L 
knockdown cells and zebrafish morphants. qPCR experiments were performed in 
triplicates.n.o. indicates no orthologue in the zebrafish. 
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CHAPTER 5: RESULTS 
STUDYING THE ROLE OF GTDC1 DURING 
NEUROGENESIS 
5.1 STUDY BACKGROUND 
This chapter focuses on a follow-up functional study of Patient CD6 that carries a 
t(2;8) translocation and diagnosed with global DD, SD and language impairment. 
Sequencing analysis of his unaffected parents revealed that this translocation is 
the only de novo SVs within coding regions, and it disrupted GTDC1 at intron 5. 
GTDC1 encodes a glycosyltransferase-domain containing 1 protein of 458 amino 
acids (AA), and its function is largely unknown. The gene was first discovered 
and characterized in human fetal library, and shown to have ~75% homology with 
its mouse orthologue.(176)   It has a glycosyltransferase group 1 domain on its C-
terminus and a transmembrane region in its N-terminus, indicating a type II 
transmembrane protein(176)  Another family member, GTDC2 also known as 
POMGNT2, was recently reported to be causative for Walker-Warburg syndrome 
through exome sequencing study on consanguineous family and functional 
validation in zebrafish model.(177) Based on the preliminary expression analysis 
in human tissues, GTDC1 is ubiquitously expressed in human tissues, including 
fetal brain, and cerebellum (Chapter 3.3).  
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In this study, the correlation of GTDC1 disruption to neurodevelopmental 
phenotype in the patient is investigated through morphological analysis on NPCs 
and neurons derived from patient’s induced pluripotent cells, and H1-NPCs 
lacking GTDC1.   
5.2 SOMATIC CELLS REPROGRAMMING FROM PATIENT’S 
FIBROBLASTS 
Somatic cells reprogramming was performed on the patient’s and control 
fibroblast cells and resulted in generation of multiple iPSCs clones for further 
characterization. The controls were derived from two healthy donors, and the data 
obtained from one of them is shown as representative as the results were similar 
for both controls. Two clones were selected for patient’s iPSCs (Clone 5 and 15). 
Each clone expressed pluripotent markers OCT4, NANOG, SSEA4 and TRA-1-
60 (Figure 39) and maintained t(2;8) karyotypes (Figure 40), which confirmed 
successful reprogramming of patient’s fibroblasts into pluripotent iPSCs, and 




Figure 39. Pluripotent markers (OCT4, NANOG, SSEA4, and TRA1-60) expression 
in iPSCs clones. Two clones of patient’s derived iPSCs (CD6 #5 and CD6#15) and 
control iPSCs showed expression of pluripotent markers, indicating successful 
reprogramming from fibroblast to iPSCs. Images are representative of two independent 
experiments and six field-images were taken for each experiment. 
 
Figure 40. Similar translocation profile is retained in patient’s iPSC clones. G-
banding karyotype of two patients’s iPSC clones (CD6 #5 and #15) showed t(2;8) 
translocation, similar to the patient’s EBV-LCL. 
 117 
 
5.3 PHENOTYPIC CHARACTERIZATION OF PATIENT’S NPCS 
AND GTDC1-DEFICIENT NPCS 
To examine cellular neurogenesis in patient’s cells, patient CD6-iPSCs were 
differentiated into NPCs by using small molecule inhibitors.(147) After one week 
of differentiation, these cells were positive for NESTIN and Ki67 as shown by the 
immunocytochemistry (Figure 41). In parallel, H1-human ES cells were 
differentiated into NPCs using similar protocol. After several passages, GTDC1 
expression was suppressed by using two shRNAs in H1-NPC, and resulted in 
50% reduction of GTDC1 mRNA expression in shGTDC1-1 and shGTDC1-2 
NPCs compared to scrambled shRNA. Similar to the result obtained in the 
patient’s NPCs, immunocytochemistry of NPCs markers NESTIN and SOX2 
performed in these cells showed comparable expression levels between 






Figure 41. Immunocytochemistry of NPCs markers (NESTIN, Ki67, and SOX2) in 
iPSCs and shGTDC1 cells. Upper Panel: Expression of Nestin (green) and Ki67 (red) in 
NPCs differentiated from patient’s iPSCs (CD6 #5 and CD6 #15) and control iPSCs. 
Lower Panel: Similarly, Nestin (green) and Sox2 (red) were expressed in shGTDC1 cells 
and shScrambled cells after differentiation from H1-hESCs. Images are representative of 
two independent experiments and six field-images were taken for each experiment. 
To evaluate whether NPCs proliferation capacity is affected, the proliferation rate 
of patient’s and shGTDC1 NPCs were evaluated by EdU-incorporation assays. 
Interestingly, patient-derived NPCs showed a significantly slower proliferation 
rate compared to control NPCs, and shGTDC1 NPCs also appeared to have 
reduced proliferation rate compared to shScrambled NPCs (Figure 42). The rate 
of proliferation in NPCs is tightly regulated by cell cycle checkpoint genes, and 
crucial to maintain the efficiency of neuronal differentiation. Therefore, 
perturbation in the cycling rate of these progenitors may alter the normal timing to 




Figure 42. Proliferation rate was measured by using flow-cytometry-based EdU-
incorporation assay. Significantly reduced proliferation rate was observed in the two 
clones of patient-derived NPCs (CD6 #5 and CD6 #15)  and shGTDC1/2 NPCs in the S-
phase. Measurements were performed in duplicates and repeated twice.  
 
Glycosyltransferases are the key players for regulating protein glycosylation, an 
important post-translational modification for protein function in diverse biological 
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processes. To investigate the glycosylation status in the patient’s cells, ICAM1 
expression was assessed in  shGTDC1 and patient’s NPCs. ICAM-1 is a recently 
described hypoglycosylation biomarker for congenital disorders of glycosylation 
(CDG) patients. In CDG-patient cells, the protein product of ICAM-1 is degraded 
and rendered unstable upon hypoglycosylation. Analysis of ICAM-1 protein 
expression by immunocytochemistry revealed distinct patterns of ICAM-1 
staining localization (Figure 43). In patient’s NPCs, dotted-like staining diffused 
in the cytoplasm was observed in both clones, compared to control NPCs and 
shScrambled NPCs that localized in the outer plasma membrane. In contrast, 
zipped-like staining pattern was observed in the shGTDC1-1 and shGTDC1-2 
NPCs. Mislocalized expression in patient’s cells may provide clues on the 
possibilities of dominant-negative effect upon GTDC1 disruption. Clearly, 
knockdown cells did not show similar staining pattern, and further experiments 




Figure 43. Glycosylation status is assessed by ICAM1 expression in NPCs. ICAM1 
(green) is expressed on the plasma membrane, as shown in control and shScrambled 
NPCs. In patient’s cells (CD6 #5 and CD6 #15) ICAM1 is mislocalized to the cytoplasm 
in a dotted-like staining, and shGTDC1 cells showed a zipped-like staining pattern. 
Images are representative of two independent experiments and six field-images were 
taken for each experiment. 
To further extend the analysis on the relevant cell type that is affected in NDDs 
patients, the NPCs were differentiated into neurons. The expression level of 
GTDC1 mRNA was reduced in patient’s neuron, indicating that reprogramming 
and differentiation process did not alter the genome characteristics. To investigate 
neuronal morphological phenotypes in patient’s and shGTDC1 neurons, 
immunocytochemistry was performed using TuJ1, early neuronal marker and 
MAP2,  a mature neuron marker, counterstained with DAPI for quantification 
analysis, and showed expression of both markers in patient’s and shGTDC1 
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neurons (Figure 44A). Notably, reduced number of neurons is more pronounced 
in the shGTDC1 cells. 
 
Figure 44 Neuronal markers expressions in patient’s cells and quantification of 
neuronal morphologies.  A) Immunocytochemistry of TuJ1 (green) and MAP2 (red) in 
patient-derived neurons (CD6 #5 and CD6 #15) and shGTDC1 neurons after 4 weeks of 
differentiation. Images are representative of two independent experiments and six field-
images were taken for each experiment. B-D) Quantification analysis of neuronal 
maturation showed lower maturation status (B), reduced soma size (C), and lower 
number of neurites per neuronal cell body (D) in the patient’s cells. *) p < 0.05, **) p < 





First, the efficiency of neuronal maturation was assessed by calculating the 
percentage of colocalization signal threshold between TuJ1-positive cells and 
MaP2-positive cells. In theory, the colocalized signal showed the number of 
differentiated neurons that undergo maturation. Reduced percentage of TuJ1 and 
MAP2-positive cells was similarly observed in patient’s neuron and shGTDC1 
neuron (Figure 44B), suggesting impaired neuronal maturation in these cells. 
Decrease in neuronal soma size has been described previously in neurons derived 
from Rett Syndrome iPSCs and Parkinson’s disease iPSCs. The soma size of 
individual neurons in patient’s and shGTDC1 cells were measured from 3-5 
different fields, and revealed similar reduction of soma size in patient’s and 
shGTDC1 neurons (Figure 44C). To measure the neurite outgrowth, neurons were 
passaged in a lower density in similar condition for patient and shGTDC1 cells, as 
well as control cells. There is a significant decrease of neurite density per 
neuronal cell body in both patient’s and shGTDC1 neurons, as compared to 
control (Figure 44D). Together, these data provide evidence of impaired neuronal 
maturation, and morphologically abnormal neuronal properties, shown by reduced 
soma size and lower number of neurites per cell body. 
5.4 TRANSCRIPTOME PROFILING OF PATIENTS AND SHGTDC1 CELLS 
To further characterize the transcriptome alteration between four types of cells 
(shGTDC1, shScrambled, Control-iPSCs, and Patient-iPSCs), exploratory 
microarray experiments were performed in NPCs and neurons. In this regard, the 
patient’s and shGTDC1 expression profiles were hypothesized to be closely 
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related due to GTDC1 loss of function in both cell types. In total, 659 and 430 
genes were differentially expressed in the patient’s NPCs and neurons, 
respectively (Figure 45). In shGTDC1 cells, 721 and 2264 genes were 
differentially expressed at NPCs stage and neurons, respectively, of which 49 and 
61 genes were found to be overlapped between patient’s cells and shGTDC1 cells 
at NPCs and neurons, respectively. 
 
Figure 45. Venn diagram of differentially expressed genes that are in common in 
NPCs and neurons between patient’s and shGTDC1 cells. Differentially expressed 
genes in each sample were extracted and analyzed with GeneSpring analysis software 
using parameters described in Chapter 2. Data were collected from two biological 
replicates and normalized with controls in one microarray slide. 
 
Hierarchical clustering showed that samples from patient’s and shGTDC1 cells 
tightly clustered with each other, and separated from the control-iPSCs and 
shScrambled cells (Figure 46), suggesting that patient’s cells and shGTDC1 cells 





Figure 46.Heatmap clustering of the differentially expressed genes that are in 
common between patient’s and shGTDC1 NPCs. Each column represent duplicate 
samples indicated in the upper panel. Genes that were highly expressed are shown in 
yellow. The dendogram show the hierarchical clustering based on the differentially 
expressed genes. Patient’s cells and shGTDC1 cells are clustered separately from the 
controls.  
 
Among the differentially expressed genes, two genes were found to be 
upregulated 5 to 8 fold consistently in the NPCs of both patient’s and shGTDC1 
cells; STMN2 and CNTN2. STMN2 encodes stathmin-2 like, which plays a role in 
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neuronal growth, and functions to stabilize microtubule. CNTN2 encodes 
contactin 2, a glycosylphosphatidylinositol (GPI) anchored neuronal membrane 
protein and has a role in axon guidance.  
To examine the biological pathways that were affected in the patient’s cells and 
GTDC1 knockdown in both stages, enrichment analysis was performed by using 
DAVID web server that show Gene Ontology categories from significantly 
altered genes. The top five most-enriched GO categories of biological processes 
that are in common between patient cells and shGTDC1 cells are shown in Figure 
48. At NPCs stage, the top GO categories were related to organ development, 
cellular growth and proliferation, cell death and survival, and cellular movement. 
The GO terms in cellular growth and proliferation might be correlated to reduced 
number of cells cycling in S-phase at NPCs stage, in both patient’s and shGTDC1 
cells. The upregulated genes in NPCs showed enrichment of embryonic 
development, nervous system development, cellular assembly, and cellular 
function and maintenance, suggesting that GTDC1 disruption has significant 
impacts on other genes that are involved in the neurodevelopmental processes. 
Among the downregulated genes in neurons, biological processes affecting 
nervous system development were affected, such as morphology of nervous 
system, neuritogenesis, organization of cytoskeleton, cellular and tissue 
development, which could explain the abnormal neuronal properties of patient’s 




Figure 48.The top five GO categories that are in common between patient’s and 
shGTDC1 cells. This analysis showed significant enrichment of nervous system 




CHAPTER 6: DISCUSSION 
The major challenge in identifying novel NDDs genes is the heterogeneous nature 
of genetic etiologies and phenotypic expression observed in these patients. Many 
symptoms are not unique to single NDD syndromes, and several NDDs have 
clusters of clinical entities in common.(4) Similarly, genetic mutations found in 
certain syndromic form of NDDs could be shared with an idiopathic NDDs, for 
example TCF4 is known to cause Pitt-Hopkins syndrome (MIM 610954)(178), 
and mutations in this gene have been reported in individuals with idiopathic DD 
as well. (179) Depending on the variants being investigated, either single-
nucleotide changes, large structural rearrangements, or epigenomic changes, the 
choice of screening method is crucial to determine diagnostic yield. In this thesis, 
the first study aimed to pinpoint candidate genes within the breakpoints of 
chromosomal rearrangements using a high-throughput sequencing approach. 
Secondly, the thesis focused on defining the functional significance of selected 
disrupted genes within the chromosome rearrangements in patients diagnosed 
with NDDs or DDs.  
First, the patients carrying known chromosomal rearrangements and diagnosed 
with symptoms of NDDs were screened through genome paired-end tag 
sequencing, to fine-map the rearrangement breakpoints and to identify potential 
additional SVs apart from the cytogenetically visible rearrangements. I further 
prioritized candidate genes for functional studies from seven cases and selected 
two genes for further characterization: GTDC1, based on trio sequencing analysis 
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availability and MED13L, based on previously reported mutations in patients with 
a similar clinical phenotype. I showed that MED13L plays a role in cranial NCCs 
development and neurodevelopment through zebrafish model and neuronal 
cultures derived from hESCs, which is likely to contribute to the craniofacial 
anomalies and ID in the patient. Finally, GTDC1 studies involved the use of 
iPSCs and human ES cells with suppression of GTDC1, in which cellular 
phenotype showed abnormal neuronal morphology in the patient’s cells.  
 6.1 CLINICALLY RELEVANT GENE DISRUPTIONS IN THE 
CHROMOSOMAL REARRANGEMENT BREAKPOINTS 
Over the last couple of years, tremendous numbers of novel candidate genes 
involved in NDDs have been reported through studies employing NGS 
technologies. Not only has this revolutionary approach enhanced the 
understanding of the underlying etiology, but also the implications of interpreting 
such variants have slowly emerged. Disease genes discovery through mapping 
genes in chromosomal breakpoints have long been applied in classical cytogenetic 
hypothesis model. This model relies on the large structural rearrangements that 
potentially disrupt, truncate or inactivate coding gene or subjected to position 
effect of regulatory elements, as the primary cause of phenotypes that segregate 
with the rearrangement. In cases where the rearrangements are transmitted to 
individuals without disease, the causality of such rearrangements in the 
expression of a phenotype is not entirely clear. In addition, other types of genetic 
mutations such as SNVs also bear functional consequences, which could alter 
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protein sequences, adding a premature termination codon, or affecting alternative 
splicing. It has also been understood that genetically heterogeneous disease such 
as NDDs are not caused by single gene disruption, but rather a combined effect of 
rare variants, either SVs or SNVs.(47, 48, 180)  
In this study, seven patients from unrelated families and two parents were 
examined through DNA-PET sequencing to assess genome-wide SVs that could 
potentially explain their phenotypic features. These patients carried specific 
chromosomal rearrangements that were interpreted as likely to be pathogenic by a 
clinical geneticist. The sequencing yielded relatively high coverage comparable to 
other studies employing similar technique in patients with chromosomal 
rearrangements.  In total, eight genes were identified at the chromosomal 
breakpoints; GNAQ, RBFOX3, UNC5D, XIAP, TMEM47, NCAPG2, GTDC1 and 
MED13L, and one gene was identified from patient’s SVs, MCPH1. These genes 
have biologically relevant functions important for normal neurodevelopment, 
involved in axon guidance, chromosomal condensation, glycosylation, 
transcriptional regulation and alternative splicing regulation. Cryptic deletions 
ranging from 3 bp to 5,462 bp were found in the breakpoint junctions revealed by 
Sanger sequencing, and microhomologies of 2-4 bp between paired breakpoints, 
suggesting a microhomology-mediated end joining (MMEJ)(181) or non-
homologous end joining mechanism (NHEJ)(182). Both pathways are major 
pathways for double strand break repair that often occurred in non-homologous 
regions of chromosomal rearrangements such as translocations or inversions, 
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involving few nucleotide deletions and short stretches of microhomologies 
between the junctions(183-185). 
Of the seven patients, four were familial cases, and one had a translocation that 
fully segregated with the disease in the family of patient CD5. The translocation 
created fusion genes GNAQ-RBFOX3 on both derivative chromosomes, which 
could not be validated on the patient’s cell line, as RBFOX3 is a neuronal-specific 
gene and is not expressed on the lymphocytes. In theory, fusion genes that are 
commonly seen in several forms of cancer, may give rise to gain of function or 
haploinsufficiency of individual genes, and could serve as an important biomarker 
for diagnostic purposes. Both genes have important roles in neuronal growth and 
development. GNAQ null mice displayed cerebellar ataxia, and delayed growth of 
neuronal cells, and RBFOX3 is an important regulator of alternative splicing of 
exons during neuronal differentiation. Since the translocation was transmitted to 
two affected sons with variable degrees of NDDs, this translocation appears to 
illustrate that the variability of expressed phenotype from a genetic mutation is a 
common phenomenon in neurological disorders. 
 
In one familial case, the inversion found in patient CD8 disrupted a causative 
gene XIAP, which has been linked to XLP2(186, 187) (XLP2 [MIM: 300635]), 
and was likely to be the cause for the immunodeficiency phenotype seen in this 
patient. Although the inversion is derived from a phenotypically normal mother, 
this could be explained by the alternate X-inactivation in the mother. Moreover, 
his monozygotic twin brother has identical symptoms, suggesting the penetrance 
 132 
 
of the causative gene in this familial case. The remaining two familial cases 
(Patient CD10 and CD14) did not show a complete segregation with the disease, 
which further complicates the interpretation of disrupted genes in the 
chromosomal breakpoint. The translocation in patient CD10 affecting UNC5D, a 
dependence receptor involved in axon guidance and neuronal migration, is 
derived from a phenotypically normal mother and is also present in his younger 
sister that displayed schizencephaly and polymicrogyria. These structural brain 
abnormalities were not present in the patient CD10, suggesting additional genetic 
factors that may influence the phenotype. However, there is an enrichment of 
CNV counts encompassing UNC5D in DD cases and DECIPHER database, 
indicating increased CNV burden in this patient that could be clinically relevant. 
 
In patient CD14, two deletions were identified from SVs analysis. A telomeric 
deletion at 7q36 that truncate NCAPG2 gene and delete three other genes VIPR2, 
WDR60, ESYT2, was inherited from his asymptomatic father. The patient 
harbored a second deletion in MCPH1 from exon 6 to 8, which was found to be 
inherited from his healthy mother. Initially, this case was complicated by the 
interpretation of apparently normal carrier parents, casting doubt on the validity of 
the identified CNVs underlying the phenotype of this patient. Interestingly, 
MCPH1 and NCAPG2 are known to interact during chromosome condensation 
preparing for mitosis, and the binding site of NCAPG2 in the MCPH1 is deleted 
in this patient. Thus, the impaired interaction due to two-hit deletions could  
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contribute to ID and severe microcephaly in this patient, as it has been described 
by Perche et al.(188) 
 
For the remaining three de novo cases, one inversion in patient CD9 did not 
disrupt any coding genes, or regulatory elements, thus the causality of the 
inversion is not proven, emphasizing the limitation of candidate gene detection 
merely through ABCR breakpoint cloning methods.  In this case, the presence of 
point mutations, and exposure to environmental factors, which could not be 
investigated through technology applied in this study, might be the contributing 
factors to the patient’s phenotype. Alternatively, position effect due to disruption 
of regulatory elements that control neighboring gene expression that has not been 
studied by ENCODE could be another possibility, which has been demonstrated 
in previous studies as significant contributing factors to the phenotype.(189-193) 
 
The remaining two de novo translocation cases disrupted potentially causative 
genes, GTDC1 and MED13L. GTDC1 was identified as the only disrupted gene in 
patient CD6 based on de novo SVs analysis using parental data. GTDC1 has a 
glycosyltransferase domain, in which most glycosyltransferases plays a role in 
catalyzing the synthesis of the carbohydrate portions of glycoproteins, glycolipids 
and proteoglycans. Mutations in glycosyltransferases have been associated with 
congenital disorders of glycosylation (CDG [MIM 602579]). MED13L is a 
Mediator complex subunit that plays a role in repression of RNA-Polymerase II-
dependent transcription. Structural rearrangements in MED13L including 
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translocation and CNVs have been reported in patients with craniofacial 
anomalies, and ID, suggesting a possible classification of new syndrome due to 
MED13L haploinsufficiency.  
In summary, gene disruption in four out of seven (~57%) patients might 
contribute to explain the underlying phenotype of these patients. By combining 
classical methods and recent technology, large-scale screening of chromosomal 
rearrangements can be performed more rapidly, and reporting gene disruptions in 
microscopically visible rearrangements is important to determine the clinically 
relevant variants, especially for undiagnosed cases. Although technology 
continues to improve, validation with longer read Sanger sequencing is still 
necessary for better annotations of SVs.  
6.2 LIMITATIONS OF DNA-PET SEQUENCING 
 
DNA-PET sequencing has been shown to be powerful in finding candidate genes 
by mapping the chromosomal rearrangement breakpoints. However, this approach 
is limited to the ability to detect large rearrangements, and is unable to detect 
single nucleotide variants. Highly repetitive sequences such as telomeric regions 
are difficult to call (as shown in Patient CD14), although this can be resolved by 
extracting the sequencing read-depth copy number information that could 
facilitate detection of subtelomeric rearrangements. Furthermore, in order to 
implement this technique faithfully in the clinic, it requires a more established 
SVs calling pipeline for a more rapid and simplified interpretation for the 
clinicians. For example, the turnaround time for DNA-PET sequencing from 
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patient’s sample collection to post-sequencing analysis could take about 1 month 
per patient, compared to less than a week turnaround time of karyotyping or 
aCGH. In addition, a much bigger study is needed to carefully classify certain 
group of patients that may benefit from DNA-PET sequencing analysis. Overall, 
this technique may not be suitable for group of patients that require a fast and 
‘actionable’ outcome or for a prenatal diagnosis, due to its turnaround time. On 
the other hand, it can be potentially applied to non-syndromic NDDs patients that 
have gone through extensive genetic testing without a conclusive diagnosis. These 
patients may benefit from a genome-wide screening that could provide novel 
insights into disruptive mutations associated with their phenotypes.     
6.3 LARGE PHENOTYPIC SPECTRUM IN PATIENTS WITH 
MED13L DISRUPTIONS 
NDD syndromes could be classified based on known genetic etiology and 
multiple overlapping clinical phenotypes. In this study, I described the large 
phenotypic spectrum of patients with distinctive facial characteristics and ID 
sharing a single gene disruption. There are eight patients that have been reported 
in the literature, and one described in this study to have mutations in MED13L. 
The clinical features among four patients largely overlap; two patients with out-
of-frame deletion, a first translocation case reported by Muncke (194), and the 
patient described in this study. All of them similarly displayed craniofacial 
anomalies that coexisted with ID. In three patients, heterozygous non-
synonymous SNVs caused cardiac defects (172), and homozygous non-
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synonymous SNVs in two siblings displayed non-syndromic ID without cardiac 
defect (174). One patient carrying a triplication of the whole gene showed 
comparably similar phenotype including the cardiac defect, craniofacial 
anomalies and muscular hypotonia, which also involved a neighboring gene 
MAP1LC3B2. Overall, cardiovascular defects were present in 7 out of 9 cases 
(78%).  
Some of the patients reported in previous studies were initially screened and 
tested negative for 22q11.2 deletion, since their clinical features resembled a well-
described neurocristopathy, Velocardiofacial syndrome (VCFS [MIM 192430]), 
or DiGeorge sequence (DGS [MIM 188400]) (VCFS/DS). This group of disorders 
is caused by defects in the development of specific neural crest that differentiates 
into organs such as thyroid, thymus and conotruncal septum of the heart.(195) In 
the early classification of patients into VCFS/DS, some patients were noted to 
have Pierre-Robin syndrome (~10%)(196, 197), and cardiac defect was not 
always present (~82% of the cases have cardiac anomalies)(198).  
In comparison to the primary symptoms of VCFS/DS, patients with MED13L 
haploinsufficiency displayed nearly identical craniofacial features such as 
upslanting palpebral fissures, bulbous nose, flat nasal root, and differing palatal 
problems including macroglossia, micrognathia or Pierre-Robin sequence. In 
addition, neurocognitive defects ranging from SD, DD, LD or ID were 
consistently seen in each individual with MED13L mutations, suggesting a 
correlation of MED13L disruption to neurodevelopmental phenotype in these 
patients. A recent study described two additional patients with craniofacial 
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anomalies and ID but without heart defects, carrying de novo exonic deletions in 
MED13L.(175) These observations support a reduced cardiac penetrance for 
MED13L haploinsufficency. Overall, these clinical data suggest a potentially 
novel classification of patients with MED13L haploinsufficiency, and could 
provide diagnostic value that may benefit patients in the future. Further screening 
in larger number of patients is required to carefully establish this diagnostic 
classification.  
6.4 MED13L HAPLOINSUFFICIENCY CONTRIBUTES TO 
CRANIOFACIAL ANOMALIES AND ID  
To interrogate the correlation of MED13L disruption and its possible involvement 
in neural crest defects, zebrafish was used to model craniofacial cartilage 
structures, as it has been shown that genes controlling the development of the jaw, 
pharyngeal arches, and midline of the skull are conserved between fish and 
human.(199) Studies in this animal model have enhanced our understanding on 
mechanisms of craniofacial development. Actually, many congenital anomalies 
involving craniofacial dysmorphism have been modeled in zebrafish (177, 200-
202). 
 I showed that craniofacial cartilage defect due to med13b loss of function is due 
to early migration defects of cranial NCCs. Since the craniofacial defects coexist 
with ID in individuals with MED13L mutations, I attempted to address whether 
loss of MED13L affect the process of neurodevelopment. By expression of 
neuronal markers in zebrafish brain, I observed lack of expression in certain brain 
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regions due to abnormal distribution of early differentiating neurons. However, 
the finding obtained in human cells was not concordant with the zebrafish data, 
which showed no remarkable differences in NPCs and neuronal morphology, 
including neuronal differentiation efficiency, proliferation rate of NPCs, and 
neuronal maturation. This could be due to lack of positional identity of 
differentiated cell type from human ES cells. Further functional analysis on these 
neurons might provide clues on perturbed neurodevelopment that is consistently 
seen in patients with MED13L haploinsufficiency.  
Interestingly, the transcriptome profile of MED13L deficient neurons showed 
enrichment of genes important for cranial neural crest induction, such as SP8 and 
FGFR3. SP8 encodes an SP family of transcription factors that plays a crucial role 
in regulation of craniofacial development through FGF signaling pathway.(203) 
Among differentially expressed genes, I showed that components of the canonical 
Wnt pathway were dysregulated in MED13L-deficient neuronal cells, suggesting 
a possible role of MED13L in Wnt signaling.  
Canonical Wnt signaling is essential to a variety of biological processes, including 
NCCs induction, neurogenesis, cell proliferation, cell fate specification, and axis 
patterning. This finding was consistent with previously published reports 
describing physical interaction between other Mediator complex subunits and 
canonical Wnt signaling pathway in mouse, Drosophila and zebrafish studies. 
Med12 hypomorphic mouse mutant had impaired canonical Wnt signaling 
pathway.(204) Transcript expression of downstream target genes of Wnt, Pygopus 
required recruitment of Mediator complex through med12 and med13 in 
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Drosophila.(205) Depletion of Med10, Med12 and Med13 enhances Wnt 
signaling pathway in zebrafish morphants.(206) MED12 has been demonstrated to 
physically interact with β-catenin, and Mediator was recruited to Wnt-responsive 
genes in a β-catenin manner.(207) The data presented in this thesis further extend 
the involvement of MED13L, as part of Mediator complex to interact with Wnt 
pathway for transcription of specific genes, which has yet to be further 
investigated. Together these expression data derived from human neuronal 
cultures provided a mechanistic insight to the patient’s craniofacial defects arising 
from altered genes and pathway that are important for early cranial NCCs 
induction and specification. 
6.5 MORPHOLOGICAL ALTERATIONS IN NEURONS DERIVED 
FROM PATIENT’S IPSCS AND GTDC1-DEFICIENT CELLS 
Since the breakthrough discovery by Yamanaka and colleagues in 2006,(146, 
208) studies using patient’s derived iPSCs have been exponentially reported over 
the last couple of years mainly in neurological and cardiac diseases. These iPSCs 
exhibited similar transcriptional and epigenetic profiles to hESCs that could also 
be used for non-invasive high-throughput drug screening, or cell replacement 
therapy. Despite the growing trend of using iPSCs to explore the cellular 
phenotype associated with diseases, there are still many issues to overcome before 
the full potential of iPSCs can be widely accepted in clinical application. One of 
the issues is the use of appropriate control for a fair-comparison to the patient’s 
phenotype, which is still highly debated in the community. Ideally, the control 
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could be derived from an unaffected family member. However, in NDDs, parents 
or older healthy individuals are not ideal, especially for iPSCs derived from skin 
fibroblast, considering the likelihood of environmental exposure such as UV 
radiation, accumulated over the years in older individuals. On the other hand, 
isogenic cell lines can be generated through the currently available genome-
editing methods and served as the most appropriate control for iPSCs-based 
disease modelling studies. Another issue is the individual cell line variability 
during iPSCs generations, which confound the ability to distinguish disease-
associated alteration. Thus, Maherali and Hochedlinger proposed a few criteria of 
ideal iPSCs to consider as true pluripotent cells, including morphological 
resemblance to ESCs, being self-renewal, low genome instability, expression of 
pluripotency genes and teratoma formation.(209) Once the iPSCs passed these 
criteria, the abnormalities seen through patient’s iPSCs could provide valuable 
insight into disease mechanism and may lead to the development of diagnostic 
tools and drugs for early intervention. 
In this study, the discovery of GTDC1 in a familial translocation from trio-
sequencing provided a compelling candidate to follow-up in functional studies, 
considering it was the only de novo candidate gene from DNA-PET screening. De 
novo mutations in sporadic NDDs cases are known to contribute to disease 
etiology and they have been studied for many years. The availability of patient’s 
fibroblast enabled somatic reprogramming into iPSCs to further extend the 
understanding of disease mechanism in similar genetic background to patient’s 
cells. The pluripotent assays of patient’s iPSCs have shown effective 
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reprogramming by expression of pluripotency markers and similar translocation 
profile in the karyotype. To investigate the disease states in relevant cell types, 
patient’s iPSCs were differentiated into NPCs and neurons, in parallel to the 
GTDC1-depleted cells and control iPSCs. The first striking observation was the 
slower proliferation rate in the NPCs derived from patient’s iPSCs and shGTDC1 
cells, although it was moderately slower in shGTDC1. Previous iPSCs studies in 
Rett syndrome(210), Timothy syndrome(211, 212) or FXS(213) did not show any 
differences in cell-cycle length between patient cells and controls. This could be 
explained by the transcriptome profile of downregulated genes, showing 
enrichment of GO terms in cell growth and proliferation, namely Cyclin E1 
(CCNE1), Cyclin D1 (CCND1), and Cyclin D2 (CCND2), which are important 
regulators for maintaining transition between cell-cycle phases. The observed 
slower proliferation rate in NPCs stage might underlie the lower maturation status 
of differentiated neurons, as it has been demonstrated by lower percentage of 
early neurons that became mature neurons in patient’s and shGTDC1 cells. 
Additionally, there were several morphological alterations observed in both 
patient’s and shGTDC1 neuronal cells, including reduced soma size and 
decreased number of neurites. Reduced soma size has also been reported 
previously in Rett syndrome iPSCs, which was supported by prior observation in 
post-mortem brain tissue of Rett patients. Post-mortem brain studies in other 
NDDs syndromes also have shown reduced neuronal soma size in the cortex of 
schizophrenia and autism patients. The underlying theory of decreased size of 
neuronal soma is that it could affect the projection of output signals and the 
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packing density of individual neurons to form a certain brain region. The final 
morphological alteration in patient’s and shGTDC1 cells is the decreased number 
of neurites as means of measuring neurite outgrowth in these cells. Reduced 
number of neurites could significantly affect the wiring connection in the brain, as 
the information between neurons is transmitted through communication of 
synapses, arising from neurite extension from individual neurons. Furthermore, 
the enriched GO terms in the upregulated genes of both patient and shGTDC1 
neurons are involved in neuritogenesis, morphology of nervous system and 
organization of cytoskeleton, which are biological processes important for 
formation of neurites and dendrites. Together these data showed profound 
morphological changes that could be explained by the transcriptome profile of 
these cells, and the finding in patient’s cells provided a comparably similar trend 
to the shGTDC1 cells, emphasizing that the arising morphological phenotypes 
could be due to disruption in GTDC1.  
Considering GTDC1 as a glycosyltransferase and mutations in glycosyltransferase 
are known to cause CDG syndrome(214-216), I further sought to determine 
whether GTDC1 disruption could lead to a novel CDG syndrome by measuring 
the glycosylation status through ICAM1 expression in patient’s cells.(217) 
Distinct staining pattern of ICAM1 was observed in the patient’s cells, as shown 
by diffused staining in the cytoplasm rather than at the plasma membrane in the 
control cells. Previous study reporting the use of ICAM1 in CDG patients showed 
complete absence of ICAM1 in patient’s fibroblast cells. However, shGTDC1 
NPCs did not show similar staining pattern as in the patient’s cells, with the 
 143 
 
protein localized to the plasma membrane in a zipped-like pattern. This 
discrepancy could be due to the genetic or epigenetic background of the patient’s 
cells, compared to a specific disruption on GTDC1 in the knockdown cells. 
Alternatively, mislocalized ICAM1 expression in the patient’s cells could be due 
to dominant-negative protein expression of the mutated allele. Additional 
experiments should be performed to test this hypothesis, such as overexpressing a 
truncated form of GTDC1 protein in H1-NPCs and check for ICAM1 localization. 
Together these data showed the possible involvement of GTDC1 in this patient’s 
neurodevelopmental phenotype. Mutation screening to identify novel patients and 
further functional assays are required to establish its potential delineation as a 
novel mild form of CDG syndrome, considering the phenotype is limited to affect 





CHAPTER 7: CONCLUSION 
 
The work presented in this thesis consisted of three major findings:  
- The genome screening conducted in seven patients with prior cytogenetic 
information led to the identification of eight genes disrupted in the 
chromosomal breakpoint regions, and one candidate gene detected from 
private SVs of one patient that was previously unexplored by karyotypic 
observation. These eight genes were expressed in the brain, and have 
biologically relevant function to the neurodevelopmental processes. In 
comparison to the laborious chromosome walking method by FISH to map 
breakpoints that would take 6-12 months, DNA-PET sequencing provided a 
more straightforward detection of breakpoints, thus faster validation by using 
PCR or FISH can be achieved by using precise coordinate derived from 
sequence data.  
- The clinical evaluation of MED13L in patients with nearly identical 
phenotypes showed a consistent phenotype, including craniofacial anomalies, 
cognitive deficits and in some cases, cardiovascular defects. Loss of function 
assays in med13b, zebrafish orthologue of MED13L, provided evidence of 
early migration defect of cranial NCCs that subsequently resulted in 
craniofacial cartilage anomalies. Transcriptome profiling of MED13L-
deficient neurons showed expression changes of cranial NCCs genes, and 
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components of Canonical Wnt signaling, suggesting that MED13L alteration 
could affect the transcriptional regulation of genes important for 
developmental processes.  
- The characterization of GTDC1 being the only disrupted gene based on 
sequencing of a trio provided a possible correlation to the neurodevelopmental 
phenotype seen in the patient. Further functional assays in neurons derived 
from patient’s iPSCs and parallel comparison to GTDC1 knockdown cells 
showed morphological defects affecting the proliferation rate of progenitor 
cells, maturation efficiency, neuronal soma size and neurite outgrowth. These 
data suggested potential implication of GTDC1 to underlie 
neurodevelopmental disturbances. Although disruptions or mutations in this 
gene have not been reported in normal individuals databases, description of 
additional patients with GTDC1 mutations are required to further strengthen 
the hypothesis of this gene as the causative gene for idiopathic NDDs.  
In summary, the work presented in this thesis showed how recent technological 
advances have improved the evaluation of chromosomal rearrangements, and 
therefore have allowed rapid identification of new developmental genes, which 
provided significant impact on the understanding of the pathophysiology of ID 
and NDDs. These findings provided clinical significance in terms of discovery of 
novel candidate genes in ABCR, and the potential involvement of MED13L and 




CHAPTER 8: FUTURE DIRECTIONS 
 
In the discovery part of this thesis, I demonstrated the application of PET 
sequencing as an alternative to WGS, and its efficacy for identification of large 
SVs. The implementation of this technique in clinics has yet to pass several 
criteria, including the requirement of large amounts of DNA (40 µg), coverage 
variability of sequencing machines, a filtering pipeline, interpretation of variants, 
turnaround time and cost-effectiveness. This study used a SOLiD sequencing 
machine that required high amount of genomic DNA. During the course of this 
study, improvements in the protocol has been implemented in the institute, by 
using lower input of DNA (5 µg), sequencing by Illumina platform, an improved 
algorithm for sequence mapping to the reference genome and variants calling. As 
the sequencing cost continues to drop, DNA-PET is potentially suited to be 
implemented in the diagnostic workup for unexplained NDDs. However, the 
turnaround time for DNA-PET sequencing (~1 month) takes much longer than G-
banding karyotyping (2-3 days) and aCGH (4 days), which is the major limiting 
factor of DNA-PET for a detailed genetic assessment. In addition, the cost of trio 
sequencing is currently still very high (SGD 5,000 per individual), suggesting that 
certain parameters will need to be considered before its potential application in 
diagnostic settings.   
In the second part of this thesis, I assessed the overlapping clinical phenotypes 
among patients with MED13L disruptions, reflecting the potential delineation of a 
novel clinical entity. Although it is clear that these patients resembled each other 
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due to MED13L disruption, additional screening of patients with MED13L 
mutations in a large number of cases would need to be performed to carefully 
delineate the novel classification. In addition, further functional study of MED13L 
can be pursued to strengthen the current hypothesis. One attempt could be 
performed by using a genome-editing approach in zebrafish, as means of a stable 
generation of mutant lines, instead of a transient-knockdown approach induced by 
morpholino. There are several genome-editing methods currently available, such 
as TALEN, Zinc-Finger Nucleases and Crispr/Cas9 system. In this way, the 
comparison between morphants and mutant fish could show whether the mutant 
lines displayed similar defects in craniofacial development and neuronal 
distribution in the brain. Further investigation of Wnt or FGF enzyme activity 
through luciferase assays in zebrafish and neuronal cells can provide an insight 
into downstream effects in MED13L-deficient cells, and this could facilitate 
cross-validation in different cell types. Characterization of Wnt pathway 
interactions with MED13L and considering its functions in various biological 
processes would be important to follow up further. This can be performed by 
injecting morpholino or genome-editing nucleases in zebrafish transgenic lines of 
Wnt-component pathway, which could help to directly visualize the distribution 
of Wnt-expressing cells in live cells.  
In addition, neurons derived from H1-derived NPCs upon MED13L knockdown 
did not show morphological alterations, and further studies would be required to 
validate its involvement in neurogenesis. Based on the transgenic zebrafish 
model, the post-mitotic neurons was not proportionally distributed in different 
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brain regions of med13b MO embryos. Thus, migration assays in MED13L-
deficient neuronal cells could be performed by time-lapse imaging of neurite 
extension from neurons plated in a very low density. Alternatively, since 
MED13L is expressed in the cerebellum, it will be interesting to modify the 
differentiation protocol into cerebellar neurons. The correct cell type could 
theoretically provide unbiased mechanism, compared to the currently applied 
general differentiation protocol.   
In the last part of the thesis, I showed several morphological alterations in neurons 
derived from patient’s iPSCs and GTDC1 knockdown cells. However, these are 
morphological observations and did not provide molecular insight into the 
neuronal activity of these cells. Electrophysiological studies are required to 
measure the firing of action potentials, an important feature of neuronal activity to 
become mature and electrophysiologically active. Patient’s iPSCs derived neurons 
and GTDC1 knockdown cells have to be depolarized using sodium (Na) or 
calcium (Ca) prior to measurement of the spontaneous excitatory and inhibitory 
postsynaptic currents. Furthermore, rescue experiments are necessary to prove the 
causality of GTDC1 whether the phenotypic defect seen in the patient’s cells can 
be restored. So far, none of the iPSCs studies in NDDs used any rescue 
experiment involving the introduction of an intact gene expression to restore the 
neuronal phenotype; rather they used pharmacological agents such as antibiotics 
to read through the premature stop codon for non-sense mutations, or IGF-1 
treatment that demonstrated a correction of neuronal phenotype. It is unclear 
whether these studies attempted to overexpress the mutated gene due to well-
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defined genetic etiology in these syndromes. As in the case of GTDC1, a single 
patient with a mutation required a rescue experiment to build a stronger case for 
its involvement in NDDs. This can be performed by overexpressing GTDC1 into 
the patient’s NPCs, and showing whether the neuronal morphological phenotypes 
could be restored. This study highlights the importance of using a combination of 
genome screening followed by functional studies in animal models and iPSCs to 
better understand the disease mechanisms at the cellular level. The potential use 
of this combined approach in clinical genetics would help to provide an insight 
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1 Del chr1 (+) :72,390,624-72,430,488 17 39,864 NEGR1 Intronic deletion 28 + + + 
2 Del chr1 (+) :109,337,135-109,357,109 15 19,974 WDR47 Deleted exon 5-8  9 + + + 
3 Del chr1 (+) :114,674,249-114,682,110 16 7,861       - - - 










TMSL3 Full length deletion 2 + - + 
GRID2 Deleted exon 1-2  46       
6 Del chr4 (+) :122,847,359-122,891,237 16 43,878       + + + 
7 Del chr6 (+) :89,226,451-89,232,156 7 5,705       + + - 
8 Del chr7 (+) :16,201,711-16,211,601 25 9,890       + + - 
9 Del chr7 (+) :142,534,798-142,604,566 16 69,768 TAS2R39 Full length  3 + - - 
          PIP Full length  67       
10 BT chr9 (+) :79,571,716; chr17(+) :74,768,401 16 NA GNAQ Bp at intron 5   + + + 
          RBFOX3 Bp at intron 2         
11 BT chr9 (-) :79,573,787; chr17(-) :74,764,804 14 NA GNAQ Bp at intron 5   + + + 
          RBFOX3 Bp at intron 2         
12 Del chr11 (+) :7,643,628-7,653,635 6 10,007 CYB5R2 Deleted exon 4-7 1 - - - 
13 Del chr15 (+) :59,473,758-59,487,405 28 13,647       + + + 
14 Del chr16 (+) :4,072,901-4,082,506 7 9,605 ADCY9 Intronic deletion 6 - - - 
Abbreviations: Del, Deletion; BT, Balanced translocation 
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Table S2. List of SVs found in patient CD10 
SV No SV Type Breakpoint Cluster Size Span (bp) Gene DNA alteration DGV 
1 Del chr1 (+) :202,173,929-202,188,904 27 14,975       
2 Del chr2 (+) :139,455,505-139,459,801 29 4,296       
3 Ins chr2:178,545,739; chr12:54,068,618 14 NA PDE11A Disruption intron 1 18 
4 Ins chr2:178,564,890; chr12:54,070,437 6 NA PDE11A Disruption intron 1 18 
5 Del chr4 (+) :92,499,237-92,504,340 29 5,103 FAM190A Intronic deletion 79 
6 Del chr6 (+) : 34,511,385- 34,517,410 31 6,025       
7 BT chr6:98,318,059; chr8:35,527,808 36 NA UNC5D Breakpoint at intron 2   
8 BT chr6:98,326,375; chr8:35,528,282 34 NA UNC5D Breakpoint at intron 2   
9 IT chr7:224,069; chr15:100,042,752 48 NA TARSL2 Disruption intron 11   
10 Del chr7 (+) :5,846,915-5,855,247 13 8,332 ZNF815 Deleted exon 4-6 6 
11 Del chr7 (+) :11,886,866-11,889,627 26 2,761       
12 Del chr7 (+) :100,369,276-100,374,934 22 5,658       
13 TD chr10 (+) : 84,405,124-84,414,680 30 22,078 NRG3 Intronic duplication 54 
14 Del chr11 (+) :62,267,054-62,270,934 13 3,880       
15 Del chr15 (+) :48,758,881-48,764,977 32 6,096 TRPM7 Intronic deletion 2 




Table S3. List of SVs found in patient CD8. 
SV No SV Type Breakpoint Cluster Size Span (bp) Gene DNA alteration DGV 
1 TD chr1 (+) :143,753,709-143,758,374 25 12,876 PDE4DIP Intronic duplication 0 
2 Del chr4 (+) :32,973,945-32,982,487 6 8,542       
3 Del chr5 (+) :97026615-97,046,690 22 20,075       
4 Del chr5 (+) :113,354,357-113,364,703 45 10,346       
5 Del chr7 (+) :12,986,617-12,995,338 24 8,721       
6 TD chr8 (+) :128,450,797-128,413,587 46 58,701       
7 Del chr8 (+) :16,778,010-16,786,728 6 8,718       
8 Del chr9 (+) :90,123,341-90,127,712 12 4,371       
9 Del chr14 (+) :83,112,675-83,120,540 56 7,865       
10 TD chr19 (+) :43,243,,485-43,164,809 16 96,613 SIPA1L3 Intronic duplication 4 
11 Del chr20 (+) :58,544,674-58,558,612 40 13,938       
12 TD chr22 (+) :49,417,248-49,424,209 17 8,643       
13 Del chrX (+) :120,059,370-120,309,394 30 250,024       
14 UI chrX:34,661,885-125,684,797 49 91,022,213       
15 PI chrX:119,984,597-122,839,027 26 2,854,430 XIAP Breakpoint at intron 1   
16 PI chrX:119,997,337-122,856,765 29 2,860,694 XIAP Breakpoint at intron 1   
17 TD chrX (+) : 34,569,874-123,107,520 23 88,554,667 TMEM47 Part of complex inversion   
18 TD chrX (+) : 123,127,427-125,658,649 30 2,555,127 ODZ1;SH2D1A Part of complex inversion   




Table S4. List of SVs found in chromosome X including lower confidence clusters 
SV
a)









Span (bp) Breakpoint A 










13 Del 30 250,024 chrX (+) :120059370 - chrX (+) :120,309,394 -    +  +  + 
14 UI 49 91,022,213 chrX (+) : 34661885 - chrX (-) :125,684,797 -         
15 PI 26 2,854,430 chrX (+) :119,984,597 RP1-296G17 chrX (-) : 122,839,027 RP1-315G1 XIAP  +  +  + 
16 PI 29 2,860,694 chrX (-) :119,997,337 RP1-296G17 chrX (+) :122,856,765 RP1-315G1 XIAP  +  +  + 
17 TD 23 88,554,667 chrX (+) :123,107,520 W12-499N23 chrX (+) : 34,569,874 RP11-330K13 TMEM47  +  +  + 
18 TD 30 2,555,127 chrX (+) :125,658,649 - chrX (+) :123,127,427 W12-499N23 
ODZ1, 
SH2D1A 
      
19 TD 26 737,420 chrX (+) :125,828,479 - chrX (+) :125,110,988 - CXorf64       
20* UI 5 9,146 chrX (+) :34,560,359 RP11-330K13 chrX (-)  34,567,696 - TMEM47  +  +  + 
21* UI 5 88,548,885 chrX (-) :34,560,395 RP11-330K13 chrX (+) :123,109,280 W12-499N23 TMEM47  +  +  + 
22* TD 4 28,847 chrX (+) :61,754,201 RP11-762M23 chrX (+) : 61,771,832 RP11-762M23    -  -  - 





Table S5. List of SVs found in patient CD9 
SV No SV Type Breakpoint Cluster Size Span (bp) Gene DNA alteration DGV 
1 Del chr1 (+):33,189,324-33,193,992 43 4,668 RNF19B Intronic deletion 0 
2 PI chr5 (+):111,962,591-165,575,819 59 53,613,228    
3 PI chr5 (-):111,972,555-165,576,628 63 53,613,479    
4 TD chr5 (+):641,668-738,952 17 97,284 TPPP Duplicated exon 1-3 47 
     CEP72 Full length duplication 42 
5 TD chr9 (+):78,960,669-78,968,871 7 6,202    
6 Del chr9 (+):106,837,792-106,843,557 44 5,765    
7 TD chr17(+):2,734,890-2,747,456 18 12,556 RAP1GAP2 Intronic duplication 17 





Table S6. List of SVs found in patient CD14 
SV No SV Type Breakpoint ClusterSize Span (bp) Gene DNA alteration DGV 
1 Del chr1 (+) :38,374,440-38,378,079 17 3,639    
2 Del chr1 (+) :177,243,686-177,246,818 24 3,132    
3 Del chr1 (+) :217,861,277-217,867,288 8 6,011    
4 Del chr2(+):66,357,659-66,361,616 13 3,957    
5 Del chr2 (+) :178,563,026-178,567,389 6 4,363 PDE11A Intronic deletion 18 
6 TD chr2(+):76,660,390-76,670,369 28 9,979    
7 Del chr4 (+) :171,064,817-171,069,617 55 4,800    
8 Ins chr6 (+) :30,666,984;chr17 (-) :25,082,330 15 NA ABCF1 Breakpoint at 3' UTR 0 
     SSH2 Breakpoint at intron 2  2 
9 Ins chr6 (+) :30,667,054;chr17 (-) :25,068,847 13 NA ABCF1 Breakpoint at 3' UTR 0 
10 Del chr7(+):26,107,987-26,120,427 9 12,440    
11 Del chr8 (+) :6,282,090-6,319,264 50 37,174 MCPH1 Deleted exon 6-9 4 
12 Del chr8(+):131,919,651-131,929,123 6 9,472 ADCY8 Intronic deletion 11 
13 Del chr10(+):65,178,815-65,186,592 8 7,777    
14 Del chr10(+):132,798,979-132,809,373 38 10,394 TCERG1L Deleted exon 9 25 
15 TD chr10(+):134,978,086-134,991,430 21 13,344 CALY Duplicated exon 4-6 17 
16 Del chr12 (+) :34,589,132-34,604,152 9 15,020    
17 Del chr13 (+) :28,375,180-28,381,616 18 6,436    
18 Del chr14 (+) :45,822,161-45,836,976 53 21,953    
19 Del chr15 (+) :50,051,999-50,061,520 35 9,521    
20 Del chr15 (+) :72,525,564-72,638,632 15 113,068 ARID3B Deleted exon 1-2 4 
     UBL7 Deleted exon 1-10 1 
21 Del chr18(+):63,040,662-63,045,286 46 4,624    
22 Del chrX (+) :41,043,082-41,048,219 8 5,137       
Abbreviations: Del, Deletion; Ins, Insertion; TD, Tandem duplication 
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Span (bp) Gene DNA Alteration DGV 
1 Del chr1(+):97,567,377-97,686,357 68 118980 DPYD intronic deletion 29 
2 Del chr1(+):245,206,262-245,210,280 62 4018       
3 Del chr2(+):53,410,893-53,413,627 6 2734       
4 Del chr3(+):198,934,253-198,938,109 35 3856 KIAA0226 intronic deletion 14 
5 Del chr3(+):198,958,247-198,960,827 22 2580 KIAA0226 intronic deletion 14 
6 Del chr3(+):199,003,740-199,007,633 58 3893 LRCH3   8 
7 Del chr5(+):99,865,951-99,874,835 38 8884       
8 Del chr6(+):140,899,577-140,951,731 80 52154       
9 Del chr7(+):26,985,897-64,394,905 43 37409008 HOXA1 to INTS4L1 large deletion N.A. 
10 Del chr8(+):52,200,993-52,241,082 78 40089       
11 Del chr9(+):10,272,864-10,316,145 90 43281 PTPRD   26 
12 Del chr10(+):85,087,405-85,092,891 53 5486       
13 Del chr12(+):36,557,212-36,563,493 11 6281       
14 Del chr13(+):22,603,539-22,608,466 43 4927       
15 Del chr13(+):106,936,748-106,941,359 8 4611 FAM155A intronic deletion 39 
16 Del chr15(+):70,506,305-70,512,147 46 5842       
17 Del chr18(+):62,928,173-62,930,606 40 2433       
18 Del chr23(+):45,669,476-45,674,724 11 5248       
19 Del chr23(+):89,208,871-89,215,941 92 7070       
20 BT chr12(+):114,971,361; chr19(+):35,770,127 52 NA MED13L breakpoint at intron 4   
21 BT chr12(-):114,971,801; chr19(-):35,769,914 70 NA MED13L breakpoint at intron 4   
22 UI chr7(+):64,497,403; chr7(-):64,533,448 53 36045 ZNF92 affecting 3' UTR   
23 UI chr7(-):26,954,838; chr7(+):64,497,640 57 37542802 ZNF92 large affected region   
24 UI chr14(-):105,289,264; chr14(+):105,397,567 7 108303       
25 UI chrX(+):105,434,960; chrX(-):105,437,562 33 2602       
26 TD chr2(+):195,606,431-195,630,007 100 23576       
27 TD chr12(+):83,454,680-83534229 71 79549       
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Table S8. List of SVs found in Patient CD6 
SV No SV Type Inheritance Breakpoint Cluster Size Span (bp) Gene DNA alteration DGV 
1 BT De Novo chr2 (-) :144,606,985;chr8 (+) :23,007,302 60 NA GTDC1 Breakpoint at intron 5  
2 BT De Novo chr2 (+) :144,606,673;chr8 (-) :23,007,044 85 NA GTDC1 Breakpoint at intron 5  
3 TD Maternal chr2 (+) :57,291,143-57,262,536 62 48,200 -   
4 TD Maternal chr3 (+) :47,037,877-47,045,232 13 8,555 SETD2 Intronic duplication 0 
5 Del Paternal chr6 (+) :15,295,552-15,299,842 9 4,290 -   
6 Del Paternal chr7 (+) :134,791,258-134,794,840 49 3,582 CNOT4 Intronic deletion 3 
7 TD Paternal chr7 (+) :151,866,685-151,876,245 22 26,951 -   
8 UI Paternal chr8 (-) :75,250,456-75,259,603 37 9,147 -   
9 UI Paternal chr8 (+) :75,248,253-75,257,941 45 9,688 -   
10 Del Paternal chr11 (+) :50,650,376-50,658,583 6 8,207 -   
11 Del Paternal chr12 (+) :118,472,836-118,478,089 53 5,253 -   
12 Del Paternal chr14 (+) :40,757,141-40,760,560 24 3,419 -   
13 Del Maternal chr19 (+) :12,268,514-12,272,220 8 3,706 -   
14 Del Paternal chr19 (+) :21,182,476-21,192,939 45 10,463 -   
15 Del De Novo chr20 (+) :31,748,702-31,753,823 6 5,121 -   
16 Del Maternal chrX (+) :67,873,609-67,881,314 43 7,705 -   
17 UI De Novo chrY (+) :11,941,563-57,398,141 7 45,456,578 -     
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Abstract
Delineating candidate genes at the chromosomal breakpoint regions in the apparently balanced chromosome
rearrangements (ABCR) has been shown to be more effective with the emergence of next-generation sequencing (NGS)
technologies. We employed a large-insert (7–11 kb) paired-end tag sequencing technology (DNA-PET) to systematically
analyze genome of four patients harbouring cytogenetically defined ABCR with neurodevelopmental symptoms, including
developmental delay (DD) and speech disorders. We characterized structural variants (SVs) specific to each individual,
including those matching the chromosomal breakpoints. Refinement of these regions by Sanger sequencing resulted in the
identification of five disrupted genes in three individuals: guanine nucleotide binding protein, q polypeptide (GNAQ), RNA-
binding protein, fox-1 homolog (RBFOX3), unc-5 homolog D (C.elegans) (UNC5D), transmembrane protein 47 (TMEM47), and
X-linked inhibitor of apoptosis (XIAP). Among them, XIAP is the causative gene for the immunodeficiency phenotype seen in
the patient. The remaining genes displayed specific expression in the fetal brain and have known biologically relevant
functions in brain development, suggesting putative candidate genes for neurodevelopmental phenotypes. This study
demonstrates the application of NGS technologies in mapping individual gene disruptions in ABCR as a resource for
deciphering candidate genes in human neurodevelopmental disorders (NDDs).
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Introduction
Apparently balanced chromosomal rearrangements (ABCR)
occur sporadically in the population or segregate within families,
with a frequency of 1 in every 2000 live births. ABCR have been
largely associated with infertility, ovarian failure and intellectual
disability (ID) when detected during pre- and post-natal investi-
gation or genetic counselling. [1,2,3,4,5,6] The risk of developing
congenital anomalies or NDDs has been estimated to be 6.1% for
de novo ABCR. [2] Although ABCR is also found in phenotypically
normal individuals, there is an increased incidence of ABCR in
NDDs patients, which may lead to novel candidate disease gene
identification through breakpoint cloning methods. Such method
has been successfully applied in characterizing disease genes
including DMD in Dystrophin for Duchenne Muscular Dystrophy
[7], DISC1 in Schizophrenia [8,9] and ATP7A in Menkes disease.
[10,11] Karyotyping, Array-CGH (aCGH) and SNP arrays are
currently first-tier diagnostic tools to investigate ABCR in pre- and
post-natal settings. [6,12,13] Balanced chromosomal aberrations
can only be detected through karyotype observation, although at a
low resolution of approximately 5–10 Million base-pairs (Mb), [14]
and subsequent Fluorescence in situ hybridization (FISH) mapping
across the breakpoints for more detailed delineation is restricted to
the investigated region. Microarrays technologies are able to
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e90852
identify copy number changes at considerable resolution but fail to
identify copy number neutral rearrangements. [15,16] Recent
advances in NGS technologies render it possible to systematically
identify genomic rearrangements including copy number neutral
events at a base-pair resolution, thus facilitating candidate disease
gene identification in the chromosomal breakpoint regions.
We have established a NGS pipeline, referred to as a DNA-PET
sequencing, [17,18,19] in which we sequence the short ends
(50 bp) of 59 and 39 tags of large-insert sizes between 7 to 11 kb
genomic DNA fragments, followed by ligating the two paired-ends
to form PET constructs and subjected to sequencing in a massive
and highly parallel manner, (Figure S1, see Supporting Informa-
tion S1) [17,20]. Hillmer and colleagues [17,18,19] have
demonstrated that large-insert fragment sizes provided higher
physical coverage with minimum sequencing efforts, and have the
advantage over short-insert sizes in terms of large genomic SVs
detection and covering complicated DNA sequence features such
as repetitive regions. We implemented this technique to analyze
the genome of four individuals with NDDs symptoms including
Developmental Delay (DD), Speech Delay (SD), Language Delay
(LD) and autistic disorder. These patients harbour cytogenetically
defined ABCR (2 familial translocation, 1 familial inversion and 1
de novo inversion), and prior aCGH analysis did not reveal
chromosomal imbalances. Our study shows that NGS technology
enables rapid identification of individual gene disruptions and
potential candidate genes in ABCR. We also demonstrated the
correlation of disrupted gene XIAP in an inversion breakpoint to
be causative for the patient’s immunodeficiency phenotype.
Results
Structural Variants Detection by DNA-PET Sequencing in
Four Patients with Developmental Delay and Speech
Disorders
By using patients’ genomic DNA as starting material, libraries
were generated and sequenced using a SOLiD platform, and we
obtained an average of 35 million non-redundant paired-end reads
(Table S1, see Supporting Information S1). The median physical
coverage using our technique was 98x, with an average of 94x
(Table S1, see Supporting Information S1). Majority of the Paired
End Tags (PETs) were mapped to the reference genome NCBI
Build 36 and referred to as concordant PETs (cPETS), which
provided the copy number information based on sequencing read-
depth. The remaining clustered PETs were referred to as
discordantly mapped PETs (dPETs), which allowed the identifi-
cation of structural variants (SVs). After filtering (see Methods
section), approximately 96% of the SV calls generated for each
library were shared with normal individuals published in the
Database of Genomic Variants [21], 1000 Genome Project SVs
Pilot release set [22,23] or previous paired-end sequencing studies
of normal individuals [24,25,26].
Using our analysis pipeline for patient-specific SVs discovery,
the extraction of normal SVs reduced this number to 7–19 events,
with a mean of 14 SVs per patient (Tables S2–S6, see Supporting
Information S1). We observed deletions as being the most frequent
SVs, comprising 58% of the total patients-specific SVs (32
deletions out of a total of 55 SVs), while tandem duplication
comprises 20%, and the remaining SVs (translocation, inversion
and insertion) comprise 21% of total SVs (Table 1). We performed
PCR analysis on 36 randomly chosen SVs with 2 sets of primers
spanning predicted breakpoint junctions. Of these, 27 SVs were
validated and produced a single, clear PCR band at expected size
range, suggesting ,75% validation rate. In parallel to DNA-PET,
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observed an average of 93% overlap between both experiments
(Table S7, see Supporting Information S1).
For each patient, we performed a case by case study to identify
the potential genes which were disrupted by the cytogenetically
visible rearrangements with the assumption that these were the
most likely causative events. We validated DNA-PET breakpoints
matching the cytogenetic rearrangements by Sanger sequencing
(Table 2), FISH and evaluated gene expression by quantitative
real-time PCR (RT-PCR). Apart from the specific chromosomal
rearrangements, we checked other SVs obtained for each patient.
Most of the SVs that coincide with coding regions have been
reported in the Database of Genomic Variants (DGV), indicating
that these SVs are likely benign (Tables S2–6, see Supporting
Information S1). We checked for the presence of regulatory
elements, such as transcription factor binding sites and epigenetic
marks, using RegulomeDB and the ENCODE dataset, on SVs
present in intra/intergenic regions and found no evidence of
known regulatory elements in any of them.
From these extensive analyses, we identified five disrupted genes
in three patients: GNAQ, RBFOX3, UNC5D, XIAP and TMEM47
(Table 2). Among them, XIAP has already been associated with X-
linked lymphoproliferative disorder 2 (XLP-2: MIM [300635]). To
evaluate the potential implication of the disrupted genes, we
assessed the occurrence of pre-existing Copy Number Variations
(CNVs) in DD cases from published studies and the DECIPHER
Consortium [27,28,29] (Table 3). Enrichment of CNV counts in
the cases versus controls was observed in RBFOX3 and UNC5D,
suggesting that altered gene dosage in these genes might have a
role in NDDs.
Breakpoint Characterization through Detailed SVs
Analysis
Case 1 (Patient CD5). In this family, the translocation
segregates with a variable degree of phenotypic manifestation.
Patient CD5 had language delay (LD) and DD during his
childhood, and his two sons (CD21 and CD22) displayed absence
of speech, DD and autistic disorder (Figure 1A). The translocation
t(9;17) was represented by two abnormally oriented clusters
corresponding to the balanced translocation between chromosome
9 and 17. Sanger sequencing refined the breakpoint coordinates in
the translocation carriers, and revealed identical breakpoint
patterns on chromosome 9 at position chr9:79,572,001–
79,572,005 and on chromosome 17 at position
chr17:74,764,927–74,767,964. There is a loss of 4 bp and
3,036 bp on chromosome 9 and 17, respectively, with a
microhomology of 3 bp between paired breakpoints (Figure 1B).
The translocation disrupted GNAQ at intron 5 on chromosome 9
and RBFOX3 at intron 2 on chromosome 17. Both disrupted genes
shared the same orientation, breakpoints lie within introns, and
the resulting fusion is predicted to be in frame. However, RT-PCR
analysis on the patient’s lymphoblastoid cell line did not reveal any
fusion transcript expression as neither gene is expressed in these
cells, reflecting the importance of relevant cell type for validation
of brain-specific genes. We checked the mRNA expression of both
genes in human tissue panel and found that both genes are highly
expressed in the fetal brain and the cerebellum (Figure 1C). GNAQ
encodes a member of the Gaq heterotrimeric protein family, and
null Gnaq mice exhibit cerebellar ataxia, and motor coordination
deficit [30]. RBFOX3 is a neuronal specific splicing factor, which is
exclusively expressed in the neuronal nuclei. There are 12 other
SVs found in this patient, and nine of them were validated by
PCR, in which 5 SVs were shared with his two affected sons (SV1,
2, 4, 6 and 13). These five SVs overlapped with known CNV
regions (SV1, 2, 4) reported in healthy individuals or were in
intergenic regions (SV6, 13) and were therefore excluded for
further analysis (Table S2, see Supporting Information S1).
Overall, the translocation segregates with LD and DD in this
family with variable penetrance, hinting a potential functional
impact.
Case 2 (Patient CD10). In the second patient (CD10), the
causative effect of the t(6;8) balanced translocation is unclear, due
to variable expression of phenotype in the translocation carriers;
his mother is asymptomatic and his younger sibling displayed
schizencephaly and DD (CD11) (Figure 2A). DNA-PET identified
abnormal paired reads matching the balanced translocation, and
Sanger sequencing refined the breakpoint coordinates on chro-
mosome 6 at position chr6:98,318,526–98,318,538 and chromo-
some 8 at position chr8:35,527,969–35,527,976. The translocation
disrupted UNC5D at intron 5 on chromosome 8, while no coding
genes were disrupted on chromosome 6 (Figure 2B). UNC5D
encodes a member of human dependence receptor UNC5 family
that is specifically expressed in the layer 4 of the developing
neocortex in rats, which makes it a biologically plausible candidate
[31,32]. Since the translocation does not fully segregate with the
disease, all coding exons of UNC5D were sequenced in each
translocation carriers, and we did not find additional point
mutations in the other allele. UNC5D mRNA is exclusively
expressed in the adult brain, fetal brain, and cerebellum
(Figure 2C), thus expression changes could not be investigated in
the patient’s lymphoblastoid cell line. Notably, we observed
enrichment of CNV counts in 15 cases described by DECIPHER
(Figure 2D). Analysis of other SVs showed 5 deletions in intergenic








CD5 t(9;17) 9 79,571,716–79,573,787 79,572,001–79,572,005 GNAQ
17 74,764,804–74,768,401 74,764,927–74,767,964 RBFOX3
CD10 t(6;8) 6 98,318,059–98,318,840 98,318,526–98,318,538
8 35,527,808–35,528,282 35,527,964–35,527,976 UNC5D
CD8 inv(X) X 119,984,597–119,984,844 119,984,613–119,984,615
X 122,839,027–122,845,538 122,839,398–122,844,862 XIAP
CD9 inv(5) 5 111,962,591–111,963,149 111,962,767
5 165,575,819–165,576,628 165,576,568–165,576,574
doi:10.1371/journal.pone.0090852.t002
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regions (SV1, 2, 11, 12, and 14) and 8 within genes (SV3, 4, 5, 6,
9, 10, 13 and 15), in which all of them overlapped with known
CNVs regions (Table S3, see Supporting Information S1).
Case 3 (Patient CD8). The third patient (CD8), carried a
maternal-derived pericentric inversion at chromosome X, between
Xp22 and Xq26 (Figure 3A). His monozygotic twin brother
harbors the same inversion. They both show signs of immunode-
ficiency combined with mild intellectual disability (ID) and LD.
SVs analysis of this patient revealed a 1.2 Mb inversion located at
chromosome Xq24–25 between paired breakpoints (Table S4, see
Supporting Information S1), which did not correspond to the large
inversion seen in the karyotype, inv(X)(p11.4;q24). Sanger
sequencing allowed us to delineate the precise breakpoint on
chromosome X at position chrX:119,984,613–119,984,615 and at
position chrX:122,839,398–122,844,862 with a loss of 1 bp and
5,463 bp on each breakpoint junction, respectively. Due to the
discrepancies between karyogram and NGS data, we traced other
SVs in chromosome X by including lower confidence SVs (cluster
size$4), and revealed a total of 10 SVs that clustered into multiple
breakpoint hotspots on the p arm (SV14, 17, 20, 21), the
centromeric region (SV22) and the q arm (SV13, 15, 16, 18, 19),
suggesting a complex chromosomal rearrangement mechanism
(Table S5, see Supporting Information S1). We verified the
breakpoints in the inversion carriers (the mother and the twin
boys) by PCR and FISH using probes RP1-315G1 (Xq25), RP1-
296G17 (Xq24), RP11-330K13 (Xp21), W12-499N23 (Xq25)
BAC and Fosmid clones (Figure 3B). These data suggested two
large sequential breaks in each arm of chromosome X (Xp21 and
Xq24–25) that resulted in tandem duplications, deletion and
isolated breakpoints (Figure 3C). This double-inversion mecha-
nism rearranged the landscape of chromosome X architecture,
and appeared as a large inversion on G-banding karyotype.
Combining DNA-PET sequencing and extensive FISH validations
allowed us to characterize the complex chromosomal rearrange-
ments in chromosome X, as a result of a for a sequential double
inversion mechanism.
This complex rearrangement disrupted two genes: XIAP and
TMEM47. The latter encodes a member of PMP22/EMP/
Claudin protein family is ubiquitously expressed in human tissues
including adult and fetal brain (Figure 3D). Two other genes were
affected by tandem duplications as part of the complex
rearrangement (SV18, 19): SH2D1A, encodes an SH2 domain
containing 1A protein (SAP), which has been associated with X-
linked lymphoproliferative syndrome type 1 (XLP-1 [MIM:
308240]). This gene was initially suspected as the primary cause
of immunodeficiency phenotype seen in the patient, although it
was rejected due to normal SAP expression in patient’s blood
lysates (see Patients and Methods). ODZ1 is the second gene
affected by this rearrangement. It encodes an Odd Oz/Ten-M
homolog 1 of Drosophila pair-rule gene involved in post-
segmentation processes, including embryonic development of the
central nervous system (CNS), eyes, and limbs in Drosophila
[33,34].
RT-PCR of the four genes revealed a total absence of
expression for XIAP1 and TMEM47 and a moderate to normal
expression for SH2D1A and ODZ1 in patient’s fibroblast cell line
compared to sex-matched controls, supporting the absence of
functional XIAP1 and TMEM47 genes in the male patient
(Figure 3E). Considering the normal expression of SAP protein
and the absence of functional gene expression of XIAP, these data
clearly suggest that XLP-2 underlies the immunodeficiency
symptoms of the affected twin boys.
Case 4 (Patient CD9). In patient 4 (CD9), sequencing
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the large inversion on chromosome 5. This inversion spans 53 Mb
on chromosome 5q22.2 (chr5:111,966,591-111,963,149) and 5q34
(chr5:165,575,819–165,576,628), with 1 bp deletion, and micro-
homologies of 3 bp between paired breakpoints. No gene was
disrupted at the breakpoint junctions (Table S6, see Supporting
Information S1), and no evidence of regulatory elements sitting at
both breakpoint coordinates was found based on RegulomeDB
and ENCODE databases. Additionally, there are 5 other patient-
specific SVs; two were located in the intergenic regions (SV5 and
6); two others were tandem duplications overlapped with known
CNVs (SV4 and 7); and one intronic deletion of 4 kb in RNF19B
gene, which has not been listed in DGV (SV1) (Table S6, see
Supporting Information S1). Based on this analysis, it seems
unlikely that the large inversion on chromosome 5 causes the
clinical phenotype. Other patient specific SVs or mutations that
cannot be identified by DNA-PET such as point mutations or
exposures of environmental factors might be the underlying cause
of the phenotypic features seen in this patient.
Discussion
In the past decade, we have seen substantial progresses for
identification of novel candidate genes in NDDs with the recent
development in technologies. Two studies of large cohorts of
patients with developmental delay described the enrichment of
large CNVs in 15% of the cases [28], and highlighted the presence
of additional large CNVs that co-exist with primary microdele-
tion/duplication syndrome in 10% of the cases as an additive
contributing factor to more severe phenotype [35]. These CNVs
have been useful to provide a better classification of microdele-
tion/duplication syndromes; however these regions often encom-
pass multiple genes and thus make it challenging to identify
plausible candidates. Recent exome sequencing study in individ-
uals with ID identified potentially causative de novo single
nucleotide variants (SNVs) with a diagnostic yield of 16%,
comparable to the CNV burden obtained in copy number studies
[36]. A more conventional approach in candidate gene identifi-
cation involves delineating candidate genes in the chromosomal
breakpoints of the ABCR [9,37,38,39]. In contrast to the
downstream effects of SNVs or CNVs, genes that are disrupted
Figure 1. Patient CD5 with translocation t(9;17). A) The pedigree of patient CD5 is indicated. The translocation is transmitted to his two sons
(CD21 and CD22). B) Translocation between chromosome 9 and 17 were validated by Sanger sequencing in three translocation carriers. The reference
sequence is indicated, showing the fusion of two genes at the genomic level: the first five exons of GNAQ fused to exon 3–14 of RBFOX3 and the first
two exons of RBFOX3 fused to exon 6–7 of GNAQ. C) mRNA expression of GNAQ and RBFOX3 showed high expression in fetal brain, adult brain and
cerebellum in human tissue panel.
doi:10.1371/journal.pone.0090852.g001
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by translocations or inversion are presumably more severely
affected, resulting generally in protein truncation or heterozygous
inactivation of the affected allele.
Recent studies have described the feasibility of using NGS
technologies to map the ABCR breakpoints in patients with
neurodevelopmental abnormalities [37,38,40,41,42,43,44]. These
technologies include (i) a shotgun sequencing approach by using
Figure 2. Patient CD10 with translocation t(6;8). A) The pedigree of patient CD10 is indicated. The familial translocation is inherited from
asymptomatic carrier mother and shared with his affected sister (CD11). B) Sanger sequencing analysis refined the chromosomal breakpoint regions
and revealed a loss of 11 bp on chromosome 6 and 8 bp on chromosome 8, with a microhomology of 3 bp between the paired breakpoints. C)
UNC5D mRNA expression in human tissue panel showed high expression in the fetal brain, adult brain and cerebellum compared to other tissues. D)
The translocation breakpoint is located at intron 1 of UNC5D indicated by the black arrow, encompasses 15 CNVs cases described in the DECIPHER.
doi:10.1371/journal.pone.0090852.g002
Figure 3. Patient CD8 with a complex chromosomal inversion. A) Karyogram of normal chromosome X compared to der(X) in patient CD8. B)
FISH validation of 10 SVs shown in Table S5 (see Supporting Information S1) with the respective FISH probes: Hybridization of RP1-296G17-Biot (SV15)
and RP1-315-Dig (SV16) were localized on the centromere of the patient’s metaphase. Probes for SV17 and SV21 on Xp21 (RP11-330K13-Biot) and
Xq25 (W12-499N23-Dig), respectively resulted in a split signal between Xp21 and the centromeric region in the patient’s chromosome. Further FISH
analysis was performed by using probe RP11-762M23-Biot on Xq11.1 (SV22) that was found to localize on the upper chromosomal arm. Probe RP11-
655E22 on Xp11.2 was localized on the lower arm of derivative chromosome X. C) Reconstructed derivative chromosome X for patient CD8. Normal
human chromosome X according to ISCN 2009 with the arrow orientation from a to d and the proposed mechanism of sequential double inversion in
patient CD8. Based on our FISH analysis, an inversion occurred first between Xp21 and Xq25, changing the orientation of p and q arm with a shift of
the centromere position towards the lower q-arm shown by inverted red arrow b and c. This was followed by the second inversion that occurred
between Xq11.1 and Xq25, altering the orientation of the q-arm (inverted green arrow c). D) Expression of TMEM47 in human tissue panel assessed by
qRT-PCR. E) Expression analysis of four disrupted genes in patient CD8 assessed by qRT-PCR.
doi:10.1371/journal.pone.0090852.g003
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the flow-sorted derivative chromosomes [40], (ii) custom jumping
libraries coupled to targeted breakpoint capture [38], which are
limited to the chromosomal breakpoint regions, (iii) standard
paired-end sequencing or large-insert jumping libraries of 3–4 kb
[37,38,41], and (iv) mate-pair sequencing of 2–3 kb insert sizes
[42,43].
Our work described the use of a genome paired end tag (DNA-
PET) sequencing with larger insert sizes between 7–11 kb
[17,18,19,45,46]. The use of an approximately 8–15 kb insert
sizes has been shown to be more advantageous in terms of SVs
detection in more complicated DNA sequence features, such as
repetitive regions or large genomic rearrangements, and also
provides higher physical coverage with minimum sequencing
efforts compared to smaller insert sizes [19,47]. We implemented
this technique to map the breakpoints of four patients with DD
harbouring cytogenetically defined ABCR, and identified specific
breakpoints for all of them. Sanger sequencing was required to
refine the breakpoints at the base pair level. The observed cryptic
breakpoint anomalies were deletions ranging from 3 bp to
5,462 bp and/or microhomologies of 2–4 bp suggesting a
microhomology-mediated end joining (MMEJ) [48] or non-
homologous end joining mechanism (NHEJ) [49]. Both are major
pathways for double strand break repair that often occurs in non-
homologous regions of non-recurrent chromosomal breakpoints
emphasizing the unique characteristics of these rearrangements.
In this study, five genes were identified within the ABCR-
breakpoint regions in three patients (GNAQ, RBFOX3, UNC5D,
XIAP, and TMEM47), and we observed various complications in
attempting to correlate these genes to the expressed phenotypes.
For one case (Patient CD8), the complex inversion pattern seen in
chromosome X resembles chromothripsis, phenomenon common-
ly found in cancer and recently, in congenital diseases, which
resulted from localized shattering of one or few chromosomes and
assembly of chromosomal pieces by non-homologous end-joining
(NHEJ), and thus appeared as complex chromosome rearrange-
ments, involving three or more breakpoints [41,42,43,50,51]. This
complex events highlight the advantage but also the limitation of
the DNA-PET technology as FISH experiments were necessary to
better understand the high order structure of the rearrangement.
The inversion breakpoint disrupted XIAP gene, which is the
primary cause of a rare form of XLP2 [52,53] (XLP2 [MIM:
300635]) and likely to be causative for the immunodeficiency
phenotype of the patient. More interestingly, these patients also
presented mild ID and LD, features that are occasionally not
associated with XLP syndromes, suggesting possibilities of
additional contributing candidate genes within the complex
rearrangements. TMEM47 is among the potentially interesting
candidate, with total absence of transcript expression in patient’s
cell line and expression in fetal to adult brain. We proposed the
need to perform mutational screening of TMEM47 in X-linked ID
patients for future studies.
For one patient (Patient CD9), there were no disrupted genes or
regulatory elements at the breakpoint regions, neither potential
other interesting SVs, showing the limitation for candidate gene
detection merely through ABCR breakpoint cloning methods.
Alternatively, exome sequencing of parent-offspring trio can be
considered as a method of choice to further investigate possible
causal variants especially in cases where there is a lack of
association between ABCR and disease.
For the two remaining familial translocations, we identified
fusion gene at the genomic level, although unverifiable at the
transcript level due to lack of expression in available cell lines
between GNAQ and RBFOX3 genes in a t(9;17) translocation in
three affected members of a family (Patient CD5) with different
level of neurological symptoms (mild to severe) and UNC5D
disruption in a family harbouring a t(6;8) translocation carried by
two affected siblings (Patient CD10) and his mother. The
translocation carriers in latter family displayed a broad range of
clinical presentations; an asymptomatic mother, her first child with
mild DD, and her second child presenting schizencephaly,
polymicrogyria and LD, suggesting additional etiological factor
underlying these features apart from the t(6;8) translocation.
Besides the large phenotypic variability between translocation
carriers seen in both families, we observed an enrichment of CNV
counts for UNC5D and RBFOX3 in NDDs-associated cases [28].
Therefore, we cannot totally exclude the possibility of high level of
variability effects in these genes. Independent validation screening
in isolated neurologically-affected patients, rather than collective
multi-symptoms cohorts, would be significantly useful to provide
significant association with specific neurodevelopmental symptoms
in these patients.
Despite the potential functions of four identified genes (GNAQ,
RBFOX3, UNC5D and TMEM47) in brain development, further
functional validations are required to establish a correlation
between these disrupted genes and patients’ clinical phenotype.
Furthermore, reporting such ABCR-disrupted genes is crucial to
determine the clinical relevance of newly identified CNVs or
SNVs encompassing these genes.
In this study, we showed the potential of a cost-effective NGS
technology to rapidly pinpoint disrupted genes within ABCR
breakpoint regions. High overlap (93%) between both NGS-and
array-based technologies shown in this study emphasizes the
importance of employing a single technique that can provide high
coverage of genome information with consistent validation rate as
a routine clinical diagnosis tool. The stringency of our filtering
pipeline can be optimized and adjusted depending on the
sequencing platforms, and this would revolutionize the character-
ization of individual genomes of patients without prior karyotypic
observation. For the implementation in the clinical settings,
unaffected parents or siblings should be included for genome
investigation to reduce the number of familial, non-pathogenic
SVs. Whilst the technology continues to improve, validation with
longer read depth by Sanger sequencing is still necessary for better
SVs annotation. Our study complements the existing application
of NGS technology in unexplained NDDs patients for better




All samples and information were collected after written
informed consent from patient’s parents was obtained and in
accordance with local institutional review board approved
protocols from National University of Singapore in Singapore,
Children’s Hospital Westmead in Sydney, Australia and Centre
Hospitalier Regional in Orleans, France. DNA samples were
obtained from peripheral blood lymphocytes and cultured skin
fibroblasts obtained from patients seen at the participating
institutes.
Patient CD5. This is a familial balanced translocation
presenting variable degree of DD and autistic features. The first
son displayed an autistic behavior and global DD at three years of
age with an absence of speech, feeding and sleeping difficulties,
habit disorders, and stereotypic movements. At 4 years, there is an
improvement in communication and speech seen in the first son.
Chromosome analysis revealed a translocation t(9;17) (see Table 1),
which is shared with his father and sibling. During genetic
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counselling, the father reported that he suffered from LD and DD
during childhood that was not explored at that time, and this has
resolved by adolescence. His second son was found to have DD
and autistic features at the age of two years. DNA tested for the
translocation was obtained from the father who was referred to as
patient CD5. Chromosome analysis in the phenotypically normal
mother revealed a normal karyotype.
Patient CD10. The patient was born at term by lower
segment caesarean section, due to breech presentation. Delay in
developmental milestones was noted at 18 months of age affecting
both walking and speech. At 9 years old, comprehension and
behavioural difficulties were noted at school. Karyotype analysis
revealed a balanced translocation t(6;8) (see Table 1). Metabolic
screening and FRAXA testing were normal. Karyotypic analysis in
his parents revealed that his mother carried the same balanced
translocation. She had no intellectual difficulties, but was reported
to have had a ‘hole in the heart’ in childhood, which closed
spontaneously. His younger sister had the same translocation
detected by amniocentesis during pregnancy. She was noted to
have plagiocephaly soon after birth. She had feeding difficulties in
early infancy, which gradually resolved. At 2 years old, she had LD
with low-average fine motor and gross motor skills. A right
intermittent exotropia was noted. An MRI head scan showed a
closed lip schizencephaly involving the right frontal lobe with
polymicrogyria in the right Sylvian fissure. MRI brain scans in her
brother and mother were normal.
Patient CD8. The patient was one of monozygotic twins. At
the age of three years, he had an acute EBV infection with
prolonged hepatosplenomegaly and abnormality of liver function
tests. Immunological investigations showed reduced IgM, de-
creased CD4 T-helper cells and decreased natural killer (NK) cell
function. Patient was suspected for XLP-1, but western blot
analysis on patient’s whole blood cell lysates showed normal
expression of SAP. At the age of five years, mild ID was diagnosed,
as well as a specific language disorder affecting his receptive and
expressive skills. Karyotype analysis revealed a complex inversion
inv(X) (see Table 1), derived from his phenotypically normal
mother. His identical twin showed similar clinical features and
carrying the same karyotype. The maternal uncle was reported to
have recurrent infections and a maternal great uncle died at eight
months of age, apparently due to liver abnormalities.
Patient CD9. The patient was born by normal delivery after
an uneventful pregnancy. Mild delay in early motor and speech
developmental milestones was reported. At age twelve, he was
found to have average intellectual ability, an expressive language
disorder, and specific learning difficulties in maths, spellings and
reading; as well as attention deficit disorder. Chromosome analysis
revealed a paracentric inversion of chromosome 5 (see Table 1).
Both parents have normal karyotypes and do not show any
phenotypic abnormality.
Cytogenetic and FISH Analysis
Karyotypes were determined from G-banding analysis using
standard protocol according to the ISCN nomenclature. FISH
analysis was carried out using protocols as described elsewhere.
[54,55] Metaphase chromosomes were prepared from Epstein-
Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) or
cultured skin fibroblast cells obtained from patients, parents or
siblings carriers by standard techniques. BAC and fosmid probes
were obtained from BACPAC Resources (Oakland, CA). Probes
were labelled by nick-translation kit (Enzo) with biotin-16-dUTP
or digoxigenin-11-dUTP (Roche). The probes were blocked with
1 mg/ml Cot-1 DNA (Life Technologies), and resuspended at a
concentration of 5 ng/ml in hybridization buffer (2xSSC, 10%
Dextran Sulfate, 1x PBS, 50% Formamide). Fluorescent signals
were visualized by avidin-conjugated fluorescein isothiocyanate
(FITC) (Vector Laboratories, CA) or anti-Digoxigenin-Rhoda-
mine (Roche). Chromosomes were counter-stained with DAPI and
the signal was analysed using a Nikon Epifluorescence Microscope
equipped with ISIS Metasystems for imaging analysis.
Genomic DNA Preparation
Genomic DNA from lymphoblastoid cell lines, fibroblast, or
blood from the patient was extracted by Qiagen Blood and Cell
Culture DNA Kits (Qiagen), according to manufacturer’s instruc-
tion. lymphoblastoid and fibroblast cell lines were maintained to a
minimum number of passages prior to DNA extraction. Quality
and quantity of the extracted DNA were measured using
NanoDrop 1000 Spectrophotometer and agarose gel electropho-
resis.
aCGH
aCGH was performed in all patient samples using the SurePrint
G3 Human 2 x 400 k aCGH Microarray (Agilent Technologies
Inc. Santa Clara) according to the manufacturer’s instruction. The
microarray slides were scanned on an Agilent Microarray
Scanner. Data were processed by Genomic Workbench software,
standard edition 5.0.14 (Agilent). We used the Aberration
Detection Method (ADM-2) algorithm to identify DNA copy
number variations (CNV). The ADM-2 algorithm identifies all
aberrant intervals in a given sample with consistently high or low
log ratio based on the statistical score. We applied a filtering
option of minimum of three probes in region and centralization
threshold of 6. We used NCBI Build 36 as a reference genome.
For smaller CNVs that were identified by DNA-PET, we
compared with the aCGH raw data and interpreted the copy
number change by looking at the individual probe ratio, using a
cutoff of 0.1 (,0.1 indicated deletion, .0.1 indicated duplication).
DNA-PET Library Construction
We constructed the DNA-PET libraries for four patients
according to Method described in Hillmer et al. [17]. Briefly,
genomic DNA was hydrosheared to 7–11 kb DNA fragments.
Long Mate Paired (LMP) cap adaptors were ligated to the
hydrosheared and end-repaired DNA fragments. The cap
adaptor-ligated DNA fragments were separated by agarose gel
electrophoresis, recovered using the QIAEXII Gel Extraction Kit
(QIAGEN) and circularized with a biotinylated adaptor that
connects the cap adaptors at both ends of the DNA fragments.
Missing 59 phosphate groups of cap adaptors created a nick on
each strand after circularization of the DNA. Both nicks were
translated outwards by .50 bp into the circularized genomic
DNA fragment by DNA polymerase I (NEB). The nick-translated
constructs were then digested with T7 exonuclease and S1
nuclease (NEB), to release paired-end tag (PETs) library
constructs. These constructs were ligated with SOLiD sequencing
adaptors P1 and P2 (Life Technologies), and amplified using 2x
HF Phusion Master Mix (Finnzymes OY) for sequencing. High
throughput sequencing of the 50 bp libraries was performed on
SOLiD sequencers (v3plus and v4, respectively) according to the
manufacturer’s recommendation (Life Technologies). Sequence
tags were mapped to the human reference sequence (NCBI Build
36) and paired using SOLiD System Analysis Pipeline Tool
Bioscope, allowing up to 12 color code mismatches per 50 bp tag.
For sample CD5 and CD8, two DNA size fractions were merged
for library construction which resulted in a reduced sensitivity to
identify small deletions.
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DNA-PET Data Curation
The majority of the PET sequences mapped accordingly to the
reference genome (concordant PETs or cPETs) with expected
mapping orientation (59 tag to 39 tag) and expected mapping
distance (according to the selected fragment size) The distribution
of cPET in the genome was used to retrieve copy number
information.5 The remaining portion of the PETs mapped
discordantly to the reference genome (discordant PET or dPETs),
classified as those with incorrect paired-tag orientation and
incorrect genomic distances. These dPETs provided information
to search for genomic rearrangements; with specific criteria for
different types of SVs according to PET mapping orientation and
genomic region as described by Yao et al. [19]. The overlapping
dPETs representing similar SVs were clustered together as dPET
clusters and counted as the cluster size, according to the procedure
as described in Hillmer et al. [17] with refined data curation as
described in Ng et al. [20].
Filtering of Normal Structural Variations (SVs)
Comparison of clusters across different genomes was performed
as described by Ng et al. [20]. We included DNA-PET data of 23
normal individuals (25 DNA-PET data sets) and the pilot release
set of 1000 Genome Project [22] from Mills et al. in the cross-
genome comparison, and identified SVs that were present in the
normal libraries. In addition, we used the breakpoint locations to
compare the identified SVs with published SVs based on paired-
end sequencing studies of 18 additional normal individuals [24,25]
and Database of Genomic Variants. The fraction of predicted SV
which overlapped with a published SV was calculated by the
percentage of overlap relative to the larger event. Thus, we
categorized SVs that overlapped by 80% or more with those
identified by these studies as normal SVs. Hence, SVs classified as
normal have been excluded to identify rearrangements which
underlie the diseases.
CNVs Screening in Public Datasets
We used the CNVs map from published data by Cooper et al.
with 15,767 cases of DD and 8,329 adult controls to screen for
deletions or duplications in our candidate genes [28]. We also
screened from DECIPHER databases, with .17,000 cases
carrying CNVs disrupting individual genes. For additional control
dataset, we screened for normal CNVs in the first release SVs set
of 1000 Genome Project Consortium of 185 individuals [22].
CNVs were counted in both cases and controls spanning candidate
genes in these datasets.
In silico Analysis of Regulatory Regions
The hg18 coordinates of genomic regions from each patient’s
SVs list were converted to hg19 in LiftOver from UCSC genome
browser. SVs coincide within introns or intergenic regions were
assessed for the probability score of functional regulatory regions
in RegulomeDB [56] and ENCODE data [57,58] in UCSC
genome browser.
Validations of Expected Breakpoints by PCR
Primers were designed by Primer3 program, and the amplicons
spanning the breakpoint were predicted by dPET clusters
according to human genome assembly NCBI Build 36. PCR
was carried out with JumpStart REDAccuTaq LA polymerase
(Sigma Aldrich Inc., St. Louis, MO) in a 50 ml reaction volume
and with 500 ng of genomic DNA as a template. The following
program was used: 1) Initial denaturation at 96uC for 30 sec, 2) 40
cycles of 15 sec at 94u, 30 sec at 58uC, 10 min at 68u, 3) 68uC for
10 min. PCR products showing single bands were purified by Gel
Extraction Kit (Qiagen) and used as templates for sequencing in
both directions by Sanger sequencing. The sequences of junction
fragments were aligned to the human genome reference sequence
using Blat [59].
Expression Analysis
Total RNA was extracted from patient’s EBV-LCL or
fibroblasts using RNAeasy kit (Qiagen). Reverse transcription of
2 mg RNA derived from patients, 2 lymphoblast controls, 2
fibroblast controls and commercially available human tissue panel
RNA (Clontech) was performed in 20 ml of SuperSCript III
Reverse Transcriptase reaction buffer (Life Technologies) using
random hexamer primers. Quantitative real-time PCR (qRT-
PCR) reactions were performed in the ABI PRISM 7500 HT
system (Life Technologies) with five-fold dilution of cDNA,
200 nM of each primer using the SybrGreen PCR Master Mix
(Life Technologies). Data were analyzed using 2DDCt method, and
normalized against control sample with human ACTB. Each
measurement was performed in triplicate. The controls used in this
study are derived from EBV-LCL or skin fibroblast cells of 4
normal individuals.
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ABSTRACT: MED13L is a component subunit of the
Mediator complex, an important regulator of transcrip-
tion that is highly conserved across eukaryotes. Here, we
report MED13L disruption in a translocation t(12;19)
breakpoint of a patient with Pierre–Robin syndrome,
moderate intellectual disability, craniofacial anomalies,
and muscular defects. The phenotype is similar to pre-
viously described patients with MED13L haploinsuffi-
ciency. Knockdown of MED13L orthologue in zebrafish,
med13b, showed early defective migration of cranial
neural crest cells (NCCs) that contributed to cartilage
structure deformities in the later stage, recapitulating
craniofacial anomalies seen in human patients. Notably,
we observed abnormal distribution of developing neurons
in different brain regions of med13b morphant embryos,
which could be rescued upon introduction of full-length
human MED13L mRNA. To compare with mammalian
system, we suppressed MED13L expression by short-
hairpin RNA in ES-derived human neural progenitors,
and differentiated them into neurons. Transcriptome anal-
ysis revealed differential expression of components ofWnt
and FGF signaling pathways in MED13L-deficient neu-
rons. Our finding provides a novel insight into the mecha-
nism of overlapping phenotypic outcome targeting NCCs
derivatives organs in patients withMED13L haploinsuffi-
ciency, and emphasizes a clinically recognizable syndromic
phenotype in these patients.
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Introduction
MED13L (MED13L; MIM #608771) is one of the subunit in the
CDK8 module of Mediator Complex, a dissociable component of
Mediator complex that has been described to have an activating or
repressing functions in regulating transcriptions [Tsai et al., 2013].
Mediator complex regulates gene expression by physically linking
transcription factors to RNA Polymerase II [Ansari and Morse,
2013; Davis et al., 2013; Nakamura et al., 2011; Tsai, et al., 2013].
Recent studies have shown that MED13L has a role in cancer path-
ways, specifically suppressing Retinoblastoma/E2F-induced growth
[Angus and Nevins, 2012], and also targeted for degradation by
FBW7 (F Box and WD repeat domain-containing 7) a tumor sup-
pressor and a component of SCF (Skp-Cullin-F box) ubiquitine
ligase [Welcker and Clurman, 2008] to disrupt CDK8-mediator as-
sociation [Davis et al., 2013].
Several studies have identified structural variants (SVs) and mu-
tations affecting MED13L in patients with heart defects, craniofa-
cial anomalies, and intellectual disability (ID) [Muncke et al., 2003;
Najmabadi et al., 2011; Asadollahi et al., 2013]. The first study
reported a patient harboring a translocation-disrupting MED13L
with a dextra-looped transposition of great arteries, 1 (dTGA1;
MIM #608808) and ID, and three additional missense mutations in
MED13L (p.Glu251Gly, p.Arg1872His, and p.Asp2023Gly) in mu-
tation screening of dTGA patients’ cohort [Muncke et al., 2003].
Subsequently, copy-number variants encompassing MED13L were
reported in three patients of which twowere out-of-frame deletions,
with conotruncal heart defect, moderate ID, hypotonia and facial
anomalies, andone triplication involving a full-lengthMED13L, and
a neighboring gene MAP1LC3B2 whom displayed a much milder
phenotype with learning disability and no major facial dysmor-
phism [Asadollahi et al., 2013]. In addition, homozygous nonsyn-
onymous variant p.Arg1416Hiswas found in two siblings presenting
isolated nonsyndromic IDwithout associated anomalies, suggesting
that disruption ofMED13Lmight underlie the overlapping pheno-
types in these individuals.
Here, we report a new patient harboring a monoallelic
translocation disrupting MED13L that displays remarkably similar
phenotypes to previously reported patients harboring MED13L
deletions, which strongly supports that haploinsufficiency of
MED13L represents a clinically recognizable entity. Using ze-
brafish as a developmental model system, we demonstrated through
C© 2014 WILEY PERIODICALS, INC.
generation and rescue of zebrafish phenotypes by morpholino
(MO)-mediated knockdown ofmed13b, the zebrafish closest ortho-
logue of MED13L, resulted in improper development of branchyal
and pharyngeal arches due to defects in early migration of neural
crest cells (NCCs), thereby recapitulating the craniofacial anoma-
lies seen in human patients. Furthermore, we analyzed the gene
expression changes upon MED13L knockdown in neurons derived
from human embryonic stem cells (hESCs) and identified signifi-




Patient sample and information were collected after written in-
formed consent from patient’s parents was obtained and in ac-
cordance with local institutional review board approved protocols
from National University of Singapore in Singapore, and CHRU de
Montpellier, hospital Arnaud-de-Villeneuve, France.
Patient
The patient is the only child of healthy and unrelated parents. She
was diagnosed with Pierre–Robin sequence at birth, characterized
by cleft palate, glossoptosis, and retrognathia. She hadmultiple limb
contractures and camptodactyly, including metatarsus adductus of
the thumb, and bilateral equinovarus foot deformity. Her electroen-
cephalogram showed epileptiform discharges with absence seizures.
At 4 years old, she had moderate intellectual disability (IQ = 50)
and language difficulties with the absence of speech. Other develop-
mental milestones were significantly delayed and she required spe-
cial education. Further speech development was delayed in isolated
words, graphism, phonological programming, and global speech
delay at the age of 14 years. MRI done at the age of 8 years revealed a
ventricule enlargement in correlation with global atrophy. Physical
examinations revealed dysmorphic features including flat occiput,
hypertelorism, flat philtrum, bulbous nose, and broad nasal bridge.
Strabismus and hirsutism were noted. She had scoliosis during pu-
berty, about 14 years old. Chromosome analysis revealed a balanced
translocation between chromosome 12 and 19 t(12;19) (q24;q12).
Both parents have normal karyotypes and did not show any phe-
notypic abnormality. Array-CGH (Agilent 244K) performed on the
patient’s genomic DNA showed no additional chromosomal imbal-
ances.
Genomic DNA
DNA sample was obtained from Epstein–Barr virus transformed
lymphoblastoid cell lines from peripheral blood lymphocytes of the
patient, and was extracted by QIAampDNABlood and Cell Culture
DNA Kit (Qiagen, Valencia, CA) according to the manufacturer’s
instruction. Quality and quantity of the extracted DNA were mea-
sured using NanoDrop 1000 Spectrophotometer and agarose gel
electrophoresis.
DNA–PET Sequencing
We constructed the DNA–PET library according to the method
described in Hillmer et al. (2011). Genomic DNA (40 μg) was
fragmented to 10 kb DNA fragments, ligated to long mate paired
cap adaptors, and end repaired. After size selection, the library was
amplified by PCR and subjected to high-throughput sequencing of
50 bp libraries using the SOLiD sequencers (v4) according tomanu-
facturer’s instructions (Life Technologies, Carlsbad, CA). Sequence
tags were mapped to human reference sequence (NCBI Build 36)
and paired using SOLiD system Analysis Pipeline Tool Bioscope,
allowing up to 12 color code mismatches per 50 bp tag.
The majority of the PET sequences mapped accordingly to the
reference genome NCBI Build 36 (concordant PETs or cPETs) with
expectedmapping orientation and expectedmapping distances. The
remaining portion of the PETs mapped discordantly to the refer-
ence genome (discordant PETs or dPETs), classified as those with
incorrect paired-tag orientation and incorrect genomic distances.
These abnormally oriented dPETs provided information for differ-
ent types of structural variations as described inHillmer et al. (2011)
and Ng et al. (2012). Filtering of SVs were performed across 23 nor-
mal individuals (25 DNA-PET data sets), the pilot release set of
1000 Genome Project SV release set, previously published paired-
end sequencing studies in 18 normal individuals, and Database
of Genomic Variants (DGV). Sequences have been submitted to
the Short Read Archive (http://trace.ncbi.nlm.nih.gov/Traces/sra)
at the National Center for Biotechnology Information (NCBI) with
the accession number SRP034864.
Sanger Sequencing Validation
Primers were designed by Primer3 program, and the amplicons
spanned the breakpoints predicted by dPET clusters according to
the human genome assembly NCBI Build 36. PCR was carried out
with JumpStart REDAccuTaq LA polymerase (Sigma–Aldrich Inc.,
St. Louis, MO) in a 50-μl reaction volume and with 500 ng of
genomicDNA template. The following programwas used: (1) initial
denaturation at 96°C for 30 sec; (2) 40 cycles of 15 sec at 94°, 30 sec
at 58°C, 10 min at 68°; and (3) 68° for 10 min. PCR products
showing single bands were purified by QiaQuick PCR Purification
Kit (Qiagen) andused as templates for sequencing in both directions
by Sanger sequencing. The sequencing of junction fragments was
aligned to the human genome reference NCBI Build 36 sequence
using Blat in the UCSC Genome Browser.
Quantitative RT-PCR
Total RNA was extracted using RNAeasy Mini kit (Qiagen). Re-
verse transcription of 2 μg RNA was performed in 20 μl of Super-
Script III Reverse Transcriptase reaction buffer (Life Technologies)
using random hexamer primers. qPCR reactions were performed in
the Viia7
TM
Real Time PCR system (Life Technologies) with 100 ng
of cDNA, 200 nM of each primer using the SybrGreen PCR Master
Mix (Life Technologies). Measurements were performed in trip-
licates. Relative mRNA expression was obtained by using 2–Ct
method and normalized against control sample with human ACTB.
For zebrafish morphants, data were normalized against zebrafish
18s ribosomal RNA or actin.
Western Blot
Lymphoblastoid cells were lysed in RIPA buffer and protease in-
hibitor, and protein concentration was measured with a Bradford
assay kit (Bio-Rad, Hercules, CA). Cell lysate (50 μg) was resolved
on a 10% SDS-PAGE and transferred to a polyvinylidinefluoride
membrane (Bio-Rad). After blocking in 5%milk for 1 hr, the appro-
priate primary antibodies were added: anti-MED13L (rabbit poly-
clonal antibody generated against the region of 550–600 amino acid,
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ab87831; Abcam, Cambridge, United Kingdom), anti-β-actin (sc-
1616; Santa Cruz, Dallas, TX) for 1 hr. After washing with TBS/0.1%
Tween-20 (TBS-T), horse-radish peroxidase-conjugated antirabbit
or goat IgG secondary antibodies was added for 1 hr. After washing
with TBS-T, signals were developed using Amersham ECL Select
detection kit (GE Healthcare, Uppsala, Sweden). Western blot ex-
periments were repeated twice.
MO Microinjection
Two antisense MO for zebrafish Mediator complex subunit 13-
like, med13b (NM 001083838) sequences were designed by the
manufacturer to target the start codon (med13b-1-Start: ATGGCA-
GAGCCCCTCGTTTGTTAGA) and the splice site between exon 14
and 15 (med13b-2-Splice: AGAACTCATCATCAAAGCGCAGTCC)
(GeneTools, Philomath, OR). Subsequently, 4 ng of each MO was
injected into the yolk of one to two cell stage embryos from wild-
type AB zebrafish strains. Injected embryos were incubated at 28.5°
until reaching the appropriate developmental stage. Consistent phe-
notype was observed in at least three independent experiments of
around 90–150 embryos each. The embryos were then fixed in 4%
paraformaldehyde in PBS (PFA/PBS) overnight in 4°C and stored
in gradual increase of methanol hydration in 100%MeOH at –20°C
overnight.
In Situ Hybridization
Whole mount in situ hybridizations were carried out as
previously described by Thisse and Thisse (2008). Antisense
DIG (Roche, BAsel, Switzerland) riboprobes were synthe-
sized: med13b (cDNA clone ID: 7050861; GE Dharmacon,
Lafayette, CO), sox10 (PCR-amplified with primers 5′-GGGATT
CAGA GCGCGAGCGA-3′ and 5′-CGCGC ATTTAGGTGACA
CTATAGAAGTGACAGGTACTAGC ATC ATG TG-3′), twist1b
(PCR amplified with primers 5′-CCCTCCGTGA CGCAGGAGGA-
3′ and 5′-CGCGC ATTTAGGTGACACTATAGAAGTG TTCGTT
GAGTGTGTGTGTTT-3′), and islet1 (PCR amplified with
primer 5′-TCCAGGCTCAAACTCCAC-3′ and 5′-GGATCCATT
AACCCTCACTAAAGGGAATGTCCGACCGTTTACTTACAG-3′).
MED13L mRNA Synthesis
Full-lengthMED13L cDNA (NM 015335.4) was amplified by us-
ing primers hMED13L-F 5′-AGGATCATGACTGCGGCAGC-3′ and
hMED13L-R 5′-TCGCGGAGGATCATGACT-3′ from human cell
line GM12878 cDNA. Full-length MED13L cDNA was subcloned
into TOPOII Dual Promoter vector by using Topo TA Cloning Kit
(Life Technologies). The validity and orientation of clones were
confirmed by PCR and sequencing. Capped mRNA was gener-
ated by using SP6 mMESSAGE Machine T3 Kit (Life Technolo-
gies) according to manufacturer’s instruction and purified by using
RNAeasy mini kit (Qiagen). mRNA rescue experiments were per-
formed by coinjection of 4 ng med13b-MO and 150 pg ofMED13L
mRNA.
Alcian Blue Staining
Embryos were fixed at 5 dpf with 4% PFA for 2 hr at room tem-
perature. After fixation, embryos were dehydrated to ethanol (50%)
for 10 min at room temperature. Embryos were then transferred
to Alcian Blue staining solution (0.4% Alcian Blue [w/v] in 70%
ethanol) to rock at room temperature overnight. To remove the pig-
mentation in older embryos, embryos were bleached the next day
in 3% H2O2 and 2% KOH for 20 min. To clear the tissue, embryos
were soaked in 20% glycerol/0.25% KOH for 30 min, and prepared
for imaging in the same solution.
Neural Progenitor Cells Maintenance
NPC differentiation of ESCs was done based on established pro-
tocols [Li et al., 2011]. Cells were first plated in clumps onmatrigel-
coated 6 well-plates using mTESR1 media (StemCell Technolo-
gies, Vancouver, British Columbia, Canada). The following day,
the media was changed with NPC media composed of DMEM-
F12/neurobasalmedia (1:1) supplementedwithN2 andB27without
vitamin A supplements (Gibco, Life Technologies) and CHIR99021
(4 μM) (StemCell Technologies), SB431542 (3 μM) (Millipore,
Billerica, MA), Compound E (0.1 μM) (Millipore), and human
LIF (10 ng/ml) (Millipore). After 7 days, cells were passaged us-
ing accutase and grown in the same basal media with CHIR99021
(3 μM), SB431245 (2 μM), and additional growth factors human
LIF (10 ng/ml), EGF (20 ng/ml) (Life Technologies), and bFGF
(20 ng/ml) (Life Technologies).
shRNA Transfection
Two sequences targeting MED13L sequences were designed and
cloned into pSUPER neo vectors (Oligoengine, Seattle, WA). Two
shRNAs were transfected into H1-NPCs by using Fugene 6 trans-
fection reagent (Promega, Madison, WI). After 48 hr, G418 (Gibco,
Life Technologies) was added into the culture for selection of sta-
bly transfected cells. The surviving cells were expanded for NPCs
characterization and neuronal differentiation.
Neuronal Differentiation
Neuronal differentiation was performed according to the pro-
tocol described by Brennand et al. (2011). NPCs were plated at a
density of 200,000 cells per 6 well on a Poly-L-Ornithine/Laminin-
coated coverslips, and grown in neuronal differentiation media
(DMEM-F12/neurobasal media [1:1] supplemented with N2 and
B27 supplements [Gibco, Life Technologies], GDNF [20 ng/ml]
[R&D Systems, Minneapolis, MN], BDNF [20 ng/ml] [R&D Sys-
tems], dibutyryl-cyclic AMP [1 mM] [Sigma–Aldrich Inc.], and
ascorbic acid [200 nM] [Sigma–Aldrich Inc.]). H1-NPCs-derived
neurons were differentiated for 4 weeks to achieve TUJ1 andMAP2-
positive neuronal cells. For characterization, neurons were passaged
using accutase and replated at a very low density (5,000 cells per 24
well) on coverslips.
Immunocytochemistry
Cells were plated on ethanol-treated coverslips and fixed with
4% paraformaldehyde in PBS at 4°C and incubated with TBS con-
taining 5% of fetal bovine serum, 1% BSA (Sigma–Aldrich Inc.),
and 0.1% of Triton X-100 (Sigma–Aldrich Inc.) for 45 min at room
temperature. Following are the primary antibodies used: Nestin
(ab22030, 1:500), Sox2 (sc17320, 1:200), Vimentin (sc7557, 1:100),
Map2 (A2320, 1:1000), and Tuj1 (PRB-435P, 1:2000). Each pri-
mary antibody was incubated with fixed cells overnight at 4°C, and
cells were subsequently stained with secondary antibody conjugated
to Alexa Fluor 594 or 488 (Molecular Probes, Life Technologies,
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Carlsbad, CA) (4 μg/ml) for 1 hr at room temperature in the dark.




Human Ref-12 Expression BeadChip microarrays (Illumina, San
Diego, CA) were used for genome-wide expression analysis. For hy-
bridization, cRNAs fromduplicate or triplicate sampleswere synthe-
sized and labeled using TotalPrep RNA Amplification Kit (Ambion,
Austin, TX), following the manufacturer’s instructions. Scanned
data from the BeadChip raw files for all samples were retrieved and
background corrected using BeadStudio, and subsequent analyses
were completed in GeneSpring GX. Data were normalized both
within and between arrays, and corrected for multiple testing ac-
cording to Benjamini–Hochberg. We defined genes as significantly
differentially expressed when FDR was <0.05.
Data Analysis
Gene ontology and pathway enrichment analysis were performed
by using DAVID Functional Annotation Bioinformatics Microar-
ray Analysis and PantherDB Classification system. Differentially ex-
pressed gene lists were exported through these systems and top GO
category were considered for P < 0.05 and after multiple testing
correction with Benjamini–Hochberg.
Results
Identification ofMED13L Disruption in a Patient with Mild
ID and Dysmorphism
We analyzed a patient with Pierre–Robin sequence at birth, mod-
erate ID, limb defects, and dysmorphic features. Prior cytogenetic
analysis revealed a de novo balanced translocation between chro-
mosome 12 and 19 t(12;19)(q24;q12). We performed a large-insert
genome paired-end tag (DNA–PET) sequencing approach as de-
scribed previously [Hillmer et al., 2011; Yao et al., 2012; Utami et al.,
2014] to finemap the translocation breakpoint, which generated ap-
proximately 66 million sequence reads and achieved 150× physical
coverage. Two abnormally oriented paired clusters corresponding
to the t(12;19) translocation were identified. The breakpoint on
chromosome 12 (chr12:114,971,734–114,971,744, hg18) disrupted
MED13L and no coding genes were found in the chromosome 19
breakpoint (chr19:35,769,937-35,769,968, hg18). Sanger sequenc-
ing validation confirmed the breakpoint junction at intron 4 of
MED13L with a 1-bp microhomology in derivative chromosome
12 at position, likely resulting in a truncated MED13L protein at
amino acid position Ser160 (Fig. 1A). The heterozygous disruption
was confirmed by capillary sequencing on coding exons ofMED13L
that did not reveal any additional mutation in the flanking exons
(Supp. Fig. S1). Both mRNA and protein expression of MED13L
were reduced in the patient’s lymphoblastoid cell lines compared
with two healthy controls, as shown by qPCR andWestern blot anal-
ysis (Supp. Fig. S2). MED13L mRNA is ubiquitously expressed in
Figure 1. Mapping the translocation breakpoint disrupting MED13L by sequencing and comparison with previously reported mutations or
disruption affecting MED13L. A: DNA–PET sequencing allowed to precisely pinpoint the translocation t(12;19) breakpoint disrupting MED13L gene
within intron 4 at position chr12:114,971,734-114,971,744 NCBI Build 36 with a loss of 10 and 1 bp microhomology, and no annotated gene at
chromosome 19 breakpoint at position chr19:35,769,937-35,769,968 with 2 bp insertions at the breakpoint junction. B: The location of mutations or
SVs within MED13L gene (NG_023366.1) and protein (NP_056150.1) consequences reported to date (see Table 1 for precise clinical presentation
of each patient). P1 is the first reported patient with translocation t(12;17), presumably resulted in p.25∗ truncated protein when this allele is
translated. P9 is the patient described in this study, harboring a translocation t(12;19) with a breakpoint at intron 4, likely resulted in a truncated
protein at p.Ser160∗. P6 and P7 have deletions of 17 Kb in exon 2 and 115 Kb in exon 3–4, respectively. Both out-of-frame deletions are located
in the N-terminal domain and resulted in shorter protein of 2,155 and 2,132 amino acid length. P2, P3, and P4 showed heterozygous mutation at
p.Glu251Gly, p.Arg1872His, and p.Asp2023Gly in mutational screening of patients with dTGA related to case P1, which do not alter the protein length.
P5 represents the two siblings in a consanguineous family harboring homozygous mutation at p.Arg1416His. P8 is not indicated in this figure, and
has a triplication involving the whole MED13L and a neighboring gene MAP1LC3B2. P1, P2, P6, P7, and P9 are located in the N-terminal MED13
domain, whereas P3 and P4 are located in the C-terminal MED13 domain. P5 is located outside N- or C-terminal MED13 domain.
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Table 1. Summary of key clinical features in patients withMED13L structural variants
















Triplication of the whole
gene (c.1?_6574+?)
(Flanagan et al., 1991)
t(12;19)(q24;q21)
(intron 4)
Inheritance De novo De novo De novo De novo De novo
Neurological features
Intellectual disability + + + (+) +
Language delay NR + + NR +
Speech Nearly absent Delayed Absent NR Absent
Ataxia + NR NR NR NR
Motor skills + + + NR +
















Ears NR Large, low-set ears Large, low-set ears NR NR






Nose NR Flat nasal root, bulbous
nose
Flat nasal root, bulbous
nasal tip
Broad nasal bridge Broad nasal bridge
Mouth NR Deep philtrum, facial
hypotonia with open
mouth appearance




















dTGA - - - -
CoA, coarctation of the aorta; dTGA, dextro-looped transposition of great arteries; pVSD, perimembranous ventricular septal defect; TAPVC, total anomalous pulmonary venous
connection; ToF, tetralogy of fallot; ID, intellectual disability; DD, developmental delay; SD, speech delay; LD, language delay; NR, not reported; (+), learning disability.
human tissues with the highest levels in cerebellum, fetal brain, and
skeletal muscle (Supp. Fig. S3). We compared the affected regions
of MED13L mutations in previously published subjects [Muncke
et al., 2003; Najmabadi et al., 2011; Asadollahi et al., 2013] (Fig. 1B)
and their clinical findings are summarized in Table 1. It was pre-
viously suggested that variants within N- or C-MED13 domains
were likely to cause cardiac phenotypes [Asadollahi et al., 2013].
However, the translocation breakpoint in our patient is within
N-terminal MED13 domain, and cardiac defect was not present
at birth and early adulthood. Interestingly, during the review of
this manuscript, two additional patients with deletions within the
N-MED13 domain were reported, and no cardiac anomalies were
noted in both patients [vanHaelst et al., 2014], suggesting a reduced
penetrance for congenital heart defect in patients with MED13L
haploinsufficiency.
Knockdown of med13b Impairs Cranial NCCs Migration
To investigate the role of MED13L underlying the broad pheno-
typic spectrum observed in these patients, we examined whether
a knockdown of med13b, with 65% protein sequence similarity to
human protein (Supp. Fig. S4), could model the observed clinical
features seen in patients. First, we checked the mRNA expression
of med13b across developmental stages between 1 and 72 hr post-
fertilization (hpf) by qPCR, and observed maternal and zygotic
transcripts during embryonic development (Fig. 2A). To determine
spatiotemporal expression of med13b, we performed in situ hy-
bridization of med13b and confirmed maternal expression at one
to two cell stage in the first blastomeres, supporting a role during
early embryogenesis (Fig. 2B and C). At 24 hpf and 48 hpf, zygotic
med13b expression became restricted to the forebrain, midbrain-
hindbrain boundary, eye, pectoral fin, and the lateral line (Fig. 2D
and E), whereas sense probe showed no specific hybridization sig-
nal (Fig. 2F). Some of these tissues require derivatives of neural
crest lineage to develop: pectoral fin arises from trunk neural crest,
lateral line arises from cranial placodal ectoderm, and eye develop-
ment involves migration of NCCs to the periocular mesenchyme
[Langenberg et al., 2008]. med13b suppression by splice-site anti-
sense MO oligonucleotides resulted in developmental defects af-
fecting eyes, head, and antero-posterior axis seen at 2 days post-
fertilization (dpf) (Fig. 3A). More than 95% of the embryos were
affected with a curved body axis, underdeveloped head, pericardial
edema, and microphtalmia, which were categorized as “severe” for
40%, and as “mild-to-moderate” for 55% of the analyzed embryos.
Coinjection of approximately 150 pg full-length human MED13L
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Figure 2. med13b mRNA expression across developmental stages
in zebrafish. A: qPCR analysis in zebrafish developmental time points
between 0 and 72 hpf showed maternal expression of med13b between
0 and 3 hpf, replaced by the activation of zygotic transcript at 6 hpf,
and gradually decreased throughout the developmental stages. Relative
mRNA expression was normalized with zebrafish actin and 18s riboso-
mal RNA (18s). In situ hybridization of med13b with antisense probe in
zebrafish embryo showed maternal expression in 1-cell (B) and 2-cell
stage (C) at the blastomeres. At 24 (D) and 48 hpf (E), the expression
was restricted to forebrain (fb), mid-hindbrain boundaries (mhb), eyes,
pectoral fin (pf), and posterior lateral line (pll). F: Sense probe, used as
a negative control, did not show any expression in the embryo. Lateral
view of the embryo, anterior to the left.
mRNA with med13b MO was sufficient to rescue the eye size of
the morphants, and fully restore head development, whereas body
length was partially rescued (Fig. 3B and C).
One of the striking observations among patients with MED13L
haploinsufficiency is the presence of craniofacial dysmorphisms (in-
cluding upslanting palpebral fissures, flat nasal root, bulbous nose,
broad forehead, deep philtrum, and palatal problems) (See Table 1).
To study the implication of med13b loss of function in craniofacial
and cartilage structure development, we checked the migration of
cranial NCCs in the morphant embryos by using sox10 that is ex-
pressed in the early migrating cranial and trunk NCCs. At 24 hpf,
the expression of sox10 was strongly present in the cranial ganglia
and otic vesicle in control embryo, whereas the NCCs migration
was delayed in the morphants, shown by clustered expression of
sox10-positive cells along the migratory cranial ganglia at a more
posterior location (Fig. 4A and A′). Upon coinjection with human
MED13L mRNA, the location of sox10 positive cells were compa-
rable to that of control embryos (Fig. 4A), suggesting that med13b
is required for proper NCCs migration. Further examination of
cartilage development on 5-day-old morphant embryos stained by
Alcian Blue, a time point when all craniofacial cartilage had been
fully formed, resulted in a severely distorted ceratohyal cartilage
(Fig. 4B). This phenotype was fully restored upon humanMED13L
mRNA introduction (Fig. 4B). Similar pharyngeal skeletal defects
have been observed in the zebrafish bielak mutants 5 dpf larvae,
with ceratohyal pointing caudally, suggesting a role in the specifi-
cation of craniofacial skeleton [Neuhauss et al., 1996]. These data
clearly support that defective cranial NCCmigration contributes to
craniofacial cartilage defects upon disruption of med13b in these
embryos.
Loss of med13b Affects Neuronal Distribution in Zebrafish
Brain
Another shared clinical feature among patients with MED13L
disruptions is mild to moderate intellectual disability. To explore
the impact of med13b knockdown in neuronal development, we
used islet1 as a marker of differentiating motor neurons, which is
expressed in the retinal ganglion cells (RGCs), hypothalamus, and
ventral telencephalon. Med13b morphants showed a lack of islet1
expression in RGCs and forebrain, and reduced expression in the
hypothalamus and telencephalon, which was restored upon human
MED13L mRNA coinjection, suggesting impaired neuronal devel-
opment in early brainpatterning (Fig. 4CandC”). Tobetter examine
events of neural differentiation, we further analyzed distribution of
neuroblasts in the developing zebrafish brain usingHuC:GFP (green
fluorescent protein) transgenic line [Park et al., 2000], where cells
that start to develop as neurons initiate expression of GFP under
the regulation of HuC promoter. At 48 hpf, we observed a decrease
in the GFP expression in the optic tectum of the midbrain in the
morphant embryos (Fig. 4D’), whereas rescued embryos showed
expression relatively similar to that in control embryos (Fig. 4D”).
These results suggest thatmed13bmay be involved in early events of
neural differentiation in the zebrafish embryo.
Knockdown ofMED13L in hESC-Derived Neural
Progenitors Did Not Affect Neuronal Differentiation
We further attempted to validate defects observed in zebrafish
morphants in human cells. To this end, we used H1-hESCs-derived
neural progenitor cells (H1-NPCs), which were differentiated into
NPCs using an established protocol. Knockdown of MED13L in
these cells by using two short hairpins RNA targeting MED13L re-
sulted in 50%–60% suppression of MED13L mRNA after 2 days of
treatment with G418 antibiotic selection, relative to the shRNA tar-
geting scrambled sequence as a control (Supp. Fig. S5). The protein
expression of nestin, SOX2, and vimentin, markers of NPCs, were
not remarkably different between shScrambled and shMED13L1/2
cells shown by immunocytochemistry, indicating that MED13L
knockdowndid not alter the cell fate, as they still retainNPC charac-
teristics (Supp. Fig. S6).NPCswere able to self-renew andproliferate
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Figure 3. Suppression of med13b resulted in developmental defects affecting head, eyes, and body axis. A: Morphology of embryos (from
left to right), uninjected clutchmate, injected with control MO, med13b MO (ranging from severe to mild), and rescue construct. Knockdown
of med13b caused morphological and growth defects in the developing zebrafish embryo. Reintroduction of human MED13L mRNA (150 pg)
restored the zebrafish wild-type phenotype. Control MO-injected embryo was indistinguishable to the uninjected embryo. med13b MO resulted in
hypomorphic head, microphtalmia, curved body axis, and pericardial edema. Phenotypes were classified into three distinct categories according
to the anteroposterior axis extension: severe, mild, and moderate, with the majority of MO-injected embryo (>40%) included in severe category.
Lateral view of embryo at 48 hpf, anterior to the left. Scale bar, 500 μm. B: Microphtalmia is one of the morphant phenotype observed, and upon
coinjection of human MED13L mRNA, the eye sizes were comparable to uninjected and control embryos. C: The body lengths of the morphants
were slightly shorter than controls, and coinjection of human MED13L mRNA (150 pg) was not sufficient to fully rescue the body size.
until a limited number of times before they becamepostmitotic. The
proliferative capacity of shMED13L1/2 NPCs was slightly increased
by 5%–8% compared with shScrambled NPCs based on quantifi-
cation of 5-ethynyl-2′-deoxyuridine (EdU)-incorporated cells and
Ki67-positive cells (Supp. Fig. S7). The NPCs were maintained at
low passage and differentiated into a mixed neuronal population,
including glutamatergic and GABAergic neurons according to the
established protocol [Brennand et al., 2011]. At 4 weeks, shMED13L
neurons showed comparably similar expression of early differentiat-
ing neuron marker, TUJ1, and mature neuron marker, MAP2, with
shScrambled cells, suggesting no significant differences of differen-
tiated neurons in cultures uponMED13L knockdown in contrast to
findings in zebrafish morphant (Supp. Fig. S8). This might be ex-
plained by a lack of information to determine specific brain regions
in the in vitro model.
Transcriptome Profile ofMED13L-Deficient Neurons
Revealed Dynamic Expression Changes of Cranial NCCs
Genes
To explore the gene expression changes upon MED13L knock-
down, we conducted exploratory microarray experiments compar-
ing shMED13L1/2 to shScrambled neurons at week 4, as this time
point is a critical transition period between neural progenitors to
becomepostmitotic neurons.We identified 1,117 genes showing sig-
nificant expression changes in shMED13L neurons (Supp. Fig. S9).
These deregulated gene list was submitted to DAVID annotation,
and significant (P < 0.05) gene ontology terms were enriched in the
developmental processes, which corroborated the functional role
of MED13L in regulating other genes during development (Supp.
Fig. S9). The top two genes being upregulated were: SP8, a zinc
finger transcription factor gene known to be crucially involved in
craniofacial development [Kasberg et al., 2013]; and FGFR3, fibrob-
last growth factor (FGF) receptor 3 gene, a repressor of bone growth
that were found nearly 10-fold upregulated in shMED13L neurons.
Both were confirmed to be upregulated in shMED13L NPCs and
med13b morphant embryos by qRT-PCR (Fig. 5A). Furthermore,
higher expressions of sp8a at olfactory vesicle and motor neurons,
and fgfr3 at diencephalon and midbrain-hindbrain boundary were
demonstrated inmed13bMO embryos compared with wild type by
in situ hybridization (Fig. 5B). Four other genes, which zebrafish
orthologues are known to be expressed in NCCs development ac-
cording to ZFIN database, such as pharyngeal arches (Calcr), lateral
line (Rspo3), and pectoral fin (Hoxa5 andAtp1a2), were significantly
downregulated (Log2 FC = –3.83 to –2.39, P < 0.05), suggesting that
MED13L suppression also affects the regulation of genes that are im-
portant for the development of NCCs derivatives (Supp. Fig. S10).
We next performed pathway-enrichment analysis using PANTHER
Web tools in the 1,117 genes and revealed 16 components within
canonical Wnt pathway being significantly differentially expressed
in shMED13L1/2 neurons (Supp. Fig. S10). We validated eight of
the genes that were selected based on their known counterpart as the
main component (ligands, antagonist, receptors, and downstream
target gene) of canonicalWnt pathway, by qRT-PCR and confirmed
microarray-predicted changes in the genes tested (Supp. Table S1),
for neurons and NPCs, as well as med13bmorphant embryos, sup-
porting the notion that Wnt signaling is deregulated in cells lacking
MED13L.
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Figure 4. med13b is required for proper NCCsmigration and neuronal distribution in zebrafish headmorphogenesis and craniofacial prominence.
sox10, cranial NCCs marker, showed expression along cranial ganglia and otic vesicle (ov) at 24 hpf in the control embryos (A). Dorsal view of
the embryo at 24 hpf, anterior to the left. Delayed migration of NCCs is depicted as clustered sox10-positive cells toward a more posterior axis
in the morphant embryos (A’). Injection of 150 pg human MED13L mRNA-restored NCCs migration shown in rescued embryo (A”). Dashed lines
outline the migratory axis of sox10-positive cells. Craniofacial cartilage formation was visualized by Alcian Blue staining at 5 dpf, and developing
normally in control embryos (B). Ceratohyal cartilage was severely distorted and shifted posteriorly in the morphants (B’). Injection of the human
MED13l mRNA rescued the wild-type phenotype (B”). M indicatesMeckel’s cartilage, pq indicates palatoquadral cartilage, ch indicates ceratohyal
cartilage, and cb indicates ceratobranchyal cartilage number 1–4. Ventral view of the embryo at 5 dpf, anterior to the left. Early differentiating
neurons were visualized by Islet1 expression in the hypothalamus (ht), forebrain (fb), and retinal ganglion cells (rgcs) at 48 hpf control embryos
(C). Islet1 expression was absent in the rgcs, and reduced in the hypothalamus and forebrain, indicating developmental delay in the morphant
embryos (C’). Upon the injection of human MED13L mRNA, the expression was restored in the rescued embryo (C”). Dashed lines outline the eye.
Dorsal view of the embryo at 48 hpf, anterior to the left. Imaging of HuC:GFP transgenic line showed distribution of developing neurons as GFP
expression across brain regions in the control embryos (D). Abnormal distribution of GFP expression in the forebrain and mid-hindbrain boundaries
were apparent in the morphants (D’), which was restored upon addition of human MED13L mRNA (D”). tc indicates telencephalon, d indicates
diencephalon, cb indicates cerebellum, ot indicates optic tectum, and mb indicates midbrain. Lateral view of the head region at 48 hpf, anterior to
the left.
Discussion
Our work provides a mechanistic insight into the functional con-
sequences ofMED13L disruption in human patients. Here, we func-
tionally demonstrated that depletion of its orthologue in zebrafish
model could partly phenocopy the craniofacial abnormalities in hu-
man and the observed phenotype can be reversed by introducing
intact human mRNA, suggesting that gene dosage is required for
normal gene function. Previous reported cases with shorter length
or presumably truncated MED13L protein displayed more severe
phenotypes [Muncke et al., 2003; Asadollahi et al., 2013; van Haelst
et al., 2014], compared with patients carrying single amino acid
substitutions associated with either isolated dTGA or ID, indicat-
ing a distinctmolecularmechanismbetween single-pointmutations
and haploinsufficiency ofMED13L [Muncke et al., 2003; Najmabadi
et al., 2011]. Patients with missense mutations have either isolated
heart defects or isolated ID,whereas patients withMED13Lhaploin-
sufficiency displayed moderate ID and craniofacial anomalies, with
a reduced penetrance of cardiac defects. Our in vivo model demon-
strated that early migration defects of cranial NCCs toward the
branchyal arches contributed to the craniofacial defect seen in 5 dpf
morphants, suggesting thatmed13b is required for early craniofacial
development. This could partly be explained by the enrichment of
cranial NCCs genes including components of Wnt and FGFs sig-
naling pathways in the transcriptome profile of MED13L-deficient
neuronal cells. FGF signaling is known to play a role in promot-
ing the fate of NCCs, and required for migration and patterning
of the cranial NCCs into the pharyngeal arches. Fgf8 is secreted by
the anterior neural ridge (ANR), and is required for cranial NCCs
proliferation, as well as the development of forebrain and midbrain
structures. Loss of FGF signaling leads to a failure of pharyngeal
arch cartilage development [Sarkar et al., 2001; David et al., 2002].
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Figure 5. Expression of sp8 and fgfr3 in NPCs, neurons and med13b morphants assessed by qPCR and in situ hybridization. A: qPCR analysis
showed similar trend of upregulated expression in MED13L-depleted cells (NPCs, neurons and pooled zebrafish embryos), thus confirmed
microarray-predicted expression changes. B: In situ hybridization experiments showed enhanced expression of both genes indicated by arrows;
(i)sp8a in the olfactory vesicle (ov) andmotoneurons (mn) along the spinal cord and (ii) fgfr3 in diencephalon (di), andmidbrain-hindbrain boundaries
(MHB) in the med13b MO embryos compared with control.
A Recent study has shown that SP8, one of the top upregulated
genes in our transcriptome data, promotes Fgf8 expression in the
ANR and olfactory pit signaling centers that regulate survival, pro-
liferation, and differentiation of the NCCs to form facial skeleton
and the anterior brain [Kasberg et al., 2013]. Studies in frogs and
mice have shown that the induction of NCCs is dependent on the
activation of Fgf andWnt pathways in the paraxial mesoderm [Ken-
gaku and Okamoto, 1993; Mayor et al., 1995; Hong et al., 2008].
Wnt signaling induces the protrusion of the frontonasal and maxil-
lary prominences, which eventually form the facial skeleton [Helms
et al., 2005; Tapadia et al., 2005; Brugmann et al., 2006]. Conditional
knockoutmice ofβ-catenin, the keynuclear effector in the canonical
Wnt signaling, resulted in brainmalformation and failure of cranio-
facial development [Brault et al., 2001]. Interestingly, other subunit
in the CDK8module ofMediator complex,MED12, has been shown
to interact physically with β-catenin [Kim et al., 2006] and recent
genetic studies in Drosophila and C. elegans have revealed that mu-
tations in other Mediator subunitsMED1, MED6, MED12, MED13,
and MED23 variously affect developmental processes regulated by
Wnt signaling [Zhang and Emmons, 2000; Treisman, 2001; Zhang
and Emmons, 2001; Janody et al., 2003; Yoda et al., 2005]. Our work
further extends the involvement of MED13L as part of Mediator
complex, showing that upon knockdown significantly deregulate
genes within Wnt signaling pathway.
There are seven additional patients with ID and congenital
anomalies documented by DECIPHER [Firth et al., 2009], con-
sisted of five deletions and twoduplications encompassingMED13L.
Complete description of additional patients with MED13L disrup-
tion becomes clinically relevant to extend the definition ofMED13L
haploinsufficiency syndrome, as initially postulated by Asadollahi
et al. (2013). This could be explored further by performing ad-
ditional mutation screening within MED13L for patients that were
tested negative forDiGeorge syndrome, or other neurocristopathies.
Considering the coexistence of ID in patients with MED13L muta-
tions and our functional validation showing abnormal regulation of
neurogenesis in the developing brain of med13b-depleted zebrafish
embryo, we further recommend adding MED13L to the ID-linked
screening panel for clinical genetic testing of ID patients.
In summary, we have presented a mechanistic correlation in pa-
tients sharing a single genedisruption andprovided an in vivomodel
ofMED13L loss-of-function that strongly suggests an implication of
defective NCCs migration during craniofacial development mim-
icking the human patients. Taken together, our study effectively
demonstrates that haploinsufficiency of MED13L is attributable to
the ID and craniofacial phenotype in our patient.
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